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ABSTRACT
Skin cancer is the one of the most diagnosed cancers in the United States with increasing
incidence of 6% every year. In 2015, it is estimated 73,870 new cases of melanoma will
be identified and 9,480 individuals will die of their disease. While melanoma only
accounts for approximately 2.4% of all cancer related deaths and is the 5th leading
diagnosed cancer (US) it is the one of the most common cancers in young adults, age 2529, particularly for young women. Of particular importance, the mean survival rate of
patients diagnosed with metastatic melanoma is six months, with five-year survival rates
of less than 5%.
One reason for the increasing incidence in young adults may be due to the use of
indoor tanning. UV exposure causes DNA damage and can induce the activation of a
metabolic pathway called autophagy. Autophagy is activated by stress, including DNA
damage, and melanoma risk is associated with UV exposure.
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Here I present three studies investigating oncogene differences in rates of
autophagy as well as the relationship of UV exposure and genotypic variants to
autophagy. In this project, I determine whether oncogene status in melanoma
differentially regulates apoptosis by modifying autophagic flux. The central hypothesis
of this project is that cutaneous malignant melanomas (CMM) with BRAF mutations may
be autophagy-addicted while tumors with NRAS mutations may be less dependent on
autophagy.
I found that BRAF/NRAS mutations differentially alter autophagic flux to suppress
apoptosis in melanoma. Our results show that oncogene status in melanoma correlates
with differential regulation of autophagic flux and that inhibition of autophagy in BRAF
mutant melanoma cells results in apoptosis. These data suggest that BRAF mutant
melanoma cells suppress apoptosis by modifying autophagic flux and that these cells may
be autophagy addicted in order to promote survival.
I also determined that proxy autophagy markers LC3 and Beclin1 are associated
with UV exposure and clinical stage when evaluating tissue sections from melanoma
patients and controls. Surprisingly, the NRAS wide-type sections had elevated LC3 levels
when compared to the NRAS mutant tissue sections suggesting that autophagy may be
inhibited NRAS in melanoma tumors. These results indicate that autophagic flux varies by
tumor stage and is associated with UVR exposure.
Finally, I also determined that several SNPs in autophagy related genes are
melanoma prognostic indictors. Of note, one SNP that has previously been shown to be
inversely associated with other diseases, with a functional variant which increases disease

viii

susceptibility was inversely associated with Breslow thickness, the most important
indicator of melanoma outcome.
The work from my study helps address the inconsistencies in the literature
regarding autophagy’s impact on melanoma progression. Furthermore, these studies
provide a basis to investigate the role ATG gene SNPs, UV exposure and in autophagy
and melanoma.
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CHAPTER ONE: INTRODUCTION

APOPTOSIS AND AUTOPHAGY: THE YIN-YANG OF HOMEOSTASIS IN CELL
DEATH IN CANCER

1

1.1 ABSTRACT
Apoptosis and autophagy are physiologically necessary pathways which are vital
for cell homeostasis. Apoptosis facilitates type I programmed cell death, while
autophagic survival mechanism counteracts apoptosis. Dysregulation in the homeostatic
balance between these two essential cellular pathways has been linked to various
diseases. We review relevant Janus molecules and their interactomes, as well as
lysosomes which play multiple roles in apoptosis and autophagy, and to discuss how
targeted interventions can be used in cancer prevention and/or therapy.
1.2 INTRODUCTION
Apoptosis and autophagy are both normal, genetically and biochemically
regulated, and physiologically necessary pathways which are vital for cell homeostasis.
Like two sides of a coin, apoptosis facilitates purposeful suicide by tightly controlled
reactions followed by phagocytosis, while autophagy usually counteracts apoptosis and
affords a survival mechanism for stressed cells until exaggerated stress or nutrition
depletion forces the cells to compromise. Interestingly, compromised cells may use
autophagy as a type II programmed cell death mechanism to die. Dysregulation in the
balance between these two essential cellular pathways has been reported to be significant
in the onset and pathogenesis of almost all diseases. Work from my laboratory research
and others has shown that inhibition of autophagy induces cell death in many cancer cell
types and chemical and genetic inhibition of autophagy increases apoptotic cell death.
Disrupted regulation of autophagy creates an environment that facilitates the initiation
and progression of many diseases including cancer. In addition, this deregulation is
associated with increased cancer risk, particularly for pancreatic, colorectal, and breast
2

cancer (Gukovsky et al., 2013). The goal of this article is twofold: (1) to review relevant
Janus molecules and their interactomes, as well as lysosomes which play multiple roles in
apoptosis and autophagy, and (2) to discuss how targeted interventions can be used in
cancer prevention and/or therapy.
1.3 APOPTOSIS (THE YIN)
Apoptosis or type I programmed cell death is an ATP-dependent, multi-step
process which occurs in response to both internal (intrinsic) and external (extrinsic)
signals and as part of normal cell development and homeostasis (Figure 1) (Elmore,
2007). Hallmark characteristics of apoptosis in the conserved, late stage include the
appearance of phosphatidylserine (PS) on the outer leaflet of the cell membrane that is
recognized by neighboring cells/macrophages which then rapidly phagocytose cells
displaying PS (Li et al.,2003). Other key features of late-stage apoptosis include an intact
membrane with signs of blebbing/membrane protrusions, cellular condensation,
chromatin condensation, and site-specific DNA fragmentation (Coleman et al., 2001). In
so processing, apoptosis does not result in inflammation and/or tissue damage as is
typical of necrosis which is acute, unregulated, and accidental cell death. The intrinsic
apoptotic signaling pathway is dependent on the formation of apoptosome, an
interactome of apoptotic protease activating factor 1 (Apaf-1), (pro-) caspase 9,
cytochrome C and (d) ATP (Zou et al., 1997). While the extrinsic pathway utilizes
transmembrane death receptors (for example FasR, tumor necrosis factor receptor 1
(TNFR1), DR3, and DR4/DR5) (Bazzoni and Beutler, 1996), and their corresponding
ligands (for example, FasL, TNF-α, Apo3L, and Apo2L) (Elmore, 2007). Apoptosis takes
place in four sequential stages: stimulus, signaling, regulation, and execution. Stimulus
3

occurs in response to ligand-receptor interaction, which is extrinsic, or intracellular stress,
which is intrinsic; an example of which is genomic toxicity. Subsequently, regulatory
proteins, such as p53, Bcl-2, Inhibitors of APoptosis (IAPs), and signaling interactomes,
such as apoptosome, fine tune this dynamic process, and then a group of Cysteineactivated ASPartate-specific proteASES (Caspases) will be activated and used for
cleaving critical proteins in cell structure, survival and proliferation. The inability to
eliminate cells with genomic instability or aberrant proliferation through apoptotic
mechanisms can eventually lead to the development of cancer. This inability to eliminate
cells is often associated with the loss of function of p53, a tumor suppressor protein
which is important in the signaling stage of apoptosis (Yu and Zhang, 2005). When p53
gets activated, it prevents the cell from replicating by stalling the cell at the G1 and G2/M
cell cycle checkpoints. Characteristic uncontrolled cellular proliferation, known as
hyperplasia, and a lack of clearance of these cells leads to accumulation of genetic and/or
epigenetic mutations, to transform proliferating cells into invasive, malignant cells.
1.4 AUTOPHAGY (THE YANG)
Autophagy is a catabolic process, which utilizes lysosomal hydrolases to recycle
and degrade cytosolic components, proteins, and other macromolecules and organelles in
response to nutrient depletion and other stresses (Figures 2 and 3) (Rikiishi, 2012). The
word autophagy literally means “eating of the self”; this process involves the cell
digesting its own intracellular components to reallocate nutrients as a means of survival
during nutritional deprivation. Autophagy is important during normal development as
well as in response to environmental stimuli and is vital to the maintenance of cellular
homeostasis and, unlike apoptosis, can be reversible. Autophagy rids the body of aged

4

and damaged organelles and can help in the elimination of pathogens. While autophagy
references typically focus on macroautophagy, other types of autophagy, including
microautophagy and chaperone-mediated autophagy, share the same lysosomal
degradation mechanism but differ in the way that material is delivered to the lysosome
(Mizushima, 2007; Sahu et al., 2011).
Similar to apoptosis, autophagy has several characteristic features, including the
formation of distinct cellular interactomes and structures (e.g., isolation
membrane/phagophore, autophagic vesicles). It has three major phases: initiation,
elongation and completion. Initiation involves the formation of a double membrane
structure (from isolation membrane to autophagosome) which captures both the
cytoplasm and organelles and then fuses with endosomes and lysosomes (becoming the
amphisome and the autolysosome, respectively) which degrades the contents of the
vesicle. The formation of this double membrane structure is a complex process involving
many AuTophaGy-related proteins (Atgs) (Schmid and Münz, 2007). Currently, over 30
genes encoding Atgs have been identified, including the microtubule-associated protein
light-chain 3 (LC3). LC3, a homologue of yeast Atg8, is required for the formation of
autophagosomal membranes. LC3 is recruited to the isolation membrane, which will
ultimately develop into the autophagosome where cellular targets are sequestered in
preparation for degradation. The autophagosome will then fuse with endosomes/
lysosomes to create the autolysosome where cellular targets are degraded (Hippert,
2006). Under nutrient-deprived conditions, autophagy can be induced at the
transcriptional and post-translational level. With regard to post-translational protein
modifications, LC3, for example, exists in both a (normal) cytoplasmic and a
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(autophagic) membrane-associated form (Kirisako et al., 1999). The process of
incorporating LC3 to the membrane is accomplished through LC3 cleavage, lipidation
and translocation. The LC3 designation is modified once cleavage has occurred as well as
when the protein is localized to the membrane. Under this nomenclature, LC3-I refers to
cytosolic localization following cleavage and LC3-II refers to a membrane bound LC3
(Kirisako et al., 1999). Atg4, a specific cysteine protease belonging to the caspase family,
initiates LC3 processing by post-translationally cleaving LC3’s C-terminal amino acid
(arginine) (Ichimura et al., 2000). This cleavage generates LC3-I. The newly exposed Cterminal glycine (Gly 116) is bound by phosphatidylethanolamine (PE), a lipid
constituent of plasma membranes, lipidation occurs next resulting in the formation of
LC3-II. Atg4 can also act by delipidating LC3 at the lysosomal fusion step and during
apoptosis Atg4 is cleaved by caspase-3 becoming highly toxic (Betin et al., 2009).
LC3-II associates with both the inner and outer membranes of the isolation membrane.
Transient conjugation of LC3 to the autophagosomal membrane through an ubiquitin like
system is essential for macroautophagy. The conversion of LC3-I to LC3-II has been
used as an indicator of autophagic state in in vitro model systems (Mizushima et al.,
2010). The biochemical reactions involved in LC3 cleavage, lipidation, and translocation
to the isolation membrane are defining features of this type of autophagy. Autophagy
uses two conjugation systems similar to the ubiquitin targeting system. For comparison,
ubiquitin directs proteins targeted for degradation to the proteasome and is activated by
an E1 enzyme. Following activation, E1 transfers the activated ubiquitin to E2 enzymes
and then with E3 enzymes catalyzes the conjugation of ubiquitin to substrates. Important
binding residues on LC3 can function in an ubiquitin-like fashion and LC3’s crystal
6

structure demonstrated folds similar to ubiquitin, illustrating the resemblance of these two
proteins in structure (Sugawara et al., 2004; Suzuki et al., 2005). Therefore, terms
ubiquitin-like, E1-like, E2-like and E3-like are applied to these autophagic ubiquitin-like
systems that produce the conjugated proteins (LC3-II-PE and Atg5-Atg12-Atg16L),
which play a role in autophagosome formation, elongation and completion. In brief, the
LC3 targeting system works with LC3 acting as the ubiquitin-like protein that is
transferred to phosphatidylethanolamine (PE), while Atg7 functions in the same manner
as an E1 enzyme; Atg3 like an E2 enzyme and the Atg12-Atg5-Atg16L complex like an
E3 ligase for the LC3-II–PE complex (Figure 4). Residues Phe 77 and Phe 79 are
located on one surface of Atg8, and residues Tyr 49 and Leu 50 are on the opposite
surface. Researchers have shown that Phe 77 and Phe 79 recognize Atg4, which can also
act as a de-ubiquitination enzyme. Residues Tyr 49 and Leu 50 act downstream of
lipidation (Amar et al., 2006) (Figure 5). In addition, these multi-complex interactions
potentially facilitate the loading of large proteins into a developing autophagosome
(Bjorkoy et al., 2005). Upstream of the LC3-II-PE linkage, Atg12 is conjugated to Atg5
to form a stable Atg12-Atg5 conjunction. This process is mediated by Atg7, an E1-like
activating enzyme, and Atg10, an E2-like conjugating enzyme. Atg16 then forms a
complex with the Atg12–Atg5 conjugate (Mizushima et al., 2002).
The isolation membrane structure serves as both a signaling platform and a compartment
for holding targeted proteins. Autophagy requires precise signaling and sorting of cargo
in order to transport the appropriate materials to the autophagosome for degradation and
recycling. The induction of autophagy causes the translocation of proteins like LC3 to the
isolation membrane from the cytosol. During the elongation of the isolation membrane,
7

the Atg5-Atg12-Atg16L complex localizes to the membrane to form a cup-shaped
structure. LC3-II then localizes to the isolation membrane, while the Atg5-Atg12-Atg16L
complex dissociates. Autophagosome formation occurs and finally the autophagosome’s
outer membrane fuses with lysosomes to form the autolysosome which can then degrade
targeted contents. LC3 is the only protein that remains associated with the completed
autophagosome. Following autolysosomal formation, lysosomal hydrolases, including
cathepsins, degrade the targeted proteins, while cathepsins degrade LC3-II on the inner
autophagosomal surface. Following target degradation, Atg4 is involved in separating
outer membrane LC3-II from the autophagosome, although LC3-II is still present in late
autophagic vesicles (Mizushima et al., 2010).
Derailed autophagy has been associated with many diseases including cancer,
neurodegenerative disease, and cardiovascular disease (Shintani and Klionsky, 2004).
Important crosstalk between apoptosis and autophagy has been identified in colorectal
cancer with possible therapeutic implications including the use of a new class of
anticancer agents, histone deacetylase (HDAC) inhibitors, which induce autophagy.
Autophagy has been shown to be induced in hormone-sensitive prostate cancer cells
either by incubation in androgen deficient medium or by treatment with an androgen
inhibitor (Kaini et al., 2012). These findings suggest that autophagy protects prostate
cancer cells during androgen deprivation allowing the cells to survive nutrient depletion.
Conversely, investigators were able to show that induction of autophagy has a pro-death
role in pancreatic cancer cells (Mujumdar and Saluja, 2010). Pancreatic tumors have been
shown to have elevated autophagy under basal conditions and studies involving
autophagy inhibition using either selective inhibitors (chloroquine) or RNA interference
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of essential autophagy genes appear to influence sensitivity to chemotherapy. In addition,
autophagy appears to play multiple roles in pancreatic cancer as a higher LC3 expression
in pancreatic cancer tissue is associated with enhanced expression of the hypoxia marker
carbonic anhydrase IX in the peripheral area, correlating with poor outcome and shorter
disease-free period (Kang et al., 2012). Moreover, melanoma cell lines have also been
shown to exhibit high basal levels of both p62 and LC3II (Xie et al., 2013) and cutaneous
malignant melanoma cells display high overall levels of autophagy (Lazova et al., 2010)
suggesting that autophagy may provide an active metabolic state for invasive melanoma
tumors.
1.5 P53 IN APOPTOSIS AND AUTOPHAGY
P53, a sequence-specific DNA binding protein, is a sensor of both DNA and
cellular stress and is commonly called the guardian of the genome for its ability to
regulate the cell cycle. The Janus or bi-functional role of p53 is illustrated by the ability
of this protein to both trigger and inhibit apoptosis and autophagy based on its subcellular
localization. Under normal low stress conditions, p53 is basally activated and promotes
DNA repair and cell survival. However, under high stress conditions or in response to
DNA damage, p53 is highly activated and upregulates cell cycle arrest and/or apoptosis.
P53 directly affects the expression of two BH3-only proteins, Bad and (t)Bid, which are
important regulators of both apoptosis as well as autophagy (Zhaorigetu et al., 2008).
P53 also induces apoptosis through transcription independent mechanisms including the
generation of reactive oxygen species (ROS) and through its direct associations with
mitochondria. P53 interacts with several apoptogenic proteins including Bax and Fas and
p53-dependent apoptosis typically follows the intrinsic apoptosis pathway. However, p53
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can also influence cell death through the death receptors. P53 has the ability to activate
the transcription of pro-apoptotic genes, including Bax, Noxa, and PUMA, and can also
trigger apoptosis through the inhibition of anti-apoptotic genes including survivin (Mirza
et al., 2002), which allows the activation of caspases. Conversely, in addition to its
inhibitory characteristics, p53 also has the ability to upregulate several processes
including the activation of the death domain receptor (DR5) for TRAIL (TNF-related
apoptosis-inducing ligand), which is activated in response to DNA damage (Wu et al.,
1997) and induces apoptosis through caspase 8 activation. Once the TRAIL receptor
binds its ligand, the receptor trimerizes facilitating the recruitment of pro-caspase 8 to the
death domain as well as the Fas-associated death domain protein (FADD). These
interactions cause the formation of a death inducing signaling complex or DISC which
then assists in the cleavage of pro-caspase 8 into its active state (Sprick et al., 2000). An
increase in p53 expression also enhances the levels of Fas on the cell surface by
promoting its ability to translocate from the Golgi (Sionov and Haupt, 1999). In apoptosis
p53 is important in the activation of the apoptosome. Upregulation of p53 is associated
with an increase in Apaf-1 expression (Haupt et al., 2003), and can also trigger apoptosis
through the upregulation of the pro-apoptotic Bcl-2 family members, such as Bax and
PUMA (Fridman and Lowe, 2003). While p53 is a strong nuclear transcription factor it
can also function in the cytoplasm where it increases mitochondrial permeability. In
general, the basal level of cytosolic p53 is present and maintained through the ubiquitin
proteasome pathway but at higher concentrations it may translocate into the
mitochondria. Once in the mitochondria, p53 interacts with both Bcl-xL and Bcl-2, down
regulating their ability to inhibit apoptosis (Tasdemir et al., 2008).

10

P53’s role in autophagy is also multifaceted. In the cytosol it operates at the
mitochondrial level to suppress autophagy through its binding to Bcl-2 and Bax
(Tasdemir et al., 2008), as well as potentially through its interactions with mTOR
(Tasdemir et al., 2008). Nuclear p53 upregulates apolipoprotein L1 (ApoL1), a novel
BH3-only, (phospho)lipid binding protein with high affinity for phosphatidic acid (PA),
that directly interacts with mTOR to increase autophagy. P53 post transcriptionally
down-regulates LC3 resulting in a reduction of autophagic flux (Figures 2 and 3). In
tumors where p53 function is lost or altered through mutations, the accumulation of
excessive LC3 may ultimately result in apoptosis. P53 helps sustain the viability of cells
by helping to maintain homeostasis and adjusting the rate of autophagy to nutrient
stimulus (Scherz-Shouval et al., 2010). Not only does the direct activation of p53 in cell
lines induce autophagy but it also upregulates the expression of the Damage Regulated
Autophagy Modulator (DRAM) gene. DRAM, a p53 target, encodes lysosomal proteins
which upregulate autophagy (Zhaorigetu et al., 2008) (Figures 2 and 3). Chemical
inhibition of p53 in cell lines results in the characteristic signs of autophagy including the
depletion of p62, the presence of GFP-LC3 in the cytoplasmic vacuoles (puncta), and the
presence of autophagosomes and autolysosomes (Tasdemir et al., 2008). In apoptosis,
p53 can activate the pro-apoptotic proteins in a transcription-independent manner and
DNA-damage leads to mitochondrial translocation of p53 and intrinsic pathway
upregulation by increasing PUMA. P53 can bind directly to the Bcl-2 family member
Bcl-xL and influence cytochrome c release through direct activation of Bax to upregulate
apoptosis. P53 can release both pro-apoptotic multi-domain proteins and BH3-only
proteins that are sequestered by Bcl-xL. Finally, the cross-talk between apoptosis and
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autophagy is shown through the ability of p53 to post transcriptional inhibition LC3 by
p53, which reduces the overall rate of autophagy ultimately causing excessive LC3
accumulation resulting in apoptosis (Scherz-Shouval et al., 2010).
Targeting p53 in order to develop novel anti-cancer treatments has broad
implications. The two major strategies include targeting of wildtype (wt.) p53 or mutant
p53. With respect to wt. p53, drugs that activate endogenous p53 at protein or
transcription levels through small molecules would be preferable. For example,
Reactivation of p53 and Induction of Tumor cell Apoptosis (RITA), which binds to and
activates p53 thereby inducing apoptosis, has shown promise in suppressing tumor
growth in culture (Roh et al., 2010). CP-31398 was the first small molecule developed
that increases expression of wt. p53 through the reduction of p53 ubiquitination. In
addition, small molecules which target p53 transcription may reduce the adverse effects
of chemotherapy or radiation in normal proliferating cells. One such compound, Pifithrin,
can reversibly inhibit p53 transcriptional activation, block p53 activation in normal cells,
and thus reduce apoptosis. In targeting mutant p53, new compounds which re-activate wt.
p53 activities through conformational changes of mutant p53 have been developed
(Wang and Sun, 2010). For example, ellipticine, P53 Reactivation and Induction of
Massive Apoptosis (PRIMA-1), and Mutant p53 reactivation and Induction of Rapid
Apoptosis (MIRA-1) have been shown to induce a conformational change of mutant p53
that revert the protein to wild type activity. Interestingly, UCN01, a bifunctional
modulator of cyclin-dependent kinases, can arrest cancer cells harboring mutant p53 at
the G2 checkpoint leading to cell death (Facchinetti et al., 2004).
1.6 THE BCL-2 FAMILY MEMBERS IN APOPTOSIS AND AUTOPHAGY
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Bcl-2 (B cell lymphoma/leukemia type 2) is a member of a family of proteins,
with the same name, that convey either pro- or anti-death signaling. The interactions of
the Bcl-2 proteins determine the fate of a cell tipping the homeostatic balance to favor
apoptosis, or autophagic survival.

The anti-death Bcl-2 members (e.g. Bcl-2 and Bcl-

xL) suppress apoptosis and promote cell survival and mutations in the Bcl-2 gene have
been shown to be associated with many cancers. The BH3-only proteins which contain a
single Bcl-2 homology (BH) domain can interact with the anti-death Bcl-2 family
members to induce apoptosis (Tuffy et al., 2010).

These interactions also trigger

downstream events which can ultimately permeabilize the mitochondrial membrane,
resulting in the release of the cytochrome c and resulting in the activation of caspases
(Figure 1) (Shintani and Klionsky, 2004). The BH3-only proteins can also propagate
stress signals and indirectly activate Bax and Bak, the pro-death members, responsible for
the induction of apoptosis and/or blockage of autophagy. For example, ApoL6, a newly
identified members of the BH3-only proteins, when overexpressed, induces apoptosis and
blocks Beclin 1-mediated autophagy simultaneously (Liu et al., 2005; Zhaorigetu et al.,
2011) (Figures 1 and 3). Interestingly, Beclin 1 has also been shown to be a bona fide
BH3-only protein, however, when overexpressed, it does not induce apoptosis but rather
autophagy (Fan et al.,2013). On the other hand, Bcl-2 interferes with Bax or Bak
function by forming heterodimers with them. When separated from Bcl-2, Bax or Bak
forms homodimers or heterodimers which allow permeabilization of the mitochondrial
membrane (Ruvolo et al., 2001). Interestingly, the interplay of Bcl-2 kinase and
phosphatase allows for rapid and reversible regulation of Bcl-2’s activity in response to
stress signals or damage (Ruvolo et al., 2001). Bcl-2 interacts either directly or indirectly
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with siblings including Bik, Bid, Bim and PUMA (see below) to affect cell death and
survival.
Bcl-2 also plays a Janus role regulating both apoptosis and autophagy through its
interactions with their common proteins linking these pathways, allowing for a more
responsive cell survival/ cell death switching mechanism. Bcl-2 inhibits both autophagy
and apoptosis through direct binding to Beclin 1 (Jegga et al., 2011). Beclin 1 is a core
component in the enzymatic complex phosphoinositides-3-kinase class III (PI3KC3)
which initiates the formation of autophagosomes (Moscat and Diaz-MecoSee 2009). Bcl2 binding to Beclin 1 allows the survival of cells when they are deprived of their growth
factors. Disruption of this interaction by pro-apoptotic proteins such as Bad and ApoL6
induces autophagy (Zhaorigetu et al., 2008, Li et al., 2007). Under starvation conditions,
the stress activated signaling molecule, c-Jun N-terminal protein kinase 1 (JNK1)
mediates the induction of multisite phosphorylation of cellular Bcl-2. This
phosphorylation results in the dissociation of Bcl-2 from Beclin 1 and the subsequent
activation of autophagy (Wei et al., 2008). Other research has indicated that cells
containing mutations in Beclin 1 inhibit its ability to bind Bcl-2 and induce autophagy
related cell death (Pattingre et al., 2005).
Other findings implicate autophagy as a mechanism of resistance to antiangiogenic therapies in colon cancer cells supporting the importance of investigations
into inhibitory approaches in the management of this disease (Selvakumaran et al., 2013).
In addition, researchers have shown that autophagosomes are actively produced in
colorectal cancer cells under nutrient starvation, and treatment with autolysosome
inhibitors like 3-methyladenine, which inhibits autophagy by blocking autophagosome
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formation through inhibition of PI3KC3, enhances apoptosis. Overall it appears that
autophagy is activated in colorectal cancers both in vitro and in vivo, and may contribute
to the cancer cell survival (Sato et al., 2007, Prabhudesai et al., 2007). Overexpression of
the pro-survival Bcl-2 family members, for example, Bcl-2 and Bcl-xL, is associated with
tumor progression, as well as resistance to chemotherapy. Bcl-2 small molecule inhibitors
(Figure 1), including mimics of BH3-only proteins and Bcl-2 antagonists, induce
activation of pro-apoptotic proteins and overcome chemoresistance in cancer cells.
Inhibitors like ABT-263 (Navitoclax) and AT-101, both mimics of the BH3-only domain,
have a broader range of targets binding to both Bcl-2 and Bcl-xL. On the other hand,
inhibitors, like GX15-070 (Obatoclax), are antagonists against only Bcl-2 and lower the
apoptotic threshold in tumor cells already damaged by chemotherapy. Functions of
several Bcl-2 drugs are listed in Table 1 and shown on Figure 3. Please refer to other
outstanding reviews and articles for details (Azmi et al., 2011; Bodur and. Basaga 2012;
Kamal et al., 2014; Bai and Wang 2014).
1.7 ATG PROTEINS IN AUTOPHAGY AND APOPTOSIS
Atgs are regulated in response to the availability of nutrients and growth factors
including amino acids. These signals are generated through a serine/threonine kinase
known as the mammalian/mechanistic target of rapamycin (mTOR) (Kamada et al.,
2004). MTOR is an important negative regulator of autophagy that exists in two distinct
complexes, mTORC1 and mTORC2. MTORC1 is typically active and serves as a
nutrient deprivation sensor. MTORC2 is a regulator of AKT phosphorylation, thus
inhibition of mTORC2 results in G1 cell cycle arrest as a consequence of the inhibition of
AKT phosphorylation (Feldman et al., 2009). Under normal conditions mTOR signaling
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results in the hyper-phosphorylation of several Atgs which leads to inhibition of the
autophagic process. For example, mTOR phosphorylates Atg13 and disrupts its binding
to two orthologs of Atg1, ULK1 and ULK2, which are required for autophagy (Grasso et
al., 2012). ULK1/2 is essential for both the initial construction of the autophagosome as
well as acting as a nutrient sensing center in a complex with Atg13 and Atg17. Atg13 in
conjunction with a second protein, FIP200, is critical for correct localization of ULK1 to
the isolation membrane and for the stability of ULK1 protein. Interestingly, ULK1 also
has bi-functionality that can be unregulated in response to activated p53, resulting in cell
death (Gao et al., 2011).
1.8 P62 IN APOPTOSIS AND AUTOPHAGY
Other proteins can facilitate the targeting of LC3. Initiation signals from
autophagy can recruit p62, a multi-domain ubiquitin-binding, signaling adaptor protein
also known as sequestosome 1 (47). P62 can assemble proteins that have been tagged by
ubiquitin through its polymerization with other p62 molecules. This ability to aggregate
permits p62 clusters to recognize, assemble, and deliver the targeted cargo into the
autophagosomes via binding to LC3. P62 aggregates are often termed speckles due to
their cytosolic visibility and these speckles act as organizing centers where p62 is able to
interact with caspase 8 as well as other factors (Sanz et al., 2000). Inhibition of autophagy
results in larger p62 speckles which appear experimentally to co-localize with poly
ubiquitinated proteins that are normally degraded by autophagy (Komatsu et al., 2007). It
is postulated that in addition to its autophagic role in aggregation p62 functions to
compact toxic proteins (Moscat and Diaz-MecoSee 2009). P62 is also implicated in the
activation of NF-κB, a transcription factor (Baldwin, 2012) that plays an important role in
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the inhibition of apoptosis. These results indicate that p62 plays a role in the apoptosis
pathway as well as in autophagy. Further experiments suggest that p62 is required for the
extrinsic apoptosis pathway in particular for the proper functioning of the death receptors
DR4 and DR5 also needs p62. These data imply that p62 speckles are signaling centers
which determine either cell survival through autophagy, triggering the NF-κB pathway,
or by aggregating caspase-8 to signal the cell to undergo apoptosis.
Research has identified two caspase cleavage sites in Beclin-1 that once cleaved
result in fragments which are unable to induce autophagy. The cleavage site at the cterminus of Beclin 1 sensitizes cells to apoptosis once cleaved was able to induce the
release of proapoptotic factors. These findings point to a mechanism by which caspase dependent generation of a cleaved Beclin-1 enhances apoptosis. In addition, growth
factor withdrawal in a murine pro-B cell line (Ba/F3) results in caspase mediated
cleavage of both Beclin-1 and PI3K (Moscat and Diaz-MecoSee 2009). Finally, research
has shown that increased ApoL6 expression has been shown to induce the degradation of
Beclin 1, which results in p62 accumulation, as well as reducing LC3-II formation and
translocation, ultimately hindering autophagy (Zhaorigetu et al., 2008).
1.9 THE LYSOSOME IN APOPTOSIS AND AUTOPHAGY
The lysosome is one of the required organelles of autophagy, as well as a way to
distinguish three different types of autophagy which are partially defined by the way the
lysosome interact with cargo (Hotchkiss et al., 2009). In general, the term autophagy
typically refers to macroautophagy, where the double membrane autophagosome
envelops its cargo, fuses with lysosomes and forms the autolysosome. Microautophagy
refers to the second mechanism where the lysosome appears to bring cargo in from the
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cytosol. Lastly, chaperone-mediated autophagy utilizes heat shock proteins to deliver
substrates to lysosomes for degradation (Hotchkiss et al., 2009).
The lysosome, a major depot of non-specific hydrolases within the cell, has a
single lipid-bilayer membrane. Changes in lysosomal structure or damage to its
membrane can lead to lysosomal destabilization. Factors including ROS, proteases, p53,
and Bcl-2 family proteins which contribute to the permeabilization of the lysosomal
membrane are similar to those which can affect apoptosis and autophagy. Lysosomal
destabilization or lysosomal membrane permeabilization (LMP) can occur in response to
cell death signals resulting in the leakage or release of the lysosomal cathepsins. The
release of cathepsins regulates apoptosis signaling and LMP can be triggered by a wide
range of apoptotic and autophagic signals including death receptor activation, ER stress,
DNA damage, and growth factor starvation (Boya and Kroemer, 2008; Chwieralski et
al.,2006; Guicciardi et al.,2004; Stoka et al.,2007). The induction of apoptosis can be
dependent on this early release of cathepsins, but it can also occur late in the apoptotic
process and amplify the death signal. The cysteine cathepsins and the aspartic protease
cathepsin D are both very abundant in the lysosome and are involved in apoptosis
signaling (66-69). Excess ROS may destabilize the lysosomal membrane resulting in the
rapid release of cathepsins to the cytosol (Werneburg et al., 2007). Cell death by LMP
has also been linked to the direct activation of caspases by lysosomal proteases (Ishisaka
et al., 1998). In addition, pro-apoptotic Bax relocates to the lysosomes and co-localizes
with Bim suggesting that this localization may result in Bax-mediated LMP and
ultimately apoptosis. Bcl-2 family members may also regulate LMP through the
mitochondria (Yuan et al., 2002). There is also evidence that LMP may occur in p53-
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induced apoptosis where p53 actually localizes to the lysosomes and triggers LMP (Li et
al., 2007). It may also upregulate LMP and Bax-mediated mitochondrial permeabilization
without translocating to the lysosome but rather through the upregulation of the gene p53
up-regulated modulator of apoptosis (PUMA) and Noxa (Oda et al., 2000; Yu et al.,
2001; Nakano and Vousden, 2001). Noxa encodes a Bcl-2 homology 3 (BH3)-only
member of the Bcl-2 family of proteins. When ectopically expressed, Noxa localizes to
the mitochondria where it interacts with and suppresses the anti-apoptotic Bcl-2 family
members and also results in the activation of caspase-9.
Following the activation of apoptosis, another protein called lysosome associated
apoptosis inducing protein (LAPF) associates with lysosomes and is essential for DNA
damage induced LMP (Li et al., 2007, Chen et al., 2005). Downregulation of either p53
or LAPF prevents the induction of LMP (48). LMP may also occur during other types of
cell death, including autophagic cell death (Kroemer et al., 2005). Transcriptional
analysis has established common binding sites both in autophagy and on lysosomal genes
showing an additional association (46). ApoL1 localizes in the cytosol and lysosomes
suggesting that ApoL1 regulated autophagy, may involve the lysosomes (Zhaorigetu et
al., 2008). The lysosome is an extremely important structure in both homeostasis and cell
death.
Targeting the lysosome by chemical inhibitors is typically accomplished using
lysosomotropic agents. It is well known that intermittent use of the lysosomotropic weak
bases like chloroquine or hydroxychloroquine can prevent cancer in mouse models. This
data suggests that chemicals which target the lysosome may be effective in cancer
prevention. Chloroquine, a weak base, functions through its preferential accumulation in
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the lysosome where it becomes protonated and cannot diffuse out (Maclean et al., 2008).
This accumulation results in the inactivation of lysosomal hydrolases, including
cathepsins, which are necessary for lysosomal degradation.
Other drugs which target the lysosome include the macrolide antibiotic
bafilomycins, particularly bafilomycin A1 (Baf-A1). This antibiotic derived from
Streptomyces griseus is a specific inhibitor of vacuolar-type H+ ATPases (V-ATPase)
and prevents maturation of autophagic vacuoles by preventing the fusion between
autophagosomes and lysosomes (Yamamoto et al., 1989). Cancer cells overexpress VATPase when compared to non-tumorigenic cells, and may be more sensitive to
treatment with Baf-A1 or concanamycin A (ConA), another potent V-ATPase inhibitor
(Figure 2; Morimura et al., 2008; Huss et al., 2002). Interestingly, am emerging drug,
Concanavalin A (ConVA), induces lysosome- and mitochondria-mediated apoptosis.
ConVA is a lectin or carbohydrate-binding protein which binds mannose displayed on
cell surfaces. ConVA is then internalized preferentially to the mitochondria, although
some endocytosed ConVA will accumulate in the lysosome and also changes the
membrane permeability on the mitochondria and initiates apoptosis. Many tumors have
increased expression of lectins on their plasma membrane, therefore ConVA
preferentially binds to tumor cells (Alonso et al., 2006). Thus, through the identification
of small molecules or chemical inhibitors that induce lysosomal permeabilization or
increase lysosomal facilitated autophagy–associated cell death, targeting the lysosome
may prove to be an effective strategy for treatment of cancer (Fehrenbacher and Jäättelä,
2005; Figure 2; Table 1).
1.10 PUMA IN APOPTOSIS AND AUTOPHAGY
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PUMA, which is a BH3-only protein (Nakano and Vousden, 2001), has an
expression pattern consistent with a causative role in p53-dependent apoptosis. PUMA is
a pro-apoptotic protein and rapidly induces apoptosis through a Bax- and mitochondriadependent pathway (Han et al., 2001). PUMA can be directly activated p53 through p53responsive elements in its promoter region and can also be induced by the
chemotherapeutic (e.g., Adriamycin/doxorubicin) in a p53-dependent fashion (Yu et al.,
2003). Protein isoforms encoded by PUMA have also been shown to localize in the
mitochondria where they interact with Bcl-2 and Bcl-xL via the BH3 domain (Yu et al.,
2003). Structural analysis has shown that PUMA directly binds to these anti-apoptotic
Bcl-2 family proteins (Day et al., 2008) and is essential for apoptosis induced by both
exogenous and endogenous p53. In cancer cell lines PUMA has been shown to dissociate
Bax and Bcl-xL to induce apoptosis (Ming et al., 2006). Following chemicals and/or
genotoxic-induced DNA damage (Yu and Zhang, 2008), both p53 and PUMA are
activated. Independent of p53, PUMA expression can also be induced by oncogenic stress
(Fernandez et al., 2003; Maclean et al., 2003), growth factor withdrawal, inhibition of
kinases including FOXO (Han et al., 2001, Maclean et al., 2003, You et al., 2006), ER
stress and altered redox (Reimertz et al., 2003;, Ward et al., 2004), as well as infection
(Castedo et al., 2004) all resulting in apoptosis upregulation. It have been shown that
nuclear factor-kB (NF-kB) can assist in p53-dependent PUMA induction through
recruitment to the PUMA promoter during response to DNA damage (Yu and Zhang,
2008). Additionally, many tumors possess p53 mutations (Vogelstein and Kinzler, 2004)
which prevent PUMA induction during DNA damage response (Yu and Zhang, 2005).
PUMA induces apoptosis through the generation of both superoxide and hydrogen
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peroxide in a Bax-dependent manner. Mitochondrial translocation and multimerization of
Bax is a critical event in mitochondrial-mediated apoptosis (Nakano and Vousden, 2001).
Interestingly, hypoxia results in metabolic changes which induce p53 to transcriptionally
activate genes including PUMA. After its activation, PUMA will interact with all the
anti-apoptotic Bcl-2 family members, releasing Bax or Bak which induce apoptosis in the
mitochondria (Yu and Zhang, 2008). The induction of PUMA causes Bax to form
multimers resulting in mitochondrial dependent cell death. PUMA has recently been
shown to induce autophagy which appears to lead to targeting of the mitochondria for
removal by autophagy, or mitophagy (Yee et al., 2009), mediated through Bax and Bak.
This is interesting since PUMA also induces apoptosis in a Bax-dependent manner (Yu et
al., 2003). In addition, the inhibition of PUMA- or of Bax-induced autophagy results in a
reduction in apoptosis suggesting that targeting mitophagy could enhance apoptosis.
Because of its role in both apoptosis and autophagy, PUMA is extremely interesting and
may provide a vital link in the communication between these two programmed cell death
pathways.
1.11 INHIBITORS OF APOPTOSIS (IAPS)
Inhibitor of apoptosis proteins (IAPs) are a family of anti-apoptotic proteins that
promote cancer cell survival. IAPs exert a range of biological activities that promote cell
survival and proliferation. X chromosome-linked IAP (XIAP) is a direct inhibitor of
caspases whereas cellular IAPs block the assembly of pro-apoptotic protein signaling
complexes and mediate the expression of anti-apoptotic molecules. In general, expression
and function of IAPs are deregulated in human cancer cells due to genetic aberrations,
increase of their mRNA or protein expression levels, or loss of endogenous inhibitors,
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such as second mitochondria-derived activator of caspase (SMAC). As IAPs are
expressed at high levels in various types of cancer and have been linked to tumor
progression, treatment failure and poor prognosis, IAPs are promising targets for cancer
therapeutic intervention (Stern et al., 2012). Several therapeutic targeting strategies that
have been designed to target IAPs thus far, such as small-molecule IAP antagonists and
antisense oligonucleotides. Among them, the most common approach is based on
mimicking the IAP-binding motif of SMAC, an endogenous IAP antagonist. These
antagonists include AT-406, and YM155. It has been shown that AT-406 selectively
inhibits the activity of XIAP, cellular IAPs 1 (c-IAP1) and 2 (c-IAP2), and melanoma
inhibitor of apoptosis protein (ML-IAP). This inhibition results in the promotion of
apoptosis (Brunckhorst et al., 2012). AEG35156, a XIAP antisense oligonucleotide, has
been shown to sensitize malignant cells to chemotherapies both in vitro and murine in
vivo models (Schimmer et al., 2009) (Table 1). Preclinical studies have indicated that the
therapeutic potential of IAP antagonists might best be exploited in combination protocols,
including conventional chemotherapeutic drugs, signal transduction modulators, death
receptor agonists or radiation therapy (Fulda and Vucic, 2012).
In conclusion, the environment encountered by tumor cells requires adaption to
low blood supply, low nutrients, and hypoxic conditions that contributes to the cell’s
avoidance of multiple cell death pathways. The loss of homeostasis between apoptosis
and autophagy has been postulated as both a causative factor in tumorigenesis as well as
an area for therapeutic intervention. In general, the autophagic survival mechanism
blocks apoptosis in most cancer types (Stern et al., 2012; Rubinsztein et al. 2012; Yao et
al., 2011; Harhaji-Trajkovic et al., 2012). In designing therapies to eliminate cancer cells,
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specifically through apoptosis rather than necrosis, one might consider (a). targeting the
activation of the cytosolic pro-apoptotic p53 interactome as well as inactivating the proautophagic p53 interactome; (b). inducing degradation of Beclin 1 and Atg5 for the
generation of pro-apoptotic form of Beclin 1-C and Atg5N; (c). mobilization of Bcl-2 and
Bcl-xL from Bax/Bak interactome to Beclin 1 interactome; and (d). activation of PUMA,
ApoL6, or ApoL1 in a cancer cell specific manner.

Thus, the crosstalk between

apoptosis and autophagy remains a highly investigated and promising area for the
identification of novel therapeutics and research into the interactions which maintain
molecular homeostasis between these two death pathways will continue to further our
understanding of the dynamics between cell death and cancer etiology.
1.12 ABBREVIATIONS:
ApoL1, Apolipoprotein L1; ApoL6, Apolipoprotein L6; AMPK, AMP-activated protein kinase;
Apaf-1, apoptotic proteinase-activating factor-1; Atg, Autophagy-related gene; BAD, Bcl-2associated death promoter; Bcl-2, B-cell lymphoma 2; Beclin 1, Bcl-2 interacting protein 1; BH3,
Bcl-2-homology-3 domain; BH, Bcl-2 homology; BID, BH3 interacting-domain death agonist;
DISC, death-inducing signaling complex; DR5, the death domain receptor; DRAM, damageregulated modulator of autophagy; FADD, FAS-associated death domain protein; FLICE, FADDlike IL-1 β-converting enzyme; FIP200，focal adhesion kinase -interacting protein FIP 200
fragment; HDAC, histone deacetylase; IAPs, inhibitors of apoptosis proteins; JNK, c-Jun Nterminal kinase; LC3, microtubule-associated protein 1 light chain 3; MAPK, mitogen-activated
protein kinase; MOMP, mitochondrial outer membrane permeabilization; mTOR, mammalian
(mechanistic) target of rapamycin; PA, phosphatidic acid; PCD, programmed cell death; PE,
phosphatidylethanolamine; PI3K, phosphoinositide 3-kinase; ROS, reactive oxygen species;
SMAC, second mitochondrial-derived activator of caspase; TNF-α, tumor necrosis factor-α;
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TRAIL, tumor necrosis factor-related apoptosis inducing ligand; TSC1/2; tuberous sclerosis
complex1/2; ULK1, unc-51-like kinase 1; TNFR1 tumor necrosis factor receptor 1; Vps34,
vacuolar protein sorting-34.

1.13 ACKNOWLEDGEMENTS
This work was supported by the pilot projects (#030-2and #0224 to CAAH and LS) of
UNM CTSC grant (8UL1TR000041), and the Ellen B. King Fund, the University Of
New Mexico School Of Medicine Research Allocation Committee Grant and the
National Institute of General Medical Sciences (1K12GM088021to ST). The authors
extend appreciation to The Molecular Epidemiology Core laboratory and the Molecular
Epidemiology and Bioinformatics Working Group for assistance with preparation of this
manuscript.
1.14 REFERENCES:
Alonso, E., Gómez, L., Madrid, J.F., and Sáez, F.J. 2006. Identification of mannose
moieties in N- and O-linked oligosaccharides of the primordial germ cells of Xenopus
embryos. Microsc. Res. Tech. 69: 595–599.
Amar, N., Lustig, G., Ichimura, Y., Ohsumi, Y., and Elazar, Z. 2006. Two newly
identified sites in the ubiquitin-like protein Atg8 are essential for autophagy. EMBO
Reports 7: 635–642.
Azmi, A.S., Wang, Z., Philip, P.A., Mohammad, R.M. and Sarkar, F.H. 2011. Emerging
Bcl-2 inhibitors for the treatment of cancer. Expert Opin. Emerg. Drugs 16:59-70.
Bai, L., and Wang, S., 2014. Targeting apoptosis pathways for new cancer therapeutics.
Annu. Rev. Med. 65:139-155.

25

Baldwin, A.S. 2012. Regulation of cell death and autophagy by IKK and NF-κB: critical
mechanisms in immune function and cancer. Immunol. Rev. 246:327-345.
Bazzoni, F., and Beutler, B., 1996. The tumor necrosis factor ligand and receptor
families. New Engl. J. Med. 334:1717-1725.
Betin, V.M., and Lane, J.D., 2009. Atg4D at the interface between autophagy and
apoptosis. Autophagy 5:1057-1059.
Bjorkoy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Overvatn, A., Stenmark,
H., and Johansen,T. 2005. p62/SQSTM1 forms protein aggregates degraded by
autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol.
171:603–614.
Bodur, C., and Basaga, H. 2012. Bcl-2 inhibitors: emerging drugs in cancer therapy.
Curr. Med. Chem. 19:1804-1820.
Boya, P., and Kroemer, G. 2008. Lysosomal membrane permeabilization in cell death.
Oncogene 27:6434–6451.
Brunckhorst, M.K., Lerner, D., Wang, S., and Yu, Q. 2012. AT-406, an orally active
antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human
ovarian cancer. Cancer Biol. Ther. 13:804-811.
Castedo, M., Perfettini, J.L., Piacentini, M., and Kroemer, G. 2005. p53-A pro-apoptotic
signal transducer involved in AIDS. Biochem. Biophys. Res. Commun. 331: 701–706.
2005. The lysosome-associated apoptosis-inducing protein containing the pleckstrin
homolog PH and FYVE domains LAPF, representative of a novel family of PH and
FYVE domain-containing proteins, induces caspase-independent apoptosis via the
lysosomal-mitochondrial pathway. J. Biol. Chem. 280: 40985–40995.

26

Chwieralski, C.E., Welte, T., and Bühling, F. 2006. Cathepsin-regulated apoptosis.
Apoptosis 11:143–149.
Coleman, M.L., Sahai, E.A., Yeo, M., Bosch, M., Dewar, A., and Olson, M.F. 2001.
Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK
I. Nat. Cell Biol. 3:339-345.
Day, C.L., Smits, C., Fan, F.C., Lee, E.F., Fairlie, W.D., and Hinds, M.G. 2008. Structure
of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in
complex with Mcl-1. J. Mol. Biol.380:958–971.
Elmore, S. 2007. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35:
495-516.
Facchinetti, M.M., De Siervi, A., Toskos, D., and Senderowicz, A.M. 2004. UCN-01induced cell cycle arrest requires the transcriptional induction of p21waf1/cip1 by
activation of mitogen-activated protein/extracellular signal-regulated kinase
kinase/extracellular

signal-regulated kinase pathway. Cancer Res. 64:3629-3637.

Fan, Y.J., and Zong, W.X. 2013. The cellular decision between apoptosis and autophagy.
Chin. J. Cancer. 323: 121–129.
Feldman, M.E., Apsel, B., Uotila, A., Loewith, R., Knight, Z.A., Ruggero, D., and
Shokat, K.M. 2009. Active-Site Inhibitors of mTOR Target Rapamycin-Resistant
Outputs of mTORC1 and mTORC2. PLoS Biol. 7:e38.
Fehrenbacher, N., and Jäättelä, M. 2005. Lysosomes as Targets for Cancer Therapy.
Cancer Res. 65: 2993-2995.

27

Fernandez, P.C., Frank, S.R., Wang, L., Schroeder, M., Liu, S., Greene, J., Cocito, A.,
and Amati, B. 2003. Genomic targets of the human c-Myc protein. Genes Dev. 17:1115–
1129.
Fridman, J.S., and Lowe, S.W. 2003. Control of apoptosis by p53. Oncogene 22: 9030–
9040.
Fulda, S., and Vucic, D. 2012. Targeting IAP proteins for therapeutic intervention in
cancer. Nat.Rev. Drug Discov. 11:109-124.
Gao W., Shen, Z., Shang, L. and Wang, X. 2011. Upregulation of human autophagy
initiation kinase ULK1 by tumor suppressor p53 contributes to DNA damage induced cell
death. Cell Death Differ. 18:1598-1607.
Grasso, D., Garcia, MN., and Iovanna, J.L. 2012. Autophagy in Pancreatic Cancer. Int J
Cell Biol. 760498, 7 pages.
Guicciardi, M.E., Leist, M., and Gores, G.J. 2004. Lysosomes in cell death. Oncogene
23:2881–2890.
Gukovsky, I., Li, N., Todoric, J., Gukovskaya, A., and Karin, M. 2013. Inflammation,
autophagy, and obesity: common features in the pathogenesis of pancreatitis and
pancreatic cancer. Gastroenterology 144:1199-1209.
Han, J., Flemington, C., Houghton, A.B., Gu, Z., Zambetti, G.P., Lutz, R.J., Zhu, L., and
Chittenden, T. 2001. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by
diverse cell death and survival signals. Proc. Natl. Acad. Sci. USA 98: 11318–11323.
Harhaji-Trajkovic, L., Arsikin, K., Kravic-Stevovic, T., Petricevic, S., Tovilovic, G.,
Pantovic, A., Zogovic, N., Ristic, B., Janjetovic, K., Bumbasirevic, V., and Trajkovic, V.

28

2012. Chloroquine-mediated lysosomal dysfunction enhances the anticancer effect of
nutrient deprivation. Pharm. Res. 29:2249-2263.
Haupt, S., Berger, M., Goldberg, Z., and Haupt, Y. 2003. Apoptosis – the p53 network. J.
Cell Sci. 116:4077-4085.
Hippert, M.M., O'Toole, P.S., and Thorburn, A. 2006. Autophagy in Cancer: Good, Bad,
or Both? Cancer Res. 66: 9349-9951.
Hotchkiss, R.S., Strasser, A., McDunn, J.E., and Swanson, P.E. 2009. Cell Death. N
Engl. J. Med. 361:1570-1583.
Huss, M., Ingenhors, G., Konig, S., Gaßel, M., Drose, S., Zeeck, A., Altendorf, K., and
Wieczorek, H. 2002. Concanamycin A, the Specific Inhibitor of V-ATPases, Binds to the
Vo Subunit c. J. Biol. Chem. 277:40544–40548.
Ichimura, Y., Kirisako, T., Takao, T., Satomi, Y., Shimonishi, Y., Ishihara, N.,
Mizushima, N., Tanida, I., Kominami, E., Ohsumi, M., Noda, T., and Ohsumi, Y. 2000.
A ubiquitin-like

system mediates protein lipidation. Nature 408: 488–492.

Ishisaka, R., Utsumi, T., Yabuki, M., Kanno, T., Furuno, T., Inoue, M., and Utsumi, K.
1998. Activation of caspase-3-like protease by digitonin-treated lysosomes. FEBS.
Letters 435:233–236.
Jegga, A.G., Schneider, L., Ouyang, X., and Zhang J. 2011. Systems biology of the
autophagy-lysosomal pathway. Autophagy 5:477-89.
Kaini, R.R., Sillerud, L.O., Zhaorigetu, S., and Hu, C.A. 2012. Autophagy regulates
lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate
cancer cells. Prostate 72:1412-1422.

29

Kamada, Y., Sekito, T., and Ohsumi, Y. 2004. Autophagy in yeast: a TOR-mediated
response to nutrient starvation. Curr. Top. Microbiol. Immunol. 279: 73–84.
Kamal, A., Faazil, S., and Malik, M.S. 2014. Apoptosis-inducing agents: a patent review
2010 - 2013. Expert Opin. Ther. Pat. 24:339-354.
Kang, R., and Tang, D. 2012. Autophagy in pancreatic cancer pathogenesis and
treatment. Am. J. Cancer Res. 2: 383–396.
Kirisako, T., Baba, M., Ishihara, N., Miyazawa, K., Ohsumi, M., Yoshimori, T., Noda T.,
and Ohsumi, Y. 1999. Formation Process of Autophagosome Is Traced with Apg8/Aut7p
in Yeast. J. of Cell Biol. 147:435–446.
Komatsu, M., Waguri, S., Koike, M., Sou, Y.S., Ueno, T., Hara, T., Mizushima, N.,
Iwata, J., Ezaki, J., Murata, S., Hamazaki, J., Nishito, Y., Iemura, S., Natsume, T.,
Yanagawa, T., Uwayama, J., Warabi, E., Yoshida, H., Ishii, T., Kobayashi, A.,
Yamamoto, M., Yue, Z., Uchiyama, Y., Kominami, E., and Tanaka, K. 2007.
Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagydeficient mice. Cell 131:1149–1163.
Kroemer, G., and Jaattela, M. 2005. Lysosomes and autophagy in cell death control. Nat.
Rev. Cancer. 5:886–897.
Lazova, R., Klump, V., and Pawelek, J. 2010. Autophagy in cutaneous malignant
melanoma. J. Cutan. Pathol. 37: 256–268.
Li, M.O., Sarkisian, M.R., Mehal, W.Z., Rakic, P., and Flavell, R.A. 2003.
Phosphatidylserine receptor is required for clearance of apoptotic cells. Science
302:1560–1563.

30

Li, N., Zheng, Y., Chen, W., Wang, C., Liu, X., He, W., Xu, H., and Cao, X. 2007.
Adaptor protein LAPF recruits phosphorylated p53 to lysosomes and triggers lysosomal
destabilization in apoptosis. Cancer Res. 67:11176–11185.
Liu, Z., Lu, H., Jiang, Z., Pastuszyn, A., and Hu, C.A. 2005. Apolipoprotein L6, a novel
proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in
cancer cells. Mol. Cancer Res. 3:21-31.
Maclean, K.H., Dorsey, F.C., Cleveland, J.L. and Kastan, M.B. 2008. Targeting
lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse
models of lymphomagenesis. J. Clin. Invest. 118:79-88.
Maclean, K.H., Keller, U.B., Rodriguez-Galindo, C., Nilsson, J.A., and Cleveland, JL.
2003. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL.
Mol. Cell Biol. 23:7256–7270.
Ming, L., Wang, P., Bank, A., Yu, J., and Zhang, L. 2006. PUMA Dissociates Bax and
Bcl-XL to Induce Apoptosis in Colon Cancer Cells. The J. Biol. Chem. 281:16034–
16042.
Mirza, A., McGuirk, M., Hockenberry, T.N., Wu, Q., Ashar, H., Black, S., Wen, S.F.,
Wang, L., Kirschmeier, P., Bishop, W.R., Nielsen, L.L., Pickett, C.B., and Liu, S. 2002.
Human survivin is negatively regulated by wild-type p53 and participates in p53dependent

apoptotic pathway, Oncogene 21: 2613-2622.

Mizushima, N. 2007. Autophagy: process and function. Genes Dev. 21: 2861-2873
Mizushima, N., Ohsumi, Y., and Yoshimori, T. 2002. Autophagosome Formation in
Mammalian Cells. Cell Struct. Funct. 27: 421-429.

31

Mizushima, N., Yoshimorim, T., and Levine, B. 2010. Methods in Mammalian
Autophagy Research. Cell 140: 313–326.
Morimura, T., Fujita, K., Akita, M., Nagashima, M., and Satomi, A. 2008. The proton
pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma.
Pediatr. Surg. Int. 24:1087-1094.
Moscat, J., and Diaz-MecoSee, M.T. 2009. p62 at the Crossroads of Autophagy,
Apoptosis, and Cancer. Cell 137: 1001-1004.
Mujumdar, N., and Saluja, AK. 2010. Autophagy in pancreatic cancer: An emerging
mechanism of cell death. Autophagy 6:997-998.
Nakano, K., and Vousden, K.H. 2001. PUMA, a novel proapoptotic gene, is induced by
p53. Mol Cell. 7: 683–694.
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T.,
Taniguchi, T., and Tanaka, N. 2000. Noxa, a BH3-only member of the Bcl-2 family and
candidate mediator of p53-induced apoptosis. Science 288:1053–1058.
Pattingre, S., Tassa, A., Qu, X., Garuti, R., Liang, X.H., Mizushima, N., Packer, M.,
Schneider, M.D., Levine, B. 2005. Bcl-2 antiapoptotic proteins inhibit Beclin 1dependent autophagy. Cell 122:927-939.
Prabhudesai, S.G., Rekhraj, S., Roberts, G., Darzi, A.W., Ziprin, P. 2007. Apoptosis and
chemo-resistance in colorectal cancer. J. Surg. Oncol. 96:77–88.
Reimertz, C., Kögel, D., Rami, A., Chittenden, T., and Prehn, J.H. 2003. Gene expression
during ER stress-induced apoptosis in neurons: induction of the BH3-only protein
Bbc3/PUMA and activation of the mitochondrial apoptosis pathway. J Cell Biol.
162:587–597.

32

Rikiishi, H. 2012. Novel Insights into the Interplay between Apoptosis and Autophagy.
Int. J. Cell Biol. 2012:317645.
Roh, J.L., Ko, J.H., Moon, S.J., Ryu, C.H., Choi, J.Y., and Koch, W.M. 2010. The p53reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis
in head and neck cancer. Cancer Lett. 325:35-41.
Rubinsztein, D.C., Codogno, P., and Levine, B. 2012. Autophagy modulation as a
potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 119: 709–730.
Ruvolo, P.P., Deng, X., and May, W.S. 2001. Phosphorylation of Bcl2 and regulation of
apoptosis. Leukemia 15:515-522.
Sahu, R., Kaushik, S., Clement, C.C., Cannizzo, E.S., Scharf, B., Follenzi, A.,
Potolicchio, I., Nieves, E., Cuervo, A.M., and Santambrogio, L. 2011. Microautophagy
of cytosolic proteins by late endosomes. Dev. Cell. 20:131-139.
Sanz, L., Diaz-MecoSee, M.T., Nakano, H., and Moscat, J. 2000. The atypical PKCinteracting protein p62 channels NF-κB activation by the IL-1–TRAF6 pathway. EMBO.
Journal 19:1576–1586.
Sato, K., Tsuchihara, K., Fujii, S., Sugiyama, M., Goya, T., Atomi, Y., Ueno, T., Ochiai,
A., and Esumi, H. 2007. Autophagy is activated in colorectal cancer cells and contributes
to the tolerance to nutrient deprivation. Cancer Res. 67:9677-9684.
Scherz-Shouval, R., Weidberg, H., Gonen, C., Wilder, S., Elazar, Z., and Oren, M. 2010.
p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under
prolonged starvation. Proc. Natl. Acad. Sci. USA. 107:18511-18516.
Schimmer, A.D., Estey, E.H., Borthakur, G., Carter, B.Z., Schiller, G.J., Tallman, M.S.,
Altman, J.K., Karp, J.E., Kassis, J., Hedley, D.W., Brandwein, J., Xu, W., Mak, D.H.,

33

LaCasse, E., Jacob, C., Morris, S.J., Jolivet, J., and Andreeff, M. 2009. Phase I/II trial of
AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined
with idarubicin and cytarabine in patients with relapsed or primary refractory acute
myeloid leukemia. J. Clin. Oncol. 27:4741-4746.
Schmid, D., and Münz, C. 2007. Innate and adaptive immunity through autophagy.
Immunity 27:11–21.
Selvakumaran, M., Amaravadi, R., Vasilevskaya, I.A., and O'Dwyer, P.J. 2013.
Autophagy Inhibition Sensitizes Colon Cancer Cells to Anti-angiogenic and Cytotoxic
Therapy. Clin. Cancer Res. 19:2995-3007.
Shintani, T., and Klionsky, D.J. 2004. Autophagy in health and disease: a double-edged
sword. Science 306:990-995.
Sionov, R.V., and Haupt, Y. 1999. The cellular response to p53: the decision between life
and death. Oncogene 18:6145-6157.
Sprick, M.R., Weigand, M.A., Rieser, E., Rauch, C.T., Juo, P., Blenis, J., Krammer, P.H.,
and Walczak, H. 2000. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1
and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12:599–
609.
Stern, S.T., Adiseshaiah, P.P., and Crist, R.M. 2012. Autophagy and lysosomal
dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol. 9:20.
Stoka, V., Turk, V., and Turk, B. 2007. Lysosomal cysteine cathepsins: signaling
pathways in apoptosis. Biol. Chem. 388:555–560.

34

Sugawara, K., Suzuki, N.N., Fujioka, Y., Mizushima, N., Ohsumi, Y., and Inagaki, F.
2004. The crystal structure of microtubule-associated protein light chain 3, a mammalian
homologue of Saccharomyces cerevisiae Atg8. Genes Cells. 9:611–618.
Suzuki, N.N., Yoshimoto, K., Fujioka, Y., Ohsumi, Y., and Inagak,i F. 2005. The crystal
structure of plant ATG12 and its biological implication in autophagy. Autophagy 1:119–
126.
Tasdemir, E., Maiuri, M.C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M., D’Amelio,
M., Criollo, A., Morselli, E., Zhu, C., Harper, F., Nannmark, U., Samara, C., Pinton, P.,
Vicencio, J.M., Carnuccio, R., Moll, U.M., Madeo, F., Paterlini-Brechot, P., Rizzuto, R.,
Szabadkai, G., Pierron, G., Blomgren, K., Tavernarakis, N., Codogno, P., Cecconi, F.,
and Kroemer, G. 2008. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol.
10:676-687.
Tasdemir, E., Maiuri, M.C., Morselli, E., Criollo, A., D'Amelio, M., Djavaheri-Mergny,
M., Cecconi, F., Tavernarakis, N., and Kroemer, G. 2008. A dual role of p53 in the
control of autophagy. Autophagy 4:810-814.
Tuffy, L.P., Concannon, C.G., D’Orsi, B., King, M.A., Woods, I., Huber, H.J., Ward,
M.W., and Prehn, J.H.M. 2010. Characterization of Puma-Dependent and PumaIndependent Neuronal Cell Death Pathways following Prolonged Proteasomal Inhibition.
Mol. Cell Biol. 30:5484-5501.
Vogelstein, B., and Kinzler, KW. 2004. Cancer genes and the pathways they control. Nat
Med. 10:789–799.
Wang, Z., and Sun, Y. 2010. Targeting p53 for Novel Anticancer Therapy. Transl. Oncol.
3:1–12.

35

Ward, M.W., Kögel, D., and Prehn, J.H. 2004. Neuronal apoptosis: BH3-only proteins
the real killers? J. Bioenerg. Biomembr. 36: 295–298.
Wei, Y., Pattingre, S., Sinha, S., Bassik, M., and Levine, B. 2008 JNK1-Mediated
Phosphorylation of Bcl-2 Regulates Starvation-Induced Autophagy. Mol Cell. 30:678688.
Werneburg, N.W., Guicciardi, M.E., Bronk, S.F., Kaufmann, S.H., and Gores, G.J. 2007.
Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of
apoptosis that is regulated by Bcl-2 proteins. J. Biol. Chem. 282: 28960–28970.
Wu, GS., Burns, T.F., McDonald, E.R. 3rd, Jiang, W., Meng, R., Krantz, I.D., Kao, G.,
Gan, D.D., Zhou, J.Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu,
G., and el-Deiry, W.S. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated
death receptor gene. Nat. Genet. 17:141-143.
Xie, X., White, E.P., and Mehnert, J.M. 2013. Coordinate Autophagy and mTOR
Pathway Inhibition Enhances Cell Death in Melanoma. PLoS ONE 8: e55096.
Yamamoto, A., Tagawa, Y., Yoshimori, T., Moriyama, Y., Masaki, R., and Tashiro, Y.
1998. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion
between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell.
Struct. Funct. 23:33-42.
Yao, J.C., Shah, M.H., Ito, T., Bohas, C.L., Wolin. E.M., Van Cutsem, E., Hobday, T.J.,
Okusaka, T., Capdevila, J., de Vries, E.G., Tomassetti, P., Pavel, M.E., Lincy, J.,
Lebwohl, D., and Öberg, K. 2011. Everolimus for advanced pancreatic neuroendocrine
tumors. N. Engl. J. Med. 364: 514–523.

36

Yee, K.S., Wilkinson, S., James, J., Ryan, K.M., and Vousden, K.H. 2009. PUMA- and
Bax-induced autophagy contributes to apoptosis. Cell Death Differ. 16:1135–1145.
You, H., Pellegrini, M., Tsuchihara, K., Yamamoto, K., Hacker, G., Erlacher, M.,
Villunger, A., and Mak, T.W. 2006. FOXO3a-dependent regulation of Puma in response
to cytokine/growth factor withdrawal. J. Exp. Med. 203:1657–1663.
Yu, J., Wang, Z., Kinzler, K.W., Vogelstein, B., and Zhang, L. 2003. PUMA mediates
the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. USA.
100:1931–1936.
Yu, J., and Zhang, L. 2005. The transcriptional targets of p53 in apoptosis control.
Biochem Biophys. Res. Commun. 331: 851–858.
Yu, J., and Zhang, L. 2008. PUMA, a potent killer with or without p53. Oncogene
27:S71-83.
Yu, J., Zhang, L., Hwang, P.M., Kinzler, KW., and Vogelstein, B. 2001. PUMA induces
the rapid apoptosis of colorectal cancer cells. Mol. Cell. 7:673–682.
Yuan, XM., Li, W., Dalen, H., Lotem, J., Kama, R., Sachs, L., and Brunk, UT. 2002.
Lysosomal destabilization in p53-induced apoptosis. Proc. Natl. Acad. Sci. USA. 99:
6286–6291.
Zhaorigetu, S., Wan, G., Kaini, R., Jiang, Z., and Hu, C.A.A. 2008. ApoL1, a BH3-only
lipid-binding protein, induces autophagic cell death. Autophagy 4:1079–1082.
Zhaorigetu, S., Yang, Z., Toma, I., McCaffrey, T.A., and Hu, C.A.A. 2011.
Apolipoprotein L6, Induced in Atherosclerotic Lesions, Promotes Apoptosis and Blocks
Beclin 1-dependent Autophagy in Atherosclerotic Cells. J. Biol. Chem. 286: 27389–
27398.

37

Zou, H., Henzel, W.J., Liu, X., Lutschg, A., and Wang, X. 1997. Apaf-1, a human protein
homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of
caspase-3. Cell 90: 405–413.

38

1.15 Chapter Table and Figures.
1.15.1 Table 1: Inhibitors of Therapeutic Targets in Autophagy and Apoptosis
Inhibitors of autolysosome
formation
Compound:
(Hydroxy) Chloroquine
Bafilomycin A1
Concanavalin A
Concanamycin A
Inhibitors of caspase inhibitors

Mechanism of Action
Lysosomotropic drug
Specific inhibitor of vacuolar H+ ATPase (VATPase)
Apoptosis induction/immunomodulating
activity
Specific inhibitor of V-ATPase

AT- 406
AEG35156
YM155

A Smac mimetic and an antagonist of the
inhibitor of apoptosis proteins (IAPs)
An antisense oligo of XIAP
Inhibits Survivin promoter activity

Inhibitors of Bcl-2
Obatoclax (GX15-070)
ABT-263 (Navitoclax)
AT101

Antagonist of Bcl-2
Potent inhibitor of Bcl-xL and Bcl-2
Binds with Bcl-2, Bcl-xL
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1.15.2 Figure 1. Apoptosis (the Yin)

Apoptosis is an ATP-dependent, multi-step process which occurs in response to both
internal (intrinsic) and external (extrinsic) signals and as part of normal cell development
and homeostasis. The intrinsic apoptotic signaling pathway is dependent on the formation
of the apoptosome, an interactome of apoptotic protease activating factor 1 (Apaf-1),
(pro-) caspase 9, cytochrome C and (d) ATP. The extrinsic pathway utilizes
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transmembrane death receptors (FasR, TNFR1, DR3, and DR4/DR5) (6), and their
corresponding ligands (FasL, TNF-α, Apo3L, and Apo2L). Apoptosis takes place in four
sequential stages: stimulus, signaling, regulation, and execution. Stimulus occurs in
response to ligand-receptor interaction (extrinsic) or intracellular stress (intrinsic).
Subsequently, regulatory proteins (p53, Bcl-2, IAPs) and apoptosomes fine tune this
dynamic process. A group of caspases are then activated and used for cleaving proteins
critical to cell survival and proliferation.
1.15.3 Figure 2. Autophagy (the Yang), Conjugation Pathways.

Autophagy uses two conjugation systems similar to the ubiquitin targeting system. The
process of attaching LC3 to the membrane is accomplished through LC3 cleavage,
lipidation and translocation. The LC3 designation is modified once cleavage has occurred
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as well as when the protein is localized to the membrane. Under this nomenclature LC3-I
refers to cytosolic localization following cleavage and LC3-II refers to a membrane
bound LC3. During the elongation of the isolation membrane, the Atg5-Atg12-Atg16L
complex localizes to the membrane to form a cup-shaped structure. LC3-II then localizes
to the isolation membrane, while the Atg5-Atg12-Atg16L complex dissociates.
1.15.4 Figure 3. Autophagy (the Yang), Autophagic flux.

Autophagy has three major phases: initiation, elongation and completion.

Initiation

involves the formation of a double membrane structure (autophagosome). The formation
of this double membrane structure is a complex process involving many Atg proteins.
LC3 is required for the formation of autophagosomal membranes. LC3 is recruited to the
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isolation membrane, which ultimately develops into the autophagosome where cellular
targets are sequestered in preparation for degradation. LC3 is the only protein that
remains associated with the completed autophagosome. The autophagosome then fuses
with endosomes/lysosomes to create the autolysosome where cellular targets are
degraded. Following autolysosomal formation, the lysosomal hydrolases, including
cathepsins, degrade the targeted proteins, while the cathepsins degrade LC3-II on the
inner autophagosomal surface. Following target degradation, Atg4 is involved in
separating outer membrane LC3-II from the autophagosome, although LC3-II is still
present in late autophagic vesicles. Crosstalk between the regulatory proteins, such as
ApoL6, ApoL1, and DRAM, can dictate the outcome of autophagic flux.
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1.15.5 Figure 4. Similar Molecules Between Two Protein Degradation
Pathways.

Transient conjugation of LC3 to the autophagosomal membrane through an ubiquitin like
system is essential for macroautophagy. Ubiquitin directs proteins targeted for
degradation to the proteasome and is activated by an E1 enzyme. Following activation,
E1 transfers the activated ubiquitin to E2 enzymes and then with E3 enzymes catalyzes
the conjugation of ubiquitin to substrates. LC3 binding residues can function in an
ubiquitin-like fashion and terms ubiquitin-like, E1-like, E2-like and E3-like are applied to
these autophagic ubiquitin-like systems producing the conjugated proteins (LC3-II-PE
and Atg5-Atg12-Atg16L). LC3 targeting system works with LC3 acting as the ubiquitinlike protein that is transferred to phosphatidylethanolamine (PE), while Atg7 functions in
the same manner as an E1 enzyme; Atg3 like an E2 enzyme and the Atg12-Atg5-Atg16L
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complex like an E3 ligase for the LC3-II–PE complex. Upstream of the LC3-II-PE
linkage, Atg12 is conjugated to Atg5 to form a stable Atg12-Atg5 conjunction. This
process is mediated by Atg7, E1-like activating enzyme, and Atg10, an E2-like
conjugating enzyme. Atg16 then forms a complex with the Atg12–Atg5 conjugate.

Figure
5 5. Biochemical reactions in Atg8 lipidation.
1.15.6
Figure
Membrane bound Atg 19 plays a central role in
cytoplasm to vacuole transport ( Cvt ) pathway
cargo sorting and transport to autophagosome

Atg19
Y49
L50

a) Atg19 Trp 49 and
Leu 50 interact with
two Atg8 hydrophobic
pocket residues
b) Atg8 residues
F77 and F79 interact
with corresponding residues
on Atg 4
c) Atg8 is transferred to Atg3

4

F77

F79
Atg4

C

G116

C

Atg7

Interaction facilitates Atg4
cleavage of Atg8 C - terminal
glycine residue (Gly 116)

Atg7

C
Atg8

Atg8

ATP dependent thioester
bond formation following
G116 cleavage

Atg3
Atg8

PE

d) Atg8 is detached from Atg3 and coupled to the amine head of phosphatidylethanolamine
(PE). This step is stimulated and facilitated by the Atg5 - Atg12 complex

Atg8 in budding yeast Saccharomyces cerevisiae shares significant homology with
mammalian LC3. In yeast Atg8, residues Phe 77 and Phe 79 are located on one surface,
and residues Tyr 49 and Leu 50 are on the opposite surface. It has been shown that Phe
77 and Phe 79 recognize Atg4, an endopeptidase and a de-conjugation enzyme. Atg4 is a
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specific cysteine protease belonging to the caspase family, initiates LC3 processing by
post-translationally cleaving LC3’s C-terminal amino acid (arginine). This cleavage
generates LC3-I. The newly exposed C-terminal glycine (Gly 116) is bound by
phosphatidylethanolamine (PE), a lipidation conjugation reaction catalyzed by Atg12-516L complex, which results in the formation of LC3-II.
1.16 Dissertation Summary: Background
The American Cancer Society estimates that in 2015, 73,870 new melanomas will be
diagnosed and 9,940 people will die from their disease. 1The 5-year survival rate for stage
IV melanoma also remains unchanged at only 15-20% but the incidence continues to
rise.1 Once melanoma has metastasized the available treatment options all have
significant challenges. Immunotherapy with IL-2 and IFN-α offers some patients
complete and long-lasting remission, but has a very low percentage of responders.
2,3

Chemotherapy, including alkylating agents (dacarbazine, temozolomide), platinum

analogs, and microtubular toxins

4

have a larger percentage of responders.

2,5

However,

these agents used alone or in combination still have less durability.6 Advances in the field
of melanoma have successfully identified targeted therapies including selective oncogene
inhibitors. Activating mutations in the BRAF and NRAS proto-oncogenes are found in
approximately 58% of primary melanomas (43% BRAF V600E; 15% NRAS
of melanoma metastases (48% BRAF

V600E

; 15% NRAS

Q61R

Q61R

) and 63%

) .7 Long term effective

treatments for invasive melanoma typically use targeted immunotherapy combined with
therapeutics that target the critical MAPK pathway through the inhibition of BRAF.

2,8

However, inhibition of these targets has not significantly increased patient survival, as
tumors eventually develop resistance.

1,9
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Recently, immunotherapy has shown

encouraging advances in metastatic melanoma treatment through the recognition of
neoantigens and through deactivation of immune checkpoint blockades, such as CTLA-4
antagonist-antibodies, and PD-L1. These have shown an increase in ten month survival
in phase I and II clinical trials.

10,11

critical mediators of melanomagenesis

While activating mutations in BRAF/NRAS are
12–14

and the most common somatic alterations in

melanoma, the mechanisms by which these mutations promote tumorigenesis are still
under investigation. One potential pathway that may provide a mechanism to support
tumorigenesis is the metabolic pathway of autophagy. Autophagy, or self-eating, is a
catabolic process that assists the removal of unnecessary or dysfunctional components,
damaged proteins and organelles through lysosomal degradation.15,16 A tightly regulated
process autophagy, plays a role in a wide variety of normal physiological processes
including energy metabolism, stress responses, growth regulation, and aging17,18 and can
be induced in response to nutrient deprivation.19 Macroautophagy, the most widely
discussed type of autophagy (referred to hereafter as autophagy) involves the initial
formation of a double membrane structure (isolation membrane) which encapsulates
organelles and targeted elements in the cell, separating these targets from the rest of the
cytoplasm and fusing them into a circular autophagosome. The autophagosome then
fuses with the lysosomes (autophagolysosome), which degrades or recycles the contents
of the vesicles. 20 Autophagy has been shown to play a Janus role in cancer,21 suppressing
the early stages of tumor formation 22,23 yet enhancing tumorigenesis in the later stages of
development.24–28 Research has shown that while autophagy plays similar roles in tumor
cells as in normal cells, tumor cells’ energetic needs are greater and they have a more
hypoxic environment, so dependence on autophagy may be greater.
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29–31

Conversely,

deficiencies in autophagy in normal cells can promote cancer through the accumulation
of damaged mitochondria and other components that autophagy normally degrades or
recycles.

32,33

Finally autophagy has been reported to control other processes relevant to

the etiology of cancer, including oxidative stress

32

inflammation

18,34,35

and both innate

and acquired immunity.21,35–38 Tumor cells have increased levels of DNA and protein
synthesis and require a constant nutrient source; autophagy appears to promote tumor
survival by providing energy to the hypoxic tumor environment or in response to
chemotherapy.

30,39–41

Autophagy also localizes to hypoxic tumor areas that occur far

from blood vessels and supports tumor cell survival.30 Importantly, the mechanism by
which BRAF and NRAS influence autophagy remains to be elucidated. Recent evidence
for metabolic resistance to BRAF inhibitors and the speculation that some cancers are
“autophagy addicted” suggests that activating mutations in BRAF may generate tumors
with this phenotype.42 There is thus a need to investigate the mechanism and extent to
which mutations in oncogenes affect the rate of autophagic flux and ultimately sensitivity
to inhibition of this process.
1.17 Single Nucleotide Polymorphisms (SNPs):
1.17.1 SNP Definition
A single nucleotide polymorphism is a DNA (germline) sequence variation that occurs
commonly within a population; in which a single nucleotide (adenine, thymine, cytosine,
or guanine) is altered. There are many types of SNPs and the most commons are those
that occur in between genes in introns (intronic). SNPs, in a majority of cases have no
clear effect on human health or development but some act as biological marker that allow
for the identification of disease associated genes. Even intronic SNPs may have on
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impact if they are located in enhancers, super enhancers, promoters or introduce splice
variants.

43–47

Some SNPs occurring near or within genes potentially play a more direct

role, effecting the functioning of an associated gene or protein stability and impacting
risk, progression or disease specific survival. 48
There is evidence that autophagy related genes have SNPs which impact the function of
both promoters as well as protein stability.49,50 The role of autophagy-related SNPs in
melanoma progression and survival has not been investigated and may provide insight
into the interactions between this disease and the autophagy pathway.
1.18 Purpose and Hypotheses
Invasive melanoma is a complex disease with an increasing incidence of 6% each year
and few clinical treatment options. The American Cancer Society estimates that in 2015
the 5-year survival rate for stage IV melanoma will remain unchanged at only 15%, even
with new therapies. One emerging hallmark of cancer is the reprogramming of energy
metabolism 51 which includes the role of autophagy.
Autophagy is a cellular recycling pathway involved in normal physiological processes
including nutrient and/or stress responses, antigen presentation, and aging. In cancer,
autophagy appears to be an important energy source for nutrient depleted tumors.29
Studies of solid tumors have shown autophagy’s role is biphasic as it initially suppresses
the early stages of tumor formation

22

and inhibits metastasis by promoting anti-tumor

inflammatory responses but later promotes metastasis by enhancing the tumor’s ability to
respond to environmental stress.

15,52

However, the mechanisms supporting the Janus

nature of autophagy remain to be elucidated.
Studies have indicated that evaluated tumors differ in their sensitivity to chloroquine
49

(CQ), a potent inhibitor of autophagy.26,53 Currently, multiple clinical trials are underway
using CQ and its derivatives to evaluate the effectiveness of these inhibitors in cancer
therapies.54,55 In melanoma, basal levels of autophagy appear to vary by tumor stage, and
higher levels of autophagic flux are associated with increased hypoxia and poor clinical
prognosis.56 In 2010, Lazova and colleagues reported that melanoma cells contain high
levels of autophagosomes, a cellular structure associated with autophagy, as measured by
the proxy marker LC3, an autophagy related (ATG) protein.57 Ma et al. (2014) reported
increased autophagy in BRAF inhibitor resistant cells.58 These findings suggest
autophagy provides metabolic support for tumors.
Other environmental and genetic factors also have an influence on autophagy.
Ultraviolet-radiation (UVR) exposure increases autophagic flux59,60 and UVR is an
established risk factor for melanoma. Furthermore, in oncogenic BRAF-mutated thyroid
cancer a single nucleotide polymorphism (SNP) in a crucial ATG gene, ATG5, has been
shown to have a positive association with cancer susceptibility and poor outcome.50 To
date there are no studies examining ATG gene SNPs in melanoma outcomes, so the role
of these variants is unclear, particularly in relation to the presence of BRAF/NRAS
oncogenes. Variants identified in these patients could affect ATG gene expression and
ultimately, influence the rate of autophagy.
The objective of the present study is to determine whether in melanoma oncogene status
and UV exposure are independently associated with levels of autophagy and if autophagy
markers associate with increased melanoma survival. Our long term goal is to reduce
mortality from melanoma by identifying novel targets for treatment using the autophagy
pathway.
50

1.19 Rationale, Hypothesis, and Specific Aims:

1.19.1 Rationale
The rationale of the proposed research is that oncogene status in melanoma differentially
suppresses apoptosis by modifying autophagic flux.

1.19.2 Hypothesis
Our hypothesis is that cutaneous malignant melanomas (CMM) with BRAF mutations
may be autophagy-addicted while tumors with NRAS mutations may be less dependent
on autophagy.

I interrogated this hypothesis through the following specific and testable aims:

1.19.3 Specific Aim 1
Determine if BRAF/NRAS mutations alter autophagic flux at the cellular level in order to
suppress apoptosis in melanoma.

1.19.4 Specific Aim 2
Determine if autophagic flux is associated with individual UV exposure and/or clinical
stage and modified by oncogenic BRAF/NRAS in melanoma tumor.

1.19.5 Specific Aim 3
51

Determine whether SNPs in ATG genes are associated with BRAF/NRAS mutations in
melanoma patients.

1.20 Overall Approach.
In order to determine if BRAF/NRAS mutations alter autophagic flux to suppress
apoptosis in melanoma, I used melanoma cell lines to quantify the complete process of
autophagy (autophagic flux), beginning with the formation of an isolation membrane,
autophagosome and eventually an autolysosome where unnecessary or dysfunctional
cellular components are degraded. 61,62 The goal was to examine the model that metabolic
stress caused by mutations in oncogenes leads to alterations in gene expression, as shown
in tissue samples, increasing the rate of autophagy, and ultimately leading to melanoma
progression. In addition, variants in autophagy genes may modify autophagic flux leading
to melanoma progression.
Our long term goal is to reduce mortality from melanoma by identifying novel targets for
treatment using the underexplored autophagy pathway. In six melanoma cell lines (e.g.
SK-Mel 2, 19, 29, 94,103, and 147) containing BRAF or NRAS mutations, the sensitivity
and cell viability associated with chloroquine (CQ) treatment were characterized by
autophagic flux, to determine decreases in cellular viability caused by autophagy
inhibition. Using quantification of LC3-II puncta and western blots, I evaluated the
differential rate of autophagy by oncogene status. These two common CMM activating
mutations, BRAF and NRAS, appear to have differential effects on the autophagy
pathway. Our data indicate that the targeting of autophagy using CQ in the BRAF
oncogenic cell lines increases apoptosis and leads to a significant decrease in viability
52

(Figure 1; Chapter 2). In addition, BRAF cell lines appear to have higher basal protein
expression of LC3-II (Figure 4; Chapter 2) and a higher number of basal LC3-II puncta
when compared to NRAS cell lines (Figure 4; Chapter 2) indicating dependence on the
autophagy pathway for survival. Finally, the induction of autophagy through serum
starvation results in differential LC3 expression as measured by number of puncta in the
BRAF and NRAS cell lines (Figure 4; Chapter 2). These results indicate that BRAF mutant
melanoma is more dependent on autophagy for survival than NRAS mutant melanoma
and that oncogene status affects the sensitivity of melanoma cells to CQ by altering
autophagic flux, subsequently increasing apoptosis. Ongoing experiments include the
evaluation of autophagy in patient samples to quantify expression of known autophagy
markers as well an evaluation of LC3-II expression correlated with oncogene status and
autophagy SNPs. These findings will be immediately translatable for patients who would
benefit from CQ co-therapy, which is approved for clinical use.

1.21 Significance of the Dissertation Study
Long term survival remains a challenge for metastatic melanoma patients as there are few
durable treatment options available. Melanoma treatment can be divided into four major
types: surgery, chemotherapy, radiation therapy and biological therapy.63 Treatment of
stage IV and recurrent melanoma may include the following: targeted therapy with
ipilimumab or BRAF inhibitors (e.g. vemurafenib); biological therapy with interleukin-2
(IL-2); chemotherapy including alkylating agents; or palliative therapy to relieve
symptoms and improve the quality of life.

63,64

Unfortunately, in most cases, treatment

fails to halt the advance of melanoma and patients do progress, typically within a few
53

months.9 Exciting immunotherapy treatment options including IL-2,

2,3,8

drugs that block

Cytotoxic T lymphocytes (CTLs) inhibitory mechanism (CTLA-4) or Programmed cell
death 1 (PD-1) boost the immune response against melanoma cells. These combinations
which circumvent the tumor’s ability to evade immune destruction are resulting in tumor
regression and increased survival, although there remains heterogeneity in responses to
treatment.65–67 The Phase Ib study of MEDI4736 for a combinations of CTLA-4 and
Programmed cell death ligand 1 (PD-L1) antagonist-antibodies have shown promising
results while illuminating the relationship between melanoma progression and immune
system.68 These results indicate that combining immunotherapy with oncogene (BRAF,
NRAS)-targeted drugs may provide durable responses in melanoma for a larger number of
patients.
In addition to evading immune destruction, another hallmark of cancer is the
reprogramming of pathways involved in energy metabolism to support continuous
growth, development and progression of cancer using mechanisms including the
autophagy pathway.51 Autophagy is often dysregulated in the hypoxic, low nutrient
regions of tumors and can support cancer survival through its ability to provide tumors an
energy source.15,18,29,34,69,70

Autophagy upregulation has been documented in lung,

prostate and other cancer types but the mechanisms supporting its role in melanoma
tumorigenesis have not been well characterized. In addition, the role of autophagy in
modifying cancer cell death or survival remains controversial.71 Interestingly, it appears
that oncogene status, an important contributor to cellular deregulation of proliferation and
apoptotic pathways in melanoma also influences the rate of autophagic flux. BRAF

V600E

mutations have been reported to promote lung tumorigenesis by utilizing autophagy’s
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ability to preserve mitochondrial function,72 and inhibition of autophagy in vemurafenibresistant melanoma decreases cell survival. The concept that oncogenes can directly
influence autophagic rates has important implications for cancer development as well as
the management of treatment options for this difficult disease. Furthermore, in nonmedullary thyroid cancers with activating BRAF mutations, a SNP in ATG5, a crucial
ATG gene, has been shown to be associated with disease susceptibility and outcome.

73

To date there are no studies examining ATG gene SNPs in melanoma progression or
survival, so the role of these variants is unclear. Variants identified in these melanoma
patients could affect ATG gene expression and ultimately influence the rate of autophagic
flux.
The significance of this proposal is that autophagy may represent a novel area for
identifying biomarkers and potential targets for treatment in melanoma. Given that
oncogenes influence autophagy and BRAFV600E melanoma cells appear to use late-stage
autophagy to maintain an active metabolic state,57,74 the current study was designed to
determine whether oncogenic mutations drive melanomas to become autophagy-addicted
for survival and if inhibition of this pathway increases apoptosis in these cells. If this is
so, we would anticipate finding that autophagy or oncogenically driven autophagy as an
important factor in progression to metastasis and death. Our study design is innovative as
it combines both molecular epidemiology and molecular biology techniques allowing the
proposed research to determine if oncogene status is an important modifier of autophagy
in melanoma moving from bench to bedside. Autophagy has been shown to promote
tumor survival
cells

54,57

21,58

and support survival of radiation and chemotherapy resistant tumor

thus highlighting the importance of investigating this process in melanoma.
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Upon completion of the proposed aims, this research will clarify the relationships
between autophagy, melanoma and oncogene status and will elucidate some of the
molecular mechanisms/pathways contributing to this disease. This project has the
potential to make a significant contribution because (i) it will characterize the cell death
response to autophagy inhibition in the context of BRAF/NRAS oncogenic status; (ii) it
will characterize the relationship at between autophagy and UV exposure in tissue
sections and (iii) it is an important first step in identifying autophagy related SNPs that
may influence autophagic flux and melanoma tumorigenesis.
1.22 Limitations of Dissertation Study
There are several limitations to this study.
1. While immortalized cells lines can provide some information about how metastasis in
melanoma is facilitated, there are limitations to using them as a resource. Some of the
strengths of cell lines are they often show similar allelic populations compared to the
actual tumors and they provide a rich source of RNA which under other circumstances
would be difficult to obtain. They also provide good model systems for evaluating
invasion and the potential for the tumors to metastasize to distant sites. Weaknesses
include an increase in chromosomal instability in many cancer cell lines as well as
chromosomal gains and losses as the number of passages increase, which could affect
experimental outcomes.
2. Problems with reliable labeling of autophagosomes have created controversies around
using immunofluorescence.62,75 To address this potential issue, I used a proven
colocalization experiment to identify the autolysosomes indicating true target degradation
and autophagy completion. Staining protocols have been developed for quantitative
56

analysis using antibodies to LC3 (ATG8). In addition, quantitative fluorescent
microscopy will be used to assess relative quantities of LC3 estimating the accumulation
of autophagic vacuoles. Although my aims have little interdependence, this aim was
limited by the reality that many cells use other mechanisms, such as methylation or
acetylation, to regulate protein expression so LC3 may stay consistently expressed under
variable conditions. Flow cytometry experiments have resulted in higher levels of cell
death (Figure 2a-d Chapter 2), so I used an alternative method to examine cell death,
Caspase activity, in order to obtain more definitive results. Furthermore, the use of the
IHC could result in variable or incomplete staining and subjective quantification of
protein expression. For this reason I developed a novel quantification method which
removes the subjective component of IHC quantification. An alternative approach would
be to use standard immunofluorescent techniques using anti-LC3 antibodies to quantify
expression of tumor cells from tumor-associated melanophages. The immunofluorescent
nature of melanoma samples makes this method a less desirable but still viable
alternative.

57

1.23 References:
1.

American Cancer Society Facts and Statistics 2015 | Research | American Cancer
Society. at
<http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/>

2.

Flaherty, K. T. & McArthur, G. BRAF, a target in melanoma: implications for
solid tumor drug development. Cancer 116, 4902–13 (2010).

3.

Buzaid, A. C. Management of metastatic cutaneous melanoma. Oncology
(Williston Park). 18, 1443–50; discussion 1457–9 (2004).

4.

Bhatia, S., Tykodi, S. S. & Thompson, J. A. Treatment of metastatic melanoma: an
overview. Oncology (Williston Park). 23, 488–96 (2009).

5.

O’Day, S. J., Kim, C. J. & Reintgen, D. S. Metastatic melanoma: chemotherapy to
biochemotherapy. Cancer Control 9, 31–8

6.

Bajetta, E. et al. Metastatic melanoma: chemotherapy. Semin. Oncol. 29, 427–45
(2002).

7.

Colombino, M. et al. Heterogeneous distribution of BRAF/NRAS mutations
among Italian patients with advanced melanoma. J. Transl. Med. 11, 202 (2013).

8.

Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with
BRAF V600E mutation. N. Engl. J. Med. 364, 2507–16 (2011).

9.

Jarkowski, A. & Khushalani, N. I. BRAF and beyond: Tailoring strategies for the
individual melanoma patient. J. Carcinog. 13, 1 (2014).

10.

Tarhini, A., Lo, E. & Minor, D. R. Releasing the brake on the immune system:
ipilimumab in melanoma and other tumors. Cancer Biother. Radiopharm. 25, 601–
13 (2010).

11.

Johnson, D. B., Peng, C. & Sosman, J. A. Nivolumab in melanoma: latest evidence
and clinical potential. Ther. Adv. Med. Oncol. 7, 97–106 (2015).

12.

Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and
MITF. Cancer Cell 23, 302–15 (2013).

13.

Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–
54 (2002).

14.

Hawryluk, E. B. & Tsao, H. Melanoma: clinical features and genomic insights.
Cold Spring Harb. Perspect. Med. 4, a015388 (2014).
58

15.

White, E., Karp, C., Strohecker, A. M., Guo, Y. & Mathew, R. Role of autophagy
in suppression of inflammation and cancer. Curr. Opin. Cell Biol. 22, 212–7
(2010).

16.

Mizushima, N. Autophagy: process and function. Genes Dev. 21, 2861–73 (2007).

17.

Shintani, T. & Klionsky, D. J. Autophagy in health and disease: a double-edged
sword. Science 306, 990–5 (2004).

18.

Choi, A. M. K., Ryter, S. W. & Levine, B. Autophagy in human health and
disease. N. Engl. J. Med. 368, 651–62 (2013).

19.

Russell, R. C., Yuan, H.-X. & Guan, K.-L. Autophagy regulation by nutrient
signaling. Cell Res. 24, 42–57 (2014).

20.

Patel, A. S. et al. Autophagy in idiopathic pulmonary fibrosis. PLoS One 7,
e41394 (2012).

21.

Rosenfeldt, M. T. & Ryan, K. M. The multiple roles of autophagy in cancer.
Carcinogenesis 32, 955–63 (2011).

22.

Sun, K. et al. Paradoxical roles of autophagy in different stages of tumorigenesis:
protector for normal or cancer cells. Cell Biosci. 3, 35 (2013).

23.

Panda, P. K. et al. Mechanism of autophagic regulation in carcinogenesis and
cancer therapeutics. Semin. Cell Dev. Biol. 39, 43–55 (2015).

24.

Zhang, J. et al. Statins, autophagy and cancer metastasis. Int. J. Biochem. Cell
Biol. 45, 745–52 (2013).

25.

Qu, X. et al. Promotion of tumorigenesis by heterozygous disruption of the beclin
1 autophagy gene. J. Clin. Invest. 112, 1809–20 (2003).

26.

Yang, Z. J., Chee, C. E., Huang, S. & Sinicrope, F. A. The role of autophagy in
cancer: therapeutic implications. Mol. Cancer Ther. 10, 1533–41 (2011).

27.

Kenific, C. M., Thorburn, A. & Debnath, J. Autophagy and metastasis: another
double-edged sword. Curr. Opin. Cell Biol. 22, 241–5 (2010).

28.

Mathew, R., Karantza-wadsworth, V. & White, E. Role of autophagy in cancer. 7,
961–967 (2007).

29.

Sato, K. et al. Autophagy is activated in colorectal cancer cells and contributes to
the tolerance to nutrient deprivation. Cancer Res. 67, 9677–84 (2007).

59

30.

Chatterjee, S. J. & Pandey, S. Chemo-resistant melanoma sensitized by tamoxifen
to low dose curcumin treatment through induction of apoptosis and autophagy.
Cancer Biol. Ther. 11, 216–28 (2011).

31.

Strohecker, A. M. et al. Autophagy sustains mitochondrial glutamine metabolism
and growth of BrafV600E-driven lung tumors. Cancer Discov. 3, 1272–85 (2013).

32.

Lee, J., Giordano, S. & Zhang, J. Autophagy, mitochondria and oxidative stress:
cross-talk and redox signalling. Biochem. J. 441, 523–40 (2012).

33.

Boland, M. L., Chourasia, A. H. & Macleod, K. F. Mitochondrial dysfunction in
cancer. Front. Oncol. 3, 292 (2013).

34.

Levine, B. & Kroemer, G. Autophagy in the pathogenesis of disease. Cell 132, 27–
42 (2008).

35.

Levine, B., Mizushima, N. & Virgin, H. W. Autophagy in immunity and
inflammation. Nature 469, 323–35 (2011).

36.

Zhou, X.-J. & Zhang, H. Autophagy in immunity: implications in etiology of
autoimmune/autoinflammatory diseases. Autophagy 8, 1286–99 (2012).

37.

Sumpter, R. & Levine, B. Autophagy and innate immunity: triggering, targeting
and tuning. Semin. Cell Dev. Biol. 21, 699–711 (2010).

38.

Oh, J. E. & Lee, H. K. Autophagy in innate recognition of pathogens and adaptive
immunity. Yonsei Med. J. 53, 241–7 (2012).

39.

Marino, M. L. et al. Autophagy is a protective mechanism for human melanoma
cells under acidic stress. J. Biol. Chem. 287, 30664–76 (2012).

40.

Martinez-Outschoorn, U. E. et al. The autophagic tumor stroma model of cancer or
“battery-operated tumor growth.” Cell Cycle 9, 4297–4306 (2014).

41.

Ávalos, Y. et al. Tumor suppression and promotion by autophagy. Biomed Res.
Int. 2014, 603980 (2014).

42.

Altman, B. J. & Rathmell, J. C. Metabolic stress in autophagy and cell death
pathways. Cold Spring Harb. Perspect. Biol. 4, a008763 (2012).

43.

Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell
155, 934–47 (2013).

44.

Martini, S. et al. From single nucleotide polymorphism to transcriptional
mechanism: a model for FRMD3 in diabetic nephropathy. Diabetes 62, 2605–12
(2013).
60

45.

De Gobbi, M. et al. A regulatory SNP causes a human genetic disease by creating
a new transcriptional promoter. Science 312, 1215–7 (2006).

46.

Martin, L. J. et al. Functional variant in the autophagy-related 5 gene promotor is
associated with childhood asthma. PLoS One 7, e33454 (2012).

47.

Erichsen, H. C. & Chanock, S. J. SNPs in cancer research and treatment. Br. J.
Cancer 90, 747–51 (2004).

48.

NCI Dictionary of Genetics Terms - National Cancer Institute. at
<http://www.cancer.gov/publications/dictionaries/genetics-dictionary?expand=S>

49.

Huijbers, A. et al. The effect of the ATG16L1 Thr300Ala polymorphism on
susceptibility and outcome of patients with epithelial cell-derived thyroid
carcinoma. Endocr. Relat. Cancer 19, L15–8 (2012).

50.

Plantinga, T. S. et al. Role of genetic variants of autophagy genes in susceptibility
for non-medullary thyroid cancer and patients outcome. PLoS One 9, e94086
(2014).

51.

Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell
144, 646–74 (2011).

52.

Xu, Y., Xia, X. & Pan, H. Active autophagy in the tumor microenvironment: A
novel mechanism for cancer metastasis. Oncol. Lett. 5, 411–416 (2013).

53.

Yang, S. et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev.
25, 717–29 (2011).

54.

Sui, X. et al. Autophagy and chemotherapy resistance: a promising therapeutic
target for cancer treatment. Cell Death Dis. 4, e838 (2013).

55.

The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic
Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine
in Patients With Advanced BRAF Mutant Melanoma - No Study Results Posted ClinicalTrials.gov. at <https://clinicaltrials.gov/ct2/show/NCT02257424>

56.

Schaaf, M. B. E. et al. The autophagy associated gene, ULK1, promotes tolerance
to chronic and acute hypoxia. Radiother. Oncol. 108, 529–34 (2013).

57.

Lazova, R., Klump, V. & Pawelek, J. Autophagy in cutaneous malignant
melanoma. J. Cutan. Pathol. 37, 256–68 (2010).

58.

Ma, X. et al. Targeting ER stress – induced autophagy overcomes BRAF inhibitor
resistance in melanoma. 124, (2014).

61

59.

Chen, L.-H. et al. Targeting protective autophagy exacerbates UV-triggered
apoptotic cell death. Int. J. Mol. Sci. 13, 1209–24 (2012).

60.

Zhao, Y. et al. Autophagy is induced by UVA and promotes removal of oxidized
phospholipids and protein aggregates in epidermal keratinocytes. J. Invest.
Dermatol. 133, 1629–37 (2013).

61.

Hansen, T. E. & Johansen, T. Following autophagy step by step. BMC Biol. 9, 39
(2011).

62.

Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for
monitoring autophagy in higher eukaryotes. Autophagy 4, 151–75 (2008).

63.

Coit, D. G. et al. Melanoma, version 4.2014. J. Natl. Compr. Canc. Netw. 12, 621–
9 (2014).

64.

Krammer, R. & Heinzerling, L. Therapy preferences in melanoma treatment-willingness to pay and preference of quality versus length of life of patients,
physicians and healthy controls. PLoS One 9, e111237 (2014).

65.

Snyder, A. et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in
Melanoma. N. Engl. J. Med. 371, 141119140020009 (2014).

66.

Dolan, D. E. & Gupta, S. PD-1 pathway inhibitors: changing the landscape of
cancer immunotherapy. Cancer Control 21, 231–7 (2014).

67.

Madore, J. et al. PD-L1 expression in melanoma shows marked heterogeneity
within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Pigment Cell Melanoma Res. 28, 245–53 (2015).

68.

Mahoney, K. M., Freeman, G. J. & McDermott, D. F. The Next ImmuneCheckpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin. Ther. 37, 764–
82 (2015).

69.

Selvakumaran, M., Amaravadi, R. K., Vasilevskaya, I. A. & O’Dwyer, P. J.
Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic
therapy. Clin. Cancer Res. 19, 2995–3007 (2013).

70.

Wu, W. K. K. et al. The autophagic paradox in cancer therapy. Oncogene 31, 939–
53 (2012).

71.

Xie, X., White, E. P. & Mehnert, J. M. Coordinate autophagy and mTOR pathway
inhibition enhances cell death in melanoma. PLoS One 8, e55096 (2013).

62

72.

Strohecker, A. M. & White, E. Autophagy promotes BrafV600E-driven lung
tumorigenesis by preserving mitochondrial metabolism. Autophagy 10, 384–5
(2014).

73.

Plantinga, T. S. et al. Role of genetic variants of autophagy genes in susceptibility
for non-medullary thyroid cancer and patients outcome. PLoS One 9, e94086
(2014).

74.

Maddodi, N. et al. Induction of autophagy and inhibition of melanoma growth in
vitro and in vivo by hyperactivation of oncogenic BRAF. J. Invest. Dermatol. 130,
1657–67 (2010).

75.

Mizushima, N., Yoshimori, T. & Levine, B. Methods in mammalian autophagy
research. Cell 140, 313–26 (2010).

63

CHAPTER TWO:
Melanoma Cells Carrying BRAF V600E or NRAS Q61R Differ in Autophagy Status
and Sensitivity
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2.1 Abstract: Metastatic melanoma has no cure. Although mutations of BRAF or NRAS
(BRAF* or NRAS*) are identified in 63 percent of melanomas, single inhibition of these
targets has not increased survival. Recently, autophagy has been examined as a potential
target for overcoming BRAF inhibitor resistance and there is evidence that survival of
melanoma cells may be autophagy-dependent. Our study investigated whether BRAF or
NRAS mutations alter autophagic flux to suppress apoptosis in melanoma, whether basal
levels of autophagic flux differ based on oncogene status and whether chemical inhibitor
of autophagy would differentially alter autophagy in BRAF* vs. NRAS* melanoma cells.
Our study has shown that autophagy is upregulated in BRAF* melanoma cells compared
to NRAS*. Interestingly, BRAF* melanoma cells demonstrated a four-fold decrease in
cell viability following treatment with 20 µM chloroquine compared < 20 percent
decreased in NRAS* cells. In addition, knockdown of BRAF gene expression
corresponded with a decrease in LC3 gene expression not seen in NRAS knockdown. Our
research supports that BRAF* melanoma cell lines have a higher basal level of
autophagic flux, are more sensitive to autophagy inhibition, and were less able to respond
to autophagy induction than NRAS* melanoma cells. Findings from this study indicate
that oncogene status influences autophagic flux and that BRAF mutant melanoma may be
addicted to autophagy for survival while NRAS mutant melanoma may not be as
dependent on this pathway.

2.2 Keywords: Autophagy; NRAS; BRAF; LC3; cell death; melanoma
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2.3 Introduction:
One of the emerging hallmarks of cancer is the reprogramming of pathways
involved in energy metabolism to support continuous growth using mechanisms like
autophagy.1 Autophagy, or self-eating, is a catabolic process that assists the removal of
unnecessary or dysfunctional components, damaged proteins and organelles through
lysosomal degradation.2 It is a tightly regulated process that plays a role in normal cell
growth and development 3and can be induced in response to nutrient deprivation.4
Macroautophagy, the most widely discussed type of autophagy (hereafter referred to as
autophagy), involves the initial formation of a double membrane structure (isolation
membrane) which encapsulates cytoplasm, organelles and targeted elements in the cell,
separating these targets from the rest of the cytoplasm and fusing them into a circular
autophagosome. The autophagosome is characterized by the microtubule-associated
protein 1A/1B-light chain 3 (LC3) protein, which is proteolytically cleaved during
autophagy and then the conjugated/ lipidated form (LC3-II) localizes to the
autophagosome membrane. Subsequently, LC3-II can be used as a proxy marker for the
rate of autophagy as Immunofluorescent punctate structures are visible using
microscopy.5 The autophagosome then fuses with the lysosomes (autophagolysosome),
which degrades or recycles the contents of the vesicles. 6 The dysregulation of autophagy
has implications for many diseases including cancer. 3,7–11
Autophagy has been shown to play a dual role in cancer11, suppressing the early
stages of tumor formation12 yet having a pro-tumorigenic influence in the later stages of
development. 13–16 Autophagic flux refers to the complete process of autophagy,
beginning with the formation of an isolation membrane, autophagosome and eventually
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an autolysosome where unnecessary or dysfunctional cellular components are degraded.17
Autophagy is often upregulated in the hypoxic, low nutrient regions of tumors and can
support cancer survival through its ability to provide tumors an energy source.18,19 This
upregulation has been documented in lung, prostate and other cancer types but
autophagy’s role in melanoma has not been well characterized.
In addition, the rate of autophagic flux appears to vary by tumor type, and it has
been reported that the effect of autophagy on cancer cells may be dependent upon the
stage of the cancer.20 For example, in early primary melanomas, autophagy has been
reported to play a role in suppression of melanoma tumorigenesis through the induction
of senescence.21
Interestingly, it appears that oncogene status, an important contributor to cellular
deregulation of proliferation and apoptotic pathways in melanoma also influences the rate
of autophagic flux. BRAF V600E mutations have been reported to promote lung
tumorigenesis by utilizing autophagy’s ability to preserve mitochondrial function.22 The
concept that oncogenes can directly influence autophagic rates has important implications
for cancer development as well as the management of treatment options for this difficult
disease.
Invasive melanoma is a complex disease with an increasing incidence and the
cause of the majority of skin cancer deaths. In 2015, the American Cancer Society
estimates that 73,870 new melanomas will be diagnosed and 9,940 people will die from
their disease. 23 The 5-year survival rate for stage IV melanoma also remains unchanged
at only 15-20% but the incidence continues to rise, as it has for the past 30 years, at a rate
of 6% every year. 24 Activating mutations in the BRAF and NRAS proto-oncogenes are
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found in approximately 58% of primary melanomas (43% BRAF V600E; 15% NRAS Q61R)
and 63% of melanoma metastases (48% BRAF V600E; 15% NRAS Q61R).25 Advances in the
field of melanoma have successfully identified targeted therapies including selective
oncogene inhibitors (BRAF/NRAS); however, single inhibition of these targets has not
significantly increased patient survival, as tumors eventually develop resistance.26,27
While activating mutations in BRAF are critical mediators of melanomagenesis28 and the
most common genetic alterations in melanoma, the mechanisms by which these
mutations promote tumorigenesis are still under investigation. Importantly, many of the
mechanism by which proto-oncogenes like BRAF influence autophagy are under
investigation. 29,30 Recent evidence for metabolic resistance to BRAF inhibitors and the
speculation that some cancers are “autophagy addicted” suggests that activating
mutations in BRAF may generate tumors with this phenotype.31 These findings
demonstrate the need to investigate the mechanism and extent to which mutations in
proto-oncogenes affect the rate of autophagic flux and ultimately sensitivity to inhibition
of this process.
Given that oncogenes influence the rate of autophagy and BRAF V600E -mutant
melanoma cells, in particular, appear to use late-stage autophagy to maintain an active
metabolic state,29,32,33 the current study was designed to determine whether protooncogene mutations differentially drive metastatic melanomas to become autophagyaddicted for survival.
2.4 Materials and Methods:
2.4.1 Cell Lines.
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Six melanoma cell lines, authenticated using short tandem repeat loci profiling by ATCC
(Table 1), were established from human metastatic melanomas at Memorial Sloan
Kettering Cancer Center and were a generous gift from Dr. Paul Chapman (SK-Mel 2,
SK-Mel 19, SK-Mel 29, SK-Mel 94, SK-Mel 103, and SK-Mel 147) (Table1). Cells were
maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10%
heat-inactivated fetal bovine serum (FBS), penicillin (250 units/ml), and streptomycin
(250 μg/ml) (Pen-Strep) and referred to as normal media (NM) or DMEM without FBS
referred to as serum free media (SFM) at 37°C and 5% CO2.
2.4.2 In Vitro Cytotoxicity Assay: Cell lines were seeded at a density 1.20X106 in 25
cm2 flasks. Twenty-four hours after plating, cells were treated with 20µM chloroquine
(CQ) and incubated at 37˚C and 5% CO2 for a period of 24 hours Synthetic CQ was
purchased from Sigma-Aldrich (C6628) and prepared in H2O (vehicle). Control cells
were treated with equivalent volume of vehicle. Following treatment, floating cells were
collected; adherent cells were washed with PBS, trypsinized and mixed with the
corresponding floating cells before staining. Cells were stained with 0.4% trypan blue
and counted to estimate the number of live and dead cells. Cell viability is expressed as
the percentage of live cells compared to the total number of cells counted. Comparisons
of percent viability in vehicle vs. treated cells were determined using one way ANOVA
with a cut-off of P<0.01.
2.4.3 Annexin 5/PI Staining – Flow Cytometry: BRAF V600E mutant melanoma cell
lines and NRAS Q61R mutant melanoma cell lines were trypsinized and incubated with
FITC-conjugated Annexin V (BD Biosciences) and propidium iodide. Ten thousand
events were analyzed by flow cytometry with CellQuest Pro software. Data is presented
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as the average percentage of viable cells +/- SD that was quantified 24 hours post
treatment with either vehicle or 20 µM CQ. Statistical significance was set at 1%.
2.4.4 Caspase Activity: Caspase 3/7 activity was quantified using the Caspase-Glo assay
kit (Promega, Madison USA) following the manufactures instructions. 24 hrs. following
vehicle or CQ treatment, the plates containing cells were removed from the incubator and
allowed to equilibrate to room temperature. 100 μl of Caspase-Glo reagent was added to
each well; the plate was gently mixed and then incubated at room temperature for 1 hour.
The luminescence of each sample was measured in a plate-reading luminometer
(Infinite® Tecan). The experiments were performed in triplicate on two separatelyinitiated cultures.
2.4.5 Immunofluorescent Staining of Lysotracker Red: Autophagic flux was assessed
using immunofluorescence imaging of LC3 as an indicator of the steady state level of
autophagosomes and co-staining with LysoTracker (red-Cy3 dye) to examine the colocalization of lysosomal vesicles and autophagosomes in the cell. Cells were grown in
normal media (NM) or serum free media (SFM), fixed, and examined by microscopy for
the presence of autophagosomes and autolysosomes visualized by autophagosome
membrane fluorescent LC3 or LysoTracker. LysoTracker Red was used to visualize
lysosomes in vehicle and CQ treated cells. Cells were grown on coverslips as described
below and once 70% confluence was reached, pre-warmed (37°C) media containing
LysoTracker Red DND-99 at 50nM concentration was added. Cells were incubated for
30 minutes under normal growth conditions (37°C, 5% CO2), and then the media was
replaced with normal media prior to imaging to ensure sufficient lysosomal staining prior
to fixation and co-staining.
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2.4.6 Immunofluorescent Staining of Microtubule-associated Protein 1 Light Chain
3 (LC3): Monolayers of cells were grown on coverslips to 70%confluence prior to
experimental treatments. Cells were grown in NM or SFM media containing DMEM
only. Cells were then treated with vehicle, 20 µM CQ, 20nmol/L Bafilomycin A1 (BAF)
(Wako) or 1 μM Rapamycin (RAP) (Sigma, St. Louis, MO). Following treatment
conditions, cells were washed twice in cold 1X PBS then fixed with 4%
paraformaldehyde for 10 min, washed with 1X PBS and incubated in blocking buffer at
room temperature for 30minutes. Cells were incubated with a selective antibody against
LC3 (Microtubule-associated protein1A/1B-light chain 3; MBL, Woburn, MA) to
evaluate autophagic flux following treatment with 20 µm CQ, 20nmol/L BAF or 1 μM
RAP or vehicle for 24 hours. Cells were labeled with LC3 primary antibody in blocking
solution for 1 hour. After 40 minutes, media containing DAPI was added to the coverslips
for the final 20 minute incubation of LC3. After washing with 1X PBS, coverslips were
incubated in anti-goat FITC-conjugated secondary antibody in blocking buffer (1:1000)
in the dark for 1 hour at room temperature and then mounted on microscope slides using
prolong gold (Life Technologies, NY). Autophagic flux was determined using the
percentage of cells displaying LC3 punctate (rather than diffuse) fluorescence out of a
100 total cells counted in three biological replicates for each cell line and treatment type
grown in cell line in either NM or a SFM for 2 hours. Formation of acidic vesicular
organelles as an indication of autophagic flux was monitored by LysoTracker DND-99
(Cy3 –red) and 4',6-diamidino-2-phenylindole (DAPI) staining was used to visualize
nuclei. BAF treatment was used to inhibit lysosomal function, resulting in a decrease in
autophagic flux. Conversely autophagic rate was increased by treating with RAP and the
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change in flux was measured. Cells were examined by Zeiss Axioskop 2MOT
microscope, magnification × 620 oil immersion objective lens, and representative images
of cells were taken. Co-localization of punctate Anti-LC3 FITC, LysoTracker (Cy3) and
DAPI staining is shown by the pink and yellow color in a composite panel. One-way
repeated measures ANOVA were used to compare means among the experimental groups
and vehicle control. Pair wise comparisons between treatment groups and vehicle control
were performed after adjusting for multiple tests to evaluate the effect of each treatment.
Statistical significance was set at 1%
2.4.7 Quantification of Co-localized Puncta: SlideBook version 5.0 software, which
analyzes the entire three-channel images by measuring the intensity of each label, was
used to quantify the number of cells displaying autophagosomes. The quantification of
cells with higher levels of LC3 puncta per cell is represented by area in microns
compared to background. Mask segments of the low- and high- FITC/Cy3 fluorescents
were created in SlideBook using in both channel images and the background was
corrected using the same threshold values for all images to be analyzed. The merged
images were then statistically analyzed using cross-mask and cross-channel functions.
The ratio of fluorescence was then calculated allowing for quantification of the number
of fluorescently-labeled co-localized puncta in fixed cells.
2.4.8 Cell Transfection and RNA Interference: For RNA interference experiments,
cells were grown in 12-well plates at a density of 1 × 105 cells/well for 24. The cells were
then transfections with siRNA using Lipofectamine 2000 (Thermo Fisher Scientific,
Waltham, MA) following the manufacturer's recommendations using a final
concentration of 10 nM siRNA against BRAF (Origene SR300470) or NRAS (Origene,
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SR303236). siRNA transfected cells were collected 24, 48 and 72 hours following
transfections. Efficiency of knockdown of the target mRNA was evaluated by real-time
PCR.
2.4.9 RNA Isolation and Real-Time PCR with SYBR Green Assay: Total RNA (1 μg)
was isolated with RNeasy Mini Kit from Qiagen (Valencia, CA) and reverse transcribed
in 50 μl at 48 °C for 2 h using High Capacity cDNA Archive Kit from Applied
Biosystems (Foster City, CA, USA). Amplification of cDNA was carried out using the
following primers and SYBR green PCR master mix in an Applied Biosystems 7900
Real-Time PCR System. The primers used for amplification are: MAP1 LC3B forward
primer (AGCAGCATCCAACCAAAATC) and reverse primer
(CTGTGTCCGTTCACCAACAG). For both BRAF and NRAS gene expression predesigned KiCqStart™ SYBR green primers were purchased (Sigma St. Louis, MO). The
threshold cycle (Ct) values, as defined by the default setting, were measured by an ABI
Prism 7900 Sequence Detection System. B-actin was used as an internal control.
Triplicate samples were measured and averaged.
2.4.10 Western Blot Analysis of LC3 Protein Expression: Cells were washed twice
with PBS and lysed for 30 min at 4°C in RIPA buffer (Sigma-Aldrich, France) prior to
harvesting by scraping. After an ultra-centrifugation at 16,000 ×g for 10 min at 4°C,
protein concentration was determined using the BCA Protein Assay Kit (Pierce, IL).
Proteins were electrophoresed on a4-20% SDS–polyacrylamide gel for 45 minutes at
200 V. Proteins were then transferred onto nitrocellulose membranes (30 min, 100 mA)
(BioRad Laboratories, France). Membranes were blocked with 3% bovine serum albumin
(BSA), 0.1% Tween 20 in 10 mM Tris–HCl pH 7.5, 0.1 M NaCl for 1 hour at room
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temperature. Incubation was overnight at 4°C with primary polyclonal rabbit anti-human
LC3 at 1:500 (Cell Signaling Technology, MA) and monoclonal anti-actin at 1:1,000
(Sigma-Aldrich, France) (loading control). Subsequently the membranes were washed
and incubated with 0.02 μg/ml Horseradish peroxidase–conjugated secondary antibody
(HRP)-conjugated IgG (Cell Signaling, MA) for 1 hour and visualized using Super Signal
West Fempto Chemiluminescent Substrate System (Pierce Biotechnology, IL). The
intensity of bands was analyzed by FluorChem™ R System and AlphaView Analysis
Software (Protein Simple, California). Three biologic replicates were generated for each
endpoint. LC3-I/LC3-II ratio has been previously used as a surrogate of autophagic flux.
However, documented differences in across cell lines and tissue dependent expression
levels of LC3-I and LC3-II as well as differences in antibody affinities for LC3-I and
LC3-II have indicated that this type of analysis has produced false-positive or falsenegative results. Additionally, as LC3-II itself is subject to autophagic degradation at the
lysosome, the current study is in agreement with the consensus to utilize overall levels of
LC3-II normalized to loading control as a measure of autophagic flux (30). One-way
repeated measures ANOVA were used to compare means among the experimental groups
and vehicle control. Pair wise comparisons between treatment groups and vehicle control
were performed after adjusting for multiple tests to evaluate the effect of each treatment.
Statistical significance was set at 1%.
2.5 Results:
2.5.1 In vitro Viability Assessments: Melanoma cell lines treated for 24 hours with
CQ demonstrated a decrease in percent cell viability as measured by trypan blue
exclusion (Figure 1). Further, differential sensitivity to this chemical inhibition of
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autophagy appeared to be influenced by BRAF/NRAS status in these cell lines. When
cultured in NM and treated with CQ, BRAF V600E cell lines (SK-MEL 2, 19 and 29) had
significantly decreased viability when compared to cells treated with vehicle (SK-MEL
19, P=0.00014; SK-MEL 29, P=0.0013; SK-MEL 94, P= 0.0008) (Figure 1A). NRAS
Q61R

cell lines (SK-MEL 2, SK-MEL 103 and SK-MEL 147) treated with the same dose

of CQ had a significantly less pronounced response with <20% decrease in viability
compared to vehicle (SK-MEL 2, P= 0.003; SK-MEL 103, P= 0.937; SK-MEL147,
P=0.005 (Figure 1B). This data suggests that oncogenic status may influence the level of
autophagic flux utilized by these cells.
2.5.2 Characterization of Apoptotic Cell Death: We used Annexin V/PI staining
and a capase3/7 activity assay in order to characterize the type of cell death associated
with the observed decrease in cell viability after treatment with CQ (Figure 2a-e; Figure
3). Overall, there was a high rate of cell death (15-20%) in the control samples
potentially due to the adherent cell removal. Despite this baseline, following CQ
treatment of BRAF cell lines, a significantly larger subpopulation of apoptotic cells was
present when compared to vehicle treated cells (21.2% vs. 48.6%). Conversely, the
NRAS cell population was predominantly composed of viable cells subsequent to CQ
treatment. Further, when compared to NRAS treated cells, BRAF treated cells had a
greater percentage of cells undergoing apoptosis demonstrating that the decrease in cell
viability seen following CQ treatment was a consequence of inhibiting autophagy rather
than overt toxicity. In addition, the activity of caspase 3/7 was over 5X greater in the
cells with 20 μM CQ compared to untreated BRAF* cells, while there was no significant
difference between the NRAS* treated or untreated cells (Figure 3)
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2.5.3 Effect of Serum Starvation on Oncogenic BRAF and NRAS Melanoma Cells.
Under nutrient-deprived conditions, autolysosomes become more acidic as demonstrated
by an increase in Cy3-red lysosomal staining of the cells. Following incubation for 0.5
hour in SFM, both NRAS and BRAF showed a marked increase in LC3-puncta colocalizing with lysosomal staining, indicating an increase in the number of autolysosomes
(Figure 4). Quantification by SlideBook software of LC3 positive puncta (~ 100 cells/
triplicate experiment) from either BRAF* and NRAS* melanoma cells grown in NM or
SFM indicated that serum deprivation induces LC3 puncta to form large structures at 0.5
hour in BRAF* cells (Figure 4a and c). Serum deprivation also induces LC3 puncta
formation at 0.5 and at 2 hours in NRAS cells (Figure 4b and c). Note that although
serum starvation induces both autophagosomes (green) and autolysosomes (yellow) in
BRAF* melanoma cells, indicating autophagic induction, the quantity of autolysosomes
are inhibited at 2 hours of serum starvation. In addition, in BRAF* cells extended serum
deprivation (2 hours) shows a decrease in LC3 size and number with continued starvation
(Figure 4a). As shown in the quantification of LC3 immunofluorescence puncta, as a
ratio of the percentage of cells displaying punctate fluorescence out of 100 cells,
compared to control cells in an average of three independent experiments the attenuated
response in BRAF* cells lines shortly after serum starvation suggesting an exhaustion of
the autophagy pathway (Figure 4).
2.5.4 Effect of Autophagy Inhibition and Induction on Oncogenic BRAF and
NRAS Melanoma Cells. Following treatment with autophagy inhibitors (BAF or CQ) or
an inducer of autophagy (RAP) BRAF* and NRAS* cells displayed differential
autophagic responses to these chemical treatments (Figure5a-e). Following CQ or BAF
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treatment BRAF cell lines reveal an up-regulation of LC3-II protein expression,
indicating a higher rate of autophagy in these melanoma cell lines as indicated by the
numerous, large LC3 puncta. These large LC3 puncta are indicative of impaired
autophagic flux and demonstrate decreases co-localization with lysosomes (red) which
represent a higher basal autophagic flux in BRAF* cells. Conversely, in the NRAS* cells
autophagic inhibition by CQ or BAF addition induces very few LC3 puncta to form large
structures. For autophay induction, RAP addition results in an increase in lysosome/LC3
co-localization as well as LC3 puncta indicating autophagy induction in both types of cell
lines. Figure 5a-e). BRAF* cells display a much higher basal level of autophagic flux as
indicated by large number of autophagosomes (green) and autolysosomes (yellow) while
RAP addition induced a substantial increase in lysosome/LC3 co-localization. The large
statistical increase in NRAS autolysosomes following RAP induction confirms the
capacity of these cells to utilize autophagy (Figure 5c) but indicates low levels of basal
autophagy.
2.5.5 Differential Rates of Autophagic Flux: Differential rates of autophagic flux
were validated using LC3 protein quantification and the LC3-II turnover assay by
western blot (Figure 6 a-e). BRAF LC3-I and LC3-II protein levels were higher than the
expression levels in represented in the NRAS cell lines. BRAF cell lines also demonstrated
significantly increased level of LC3-II expression after CQ treatment, suggesting a break
in autophagy flux. A subsequent accumulation of LC3-II that would have otherwise been
degraded following conjugation into the inner autophagosomal membrane during the
completion of autophagic flux may explain the eventual increase in LC3-II levels.
Conversely, NRAS cell lines demonstrated a negligible change in LC3-II expression
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following inhibition of autophagy, suggesting that these cells are not as dependent on this
process.
2.5.6 Association of LC3 Gene Expression with NRAS/BRAF Expression: Gene
expression experiments examining the relationship between NRAS, BRAF and LC3 using
RT-PCR indicate a trend between BRAF expression and LC3 expression in our cell lines.
LC3 gene expression decreased at 24, 48 and 72 hours following BRAF knockdown.
While LC3 gene expression did decrease slightly at 24 hours following NRAS knockdown
there was no continued trend with NRAS expression.
2.6 Discussion.

2.6.1 BRAFV600E or NRASQ61R Genotype Determines Melanoma Sensitivity to CQ
Treatment.
In this study, our data demonstrated CQ attenuated cell viability in BRAFV600E cell
lines when compared to NRAS Q61R cell lines treated with an equivalent dose. This data
implies a variation in the basal levels of autophagic flux of these two oncogenic cell lines
that are subsequently differentially affected by chemical inhibition.
Upregulation of autophagy related (ATG) genes results in the conjugation of
cytosolic LC3 (LC3-I) to form LC3-II-PE which is recruited to the autophagosomal
membranes.6 When the intra-autophagosomal components are degraded by lysosomal
hydrolases, LC3-II-PE is also degraded. Lysosomal turnover of LC3-II-PE reflects
autophagic flux, and the detection of LC3 by immunofluorescence is a reliable method
for monitoring autophagy.34 CQ disruption of lysosomal function causes a dysregulation
in autophagosome turnover resulting in an increase in the number of autophagosomes
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present in the cell.5,34 Similarly, a defect in autophagy turnover results when autophagy
has been induced but there is limited autophagic flux. Subsequently, this leads to a
reduction in the overall rate of autophagic flux and an increase in type II cell death. Our
data support that BRAF* cells are dependent on late-stage autophagy for maintenance of
an active metabolic state and undergo apoptosis when treated with autophagy inhibiting
agents such as CQ (Figures 1-5). 35,36 Some cancer cell types have been shown to rely on
autophagy for survival as evidenced by an increase in autophagosome production and
autophagic flux while under nutrient depleted conditions (Figure 4). 18,37,35 Further, this
dependence on autophagy for survival has been described as “autophagy-addiction”.31
To that end, recent reports in the literature have revealed that tumor cells harboring BRAF
V600E

mutations develop an addiction to autophagy as a means to preserve mitochondrial

function, as well as for glutamine metabolism, suggesting that oncogene mutation status
may dictate basal levels of autophagy. 38 These findings suggest that inhibiting autophagy
may be a powerful strategy for BRAF V600E -driven malignancies that develop resistance
to selective inhibition.
2.6.2 Oncogene status dictates melanoma CQ sensitivity, altering autophagic
flux and increasing apoptosis. Through in vitro assays we showed a significant
decrease in cell viability following inhibition of autophagy in BRAF V600E melanoma cell
lines which we then characterized as apoptotic cell death. Supporting the idea that
oncogene status alters autophagic flux, we observed a diminished effect on cell viability
in NRASQ61R after CQ treatment. This phenomenon was evident as an 8-fold difference in
the IC50 for CQ in BRAFV600E melanoma cell lines compared to NRASQ61R was observed
(Table 1; Figure 1). We verified that the reduction in cell viability following CQ
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exposure resulted in a significant increase in apoptotic cell death in BRAF* cell lines
following CQ inhibition compared to the NRAS* cell lines (Figure 2 and 3). These data
indicate that BRAF V600E melanoma cell lines are more sensitive to CQ induced inhibition
of autophagy and that inhibition of autophagy in these cells as shown by our data
(Figures 2 and 3) results in apoptotic cell death. While CQ is currently being investigated
in cancer trials, without a clear understanding of the biological mechanisms underlying
the mode of action for this treatment, we may be unable to appropriately target those
patients who can benefit from this combination therapy. Our data indicate that only
patients with BRAF* melanomas may be responsive to autophagy inhibition with CQ as a
co-therapy (Figure 1-3; Figure 5).
2.6.3 BRAF cells have more basal LC3 puncta and, following autophagy
inhibition or induction, oncogenic cell lines display different rates of
autophagic flux. In this study dysregulation is represented by higher basal expression of
LC3-II puncta in the BRAF V600E cell lines compared to NRAS Q61R cell lines (Figure 4
and 5). Thus these data are consistent with the hypothesis that cell lines with BRAF V600E
mutations may be more dependent upon autophagy for survival than NRAS Q61R cell lines.
In addition, the inability of BRAF* cells to upregulate autophagy over 2 hours following
serum starvation (Figure 4) reinforcing the elevated basal level maintained in these cells.
The failure of these cells to have the capacity to increase autophagic degradation rates in
response to serum deprivation suggests these cells have upregulated basal autophagy to
threshold. 39 The data that NRAS*cells can increase autophagy following serum starvation
as well as following RAP induction indicate that these cells can use the autophagy
pathway to survive nutrient depletion but they are not dependent upon this pathway under
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basal conditions. In addition, we demonstrated an increase size in LC3 puncta in CQtreated BRAF V600E cell lines (Figure 4), suggesting autophagosome accumulation as a
consequence of lysosomal inhibition by CQ. By contrast, we did not observe the same
level of LC3-II aggregation and autophagosome accumulation in the NRAS Q61R cell lines
treated with the same dosage of CQ. Further, using the western assay, we showed a
decrease in overall LC3-I and an increase in LC3-II protein expression following CQ
treatment (Figure 6) in BRAF* cells but not a corresponding decrease in NRAS* cells
indicating that autophagy is induced at higher basal levels in BRAF* than NRAS*
melanoma cells.
To determine if BRAFV600E was associated with autophagy activation, we
knocked down either BRAF or NRAS in melanoma cells and evaluated the corresponding
change in LC3 gene expression (Figure 7). These results indicate showed knock-down of
BRAF significantly decreased LC3 expression. These results are consist with the
association of the BRAF* and increased rates autophagy. We did not see a corresponding
consistent trend with NRAS knockdown providing evidence that, while BRAF* correlates
with LC3 expression, NRAS* expression does not. Previously, a positive correlation
between LC3 protein and levels of BRAF has been also reported lending further support
to our conclusions.32
Currently, BRAF inhibition is accomplished clinically by treatment with
vemurafenib, a specific BRAF V600E ATP-competitive, small-molecule inhibitor. Studies
have reported the development of NRAS mutation in patients following vemurafenib
treatment for BRAF melanoma.40 This important finding reiterates the significance of
understanding the biological mechanisms underlying the induction of the autophagy
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pathway, as BRAF inhibition resistant tumors might also lose their sensitivity to
chloroquine following acquisition of NRAS mutations. BRAF is an amino acid sensor and
has been shown to positively regulate autophagy in colon cancer cells. Under nutrient
deprivation conditions or with constitutive activation of BRAF, MAPK is induced and
results in the upregulation of autophagy. As part of the MAPK pathway, Extracellular
Signal-regulated Kinase (ERK) regulates the maturation of autophagic vacuoles and
constitutive activation of the MAPK.41 MAPK activation results in the inhibition of
mTORC1/2, as well an increase in the expression of Beclin 1 (Atg6), a protein with a
central role in autophagy initiation. Through these interactions we speculate that BRAF
may be facilitating an increase in basal autophagic flux (Figure 8). This speculation is
supported by recent data reporting that the use of combination BRAF and autophagy
inhibitors promoted tumor regression in BRAF inhibition -resistant xenografts.42
Limitations of our study include the absence of the characterization of the rate of
autophagic flux in a BRAF/NRAS wildtype cell line. However, as melanoma is a highly
mutagenic cancer, even a cell line that that expressed wildtype NRAS and BRAF would
have other mutations which might impact autophagy independently diminishing the
relevance of this comparison.
In the current study we determined that autophagy was up-regulated in BRAFV600E
melanoma cells when compared with NRASQ61R melanoma cells as measured by
immunofluorescence and western blot analyses and that inhibition of autophagy resulted
in apoptotic cell death specifically in the BRAF* cells. Finally we identified a trend in the
gene expression of a proxy marker of LC3 and BRAF expression but no corresponding
trend with NRAS expression.
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Despite the recent success of BRAFV600E specific inhibitors, chemo-resistance quickly
occurs which suggests that other signaling mechanisms, like autophagy, may contribute to
progression in this subtype of melanoma. Our findings implicate a positive association

between the expression of BRAF V600E mutations in melanoma cells lines and the rate of
autophagic flux. While both BRAF and NRAS mutations activate ERK/MAPK
signaling,43 our research reveals that melanoma cells harboring BRAF V600E mutations
utilize autophagy as a metabolic resource to a greater extent than NRAS* cells. In
addition, the BRAF* and NRAS* pathways, may have opposing effects on the rate of
autophagic flux in melanoma. Our results indicate that BRAF* melanoma cells are
addicted to autophagy and support BRAF activation of autophagy, potentially through
Beclin1, 44,45 thereby promoting tumor survival (Figure 8). 30,43
In conclusion, BRAF* melanoma cancer cells are more susceptible to autophagic
inhibition, while NRAS* melanoma cells appear less dependent on this pathway which
implicates this process as a viable and attractive target for future therapies. The
identification of an association of autophagy dependence and BRAF V600E melanoma
suggests that drugs like CQ, that suppress this process, may also have therapeutic
potential for aggressive tumor types and that there is differential activation of the
autophagy pathway in BRAF* vs. NRAS* melanomas.
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2.9 Tables and Figures
2.9.1 Table 1: Oncogene status and gender summary for Memorial Sloan
Kettering melanoma cell lines (SK-Mel).

Table 1: Memorial Sloan Kettering Melanoma Cell
Cell Line Gender
p53
B-RAF
N-Ras
19
Female
WT
V600E
WT
29
Male
WT
V600E
WT
94
Male
WT
V600E
WT
2
Male
WT
WT
Mut/Q61R
103
Male
WT
WT
Mut/Q61R
147
Male
WT
WT
Mut/Q61R

2.9.2 Figure 1: Cell Treatment with 20 µM CQ. Average percentage of viable cells
(n=3) following treatment with vehicle or 20 µM CQ (A) BRAF V600E mutant melanoma
cell lines (SK-Mel 2, 19, 29) (B) NRAS Q61R mutant melanoma cell lines (SK-Mel 94,
103, 147) (mean ± SD *, P <0.01; **, P <0.001; ***, P <0.0001).
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2.9.3 Figure 2a-d: Annexin V/PI staining by flow cytometry. Flow cytometric
analysis of melanoma cell apoptosis in culture. Untreated and CQ treated cells collected
after 24 h of culture were stained with PI and FITC-labelled Annexin V. Two melanoma
cell lines, one BRAF and one NRAS were treated either with vehicle (Figure 2a and c) or c
20 µM CQ (Figure 2b and d) for 24 hours prior to staining with Annexin V and
propidium iodide (PI). Viable cells with intact membranes were represented by the
unstained portion (Annexin V and PI negative) in the lower left, while and Annexin V
stained cells, indicating early apoptotic cells, are represented in the lower right (Annexin
V positive/ PI negative). The upper left portion represents necrotic cells (Annexin V
negative/PI positive) while cells with disrupted membranes are undergoing late apoptosis
or are already dead are represented in the upper right (Annexin V positive/ PI positive).
Insets represent the percentage of cells in each quadrant.
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2.9.4 Figure 3a-b: Caspase activity luminescence assay. BRAF (SK-MEL19) or
NRAS (SK-MEL 103) mutant cells were treated with either vehicle or 20μM chloroquine
for 24 h. Following treatment the caspase 3/7 activity of each triplicate group of cells was
quantified by a luminescence assay. Data are mean ± SD of two sets of different triplicate
experiments. * P < 0.005.
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2.9.5 Figure 4a-c: Immunofluorescent staining of melanoma cell lines before
and after autophagy induction by serum starvation. (A-B) Autophagy was
induced by serum starvation through culture in serum-free medium (SFM) for indicated
time points. Control cells were cultured in normal media (NM) containing FBS and
vehicle. Live cells were treated with lysotracker and then cells were fixed prior to
additional staining with Anti-LC3 FITC and DAPI. Composite images of LC3 (green)
with lysosomal (red) and nuclear stain (blue) or co-localization shown by yellow dual
staining of LC3 (green) with lysosomal (red). Cells were examined by Zeiss Axioskop
2MOT microscope × 620. *P < 0.05. A) BRAF mutant melanoma cells in NM or SFM.
B) NRAS mutant melanoma cells in NM or in SFM. C) Histogram of quantification of
LC3 immunofluorescence puncta as a ratio of the percentage of cells displaying punctate
fluorescence out of 100 cells compared to control cells in an average of three independent
experiments. *P < 0.05.
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2.9.6 Figure 5a-e: The effect of autophagic chemical inhibition by CQ or BAF
treatment, or RAP induced autophagy, in melanoma cells.
Oncogenic melanoma cells were treated with vehicle, (A) rapamycin (1 μM)(RAP), (D)
cloroquine (CQ)(20 µM) or (D) bafilomycin A (BAF)(20nmol/L) for three hours.
Quantification of autophagy induction (C) or inhibition (E). Control cells were cultured
in normal media containing FBS and vehicle. Live cells were treated with lysotracker and
then cells were fixed prior to additional staining with Anti-LC3 FITC (green) and DAPI
nuclear stain (blue). Composite images of LC3 (green) with lysosomal (red) and nuclear
stain (blue) or co-localization shown by yellow dual staining of LC3 (green) with
lysosomal (red). Cells were examined by Zeiss Axioskop 2MOT microscope. × 620.
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2.9.7 Figure 6a-b: Western blot analysis of LC-3B.
(A) Western blot and (B) Quantitative Analysis of (A). Relative LC3 protein expression
in BRAF and NRAS mutant melanoma cell lines when treated with vehicle (-) or 20 µM
CQ (+) for 24 hrs. (B) Protein quantification from Western blot using densitometry of
LC-3B-II in BRAF or NRAS mutant melanoma following treatment with vehicle or 20
µM CQ as indicated. Results are shown as arbitrary units (AU) normalized to β-Actin
(mean ± SD; **, P < 0.01; ***, P < 0.001; n =3).

A.

B

.

SK-MEL 103

SK-MEL 19

2.9.8 Figure 7: Suppression of BRAF or NRAS mRNA expression by siRNA.
SK-Mel cells were transiently transfected with si-BRAF; si-NRAS or scrambled siRNA
(Scramble). Twenty-four, forty-eight or seventy-two hours after siRNA or scramble
treatment, total RNA was extracted from transfected cells and quantified using real-time
PCR. Expression levels of BRAF and LC3 mRNA were significantly suppressed by si-
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BRAF (A) and expression levels of NRAS mRNA were significantly suppressed by siNRAS (B) but had an insignificant influence on LC3 mRNA. Results are normalized to
the expression level of B-actin mRNA and are expressed as the ratio of BRAF, NRAS or
LC3 expression to scramble. Data are presented as mean ± SD of three replicate
experiments.

2.9.9 Figure 8: Melanoma cells with activating BRAF* or NRAS* have
differential dependence on autophagy
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CHAPTER THREE:
Quantitative Analysis of Immunohistochemistry in Melanoma Tumors and LC3
and Beclin 1 Expression in Melanoma Lesions: Association with UV Exposure
and Prognostic Indicators.
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Supplemental note: Due to the current subjective quantification of protein expression, in
order to rigorously address whether autophagic flux is associated with UV exposure
and/or clinical stage and modified by oncogenic BRAF/NRAS in melanoma tumors, I
developed a novel quantification method which removes this aspect from the evaluation
of proteins by IHC in melanoma.
3.1 Abstract:
Aims: Interpretation of protein expression, by immunohistochemistry (IHC), in
melanoma tissue sections is difficult and subjective. Inter/intra-observer variability even
among experienced dermatopathologists and inherent pigmentation, make diagnostic
reproducibility challenging.
Methods: We sought to identify a quantitative method for measuring IHC protein
expression in melanoma tissues. In the current study, we used IHC HRP-DAB with an
Azure counterstain, to develop a quantitative measurement of protein expression using
spectral imaging technology.
Results: We examined the distribution of mean intensities from DAB-labeled protein in
different participants using different Azure reference spectra to remove (unmix) melanin
stain. We identified no significant differences in mean DAB intensities (p=0.73; KruskalWallis).
Conclusions: To our knowledge, this is the first study to use spectral imaging to quantify
IHC protein expression in melanoma lesions. Using this methodology, the absorbance
spectra of the reference is not affected by overall label intensity, allowing IHC
interpretation to be independent of high visual contrast chromogens. This has important
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implications particularly for pigmented tissue sections. This quantification method
reduces the subjectivity of protein expression analysis and provides a valuable tool for
accurate evaluation.
Keywords: Immunohistochemistry; melanoma; spectral imaging

3.2 Introduction:
Immunohistochemistry (IHC) is an important technique to both researchers and
clinicians1, and is used to identify the presence and location of protein2. Most cancer
research employing IHC utilizes formalin-fixed paraffin embedded (FFPE) tissues that
have been sectioned and mounted onto slides. For clinicians, IHC is particularly
important in the diagnosis of cancers, including melanoma, as it allows for identification
of overexpressed proteins. These protein biomarkers, for example S100 and HMB-45 in
melanoma, can predict disease progression and identify potential therapeutic targets.
Standard IHC is a multi-step technique that has two major stages—antigen
retrieval/staining and analysis. The first step in the staining stage is deparaffinization and
rehydration of the tissue section. The tissue section is incubated in a buffer under high
heat to remove cross-links formed during the fixation process and “expose” proteins of
interest. Antigen retrieval unmasks antigens within the tissue section for binding to
antibodies, followed by a series of steps to block antibody binding to non-specific
proteins and the removal of endogenous peroxidases. Next, the tissue is incubated with a
high affinity primary antibody specific to the protein of interest. Visualization of the
protein is accomplished using a chromogen substrate and an enzyme, such as horseradish
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peroxidase (HRP), is conjugated to either the primary antibody or a secondary antibody
against the primary antibody.
The addition of the chromogen bound to the substrate-conjugated antibody results in
substrate cleavage, producing a colored stain at that location, and thereby indicating the
presence of the target protein. The most commonly utilized substrate-chromogen
combination is HRP (substrate) 3,3’-Diaminobenzidine (DAB) (chromogen), which
results in a brown stain and there are a limited number of substrate-chromogen
combinations available for IHC 3.

Once the tissues are developed, they are dehydrated and mounted with a stabilizing
mounting medium and coverslip for visualization. The stains are visualized using
microscopy and quantified through a variety of methods. Current IHC analysis is semiquantitative; typically several readers use a subjective scoring system. The scores are
subsequently compared in order to assess inter-reader variability4.

The limitations of this semi-quantitative method have been particularly troublesome in
melanoma, because the melanin pigment is brown, creating challenges for both
researchers and clinicians to accurately differentiate between DAB staining and melanin,
potentially impacting accurate diagnoses. Given the importance of this tool, there is a
need for a non-subjective quantitation method that can be applied to IHC in melanoma
tissue sections.
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In 1991, Kamino and Tam identified that Azure B, hereafter referred to as Azure, acts as
an appropriate counterstain in melanoma sections5. They reported that Azure stains
melanin green-blue, allowing for its identification in contrast to the surrounding tissue.
However, this method was still quantified using the scoring system, and therefore relies
on subjective interpretation.
Azure, a cationic dye, is one of the major metabolites of methylene blue and is used in
chromosomal tissue staining6. While the selective binding is not well characterized in the
literature, we propose, as a provisionary mechanism, that the heterocyclic nitrogen in
Azure functions as a base7 to deprotonate carboxylic acids found in melanin. This would
allow for ionic interactions between melanin’s anion and the cations in Azure. Acidic
interplay, in conjunction with hydrogen bonding, likely results in the preferential staining
of the melanin (Supplemental Figure 1).
With advances in imaging and associated software, we sought to identify a quantitative
method for measuring protein expression in melanoma tissues. In the current study, we
used IHC HRP-DAB staining in melanoma tissues, with Azure as a counterstain, to
develop a quantitative measurement of protein expression using spectral imaging
technology.

3.3 Methods:
3.3.1 Tissue samples:
Melanoma tissue sections were obtained from two different sources: University of
California Surgical Pathology Laboratory and the University of New Mexico Hospital
(UNMH) Surgical Pathology Laboratory. California Surgical tissues were selected from a
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residual bio-repository of de-identified FFPE tumor blocks from patients diagnosed with
malignant melanoma between 1990 and 1999 in Los Angeles County. New Mexico
tissues were selected from the University of New Mexico Ultraviolet Light Exposure and
Immunosuppression in Melanoma bio-repository (INST 0815 HRRC 08-433).
Non-pigmented control tissue was obtained from breast reduction mammoplasty surgery
between November 2007 and January 2011 as previously described8. This sample was
collected with IRB approval and was de-identified.
3.3.2 Immunohistochemistry (IHC):
All IHC protocols were performed according to the antibody manufacturer’s instructions.
Briefly tissue sections were stained with antibody produced in rabbit and generated
against a C-terminus peptide in G protein-coupled estrogen receptor 1 (GPER) (clone
number 8073) at a dilution of 1:200 for one hour and fifteen minutes. The GPER
antibody was a generous donation from the laboratory of Dr. Eric Prossnitz. Tissue
sections were then incubated with 1:100 dilution of secondary goat anti rabbit-HRP
antibody for one hour (Sigma, St. Louis, MO).
HRP activity was visualized using the Liquid DAB Plus Substrate Kit (Life
Technologies, Carlsbad, CA) according to manufacturer’s instructions. Following
incubation with DAB, sections were stained with Azure for 10 minutes5. Tissue sections
were then dehydrated and mounted with a coverslip using permount.
3.3.3 Image Acquisition and Analysis:
Brightfield, spectral images of IHC labeled sections were generated at the UNM Cancer
Center Fluorescence Microscopy and Cell Imaging Shared Resource using a Nikon
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TE2000 microscope (Melville, NY) in transmitted light mode, which had been adjusted
for Koehler illumination. Images were obtained using a 60x oil objective, at 1.5x
intermediate magnification, and a Nuance Spectral Imaging Camera and software (Perkin
Elmer). The Nuance camera uses a liquid crystal tunable filter (LCTF), set to collect
transmitted light in 20 nm bandwidths, at 10 nm step intervals, from 420 to 720 nm. The
resulting spectral image cube consists of 16 separate images each acquired at a different
wavelength range. Each pixel in the resulting image cube has an absorbance spectrum
that depends on the absorbing materials (labels) that are present at that pixel location.
Nuance camera software controls both the LCTF and spectral image acquisition. Prior to
imaging of the tissues, a 100% transmission reference image cube was acquired from a
region of the slide with no tissue or other debris and was used to convert all images to
optical density (OD) images. Spectral image cubes collected from melanoma sections
labeled only with Azure or anti-GPER-DAB were used to generate pure absorbance
spectra for each of these labels. These pure spectra were then used by the Nuance
software to unmix (using a linear unmixing algorithm) image cubes acquired from slides
labeled with both Azure and DAB, generating single component images of each label.
Absorbance spectrum imaging and unmixing of IHC labeled sections has been previously
described9.
Three reference spectra (pure absorbance spectra) of Azure were generated from 3
separate patient tumors, each labeled only with Azure. A single reference spectrum of
GPER-DAB was generated from a GPER-positive, non-pigmented tissue section labeled
only with anti-GPER DAB. To quantify the staining, we generated three spectral
libraries, each consisting of two spectra: 1) GPER-DAB reference spectrum and Azure
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spectrum from patient tumor section A; 2) GPER-DAB reference spectrum and Azure
spectrum from patient tumor section B; 3) GPER-DAB reference spectrum and Azure
spectrum from patient tumor section C.
Additional tissue sections from the same three patient tumors were doubly labeled with
GPER-DAB and Azure and spectral image cubes were acquired with the Nuance camera.
These spectral image cubes were unmixed with each of the three spectral libraries
described above. The Azure component images show location of the counterstain and
tissue structure; GPER-DAB component images show GPER-expressing cells in the
section.
GPER-DAB component images were exported from the Nuance software as TIF images,
imported into Slidebook software 6.0 (3i, Intelligent Imaging Innovations, Denver) and
the GPER-DAB staining was quantified. Component GPER-DAB images were inverted
from absorbance to pseudofluorescence for analysis. In the inverted images, higher
pseudofluorescence intensity corresponds to higher absorbance (DAB concentration). A
segment mask was created by setting a threshold to eliminate background. Intensity
values above the threshold represent DAB labeling. A single threshold level was
determined by examination of multiple images and was used for quantifying all of the
DAB component images. Segmentation masks were created on each doubly labeled
patient section. Utilizing the mask statistics function in Slidebook, we exported the mean
intensity value of each masked region in the GPER-DAB component images for
statistical analysis.
3.3.4 Statistics:
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Mean intensity of anti-GPER-DAB in the three sections stained with GPER-DAB and
Azure was compared following unmixing with the three reference spectral libraries
described above, generating three mean intensities of GPER-DAB staining for each of the
participants. Since the distribution of mean intensities of GPER-DAB staining
(distribution) might not meet normality assumptions, we used the Kruskal–Wallis oneway analysis of variance (ANOVA) to compare the distributions. The null hypothesis
was that the distributions for each of the participants would be equal. The alternative
hypothesis is that the distribution for at least one of the participants is different from the
distribution for other participants.
3.4 Results:
3.4.1 Azure reference spectra do not vary between tissue sections:
Because the absorbance spectrum of melanin may vary from person to person, the
spectrum of Azure bound to melanin may also vary from person to person, as the melanin
pigment masked by Azure staining will be included in the absorbance spectrum.
Additionally, we were concerned that the affinity of Azure to bind to melanin may also
vary from person to person. To address these concerns, we compared Azure spectra
across melanoma tissues samples from three different participants.
Figure 1 shows the three Azure reference spectra (blue, green, and red lines) generated
from melanoma tissues sections labeled with Azure only from three different participants.
A GPER-DAB reference spectrum (brown line) was generated in a non-pigmented tissue
section stained only with GPER-DAB. Importantly, the three Azure spectra overlap and
are visually comparable (Figure 1).
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3.4.2 Quantification of GPER-DAB staining in tissue sections with Azure
counterstain:
As described previously, from the spectra represented in Figure 1, we generated three
spectral libraries which included one Azure spectra derived from the three different
participants and the GPER-DAB spectra derived from the non-pigmented tissue section.
Each of these spectral libraries is named A, B, or C (Figure 2 and Table 1) consistent
with the participant (A, B, or C) from which the Azure spectra was derived.
Melanoma sections stained with both GPER-DAB and Azure for each participant (A, B,
and C) were imaged with the Nuance spectral camera, generating spectral image cubes,
referred to in Figure 2 as Original Image. The Nuance software creates a single image
representation of the spectral cube, using a lookup table that maps different patterns of
absorbance to different colors which we refer to as the original image. Although the
original image appears to show good localization of label, accurate location information
is obtained only after unmixing the original image, using a spectral library with reference
spectra for each of the labels on the section. The original image from participant A is
shown in Figure 2.
Using spectral library A, comprised of the Azure spectra from participant A and the
spectra from the non-pigmented GPER-DAB tissue, we unmixed the original image from
participant A. We also unmixed the original image from participant A using the spectral
libraries that included Azure spectra generated from participants B and C. As shown in
Figure 2, these GPER-DAB component images appear nearly identical.
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Similarly, we unmixed the original images from participants B and C with all three
spectral libraries, resulting in three GPER-DAB component images per participant, and
nine GPER-DAB component images total for participants A, B, and C. The component
images for GPER-DAB are shown for participant A in Figure 2, and the mean intensities
are reported for each of the nine GPER-DAB component images in Table 1.
To compare the distribution of mean GPER-DAB intensities of participants compared to
themselves but unmixed with different Azure reference spectra, we performed a KruskalWallis test and identified no significant differences (Table 1). These results indicate that
the reported mean intensities vary slightly depending on the Azure reference spectra.
However, these differences are not significant for any of the patient samples (p=0.73
p>0.05; One-way ANOVA with Kruskal-Wallis). Importantly, this suggests that one
Azure reference spectrum is sufficient to unmix dual-stained images from multiple
participants, eliminating the need for a separately stained section and Azure reference
spectrum for every individual.
3.5 Discussion:
We have shown that using Azure as a counterstain in pigmented tissue sections, such as
melanoma tumors, allows for quantification of HRP-DAB staining using spectral imaging
techniques. Acquisition of spectral images of IHC stained melanoma tissue samples and
subsequent unmixing using reference spectra, allows DAB-labeled protein to be
quantified without interference from highly pigmented melanin. Although not
demonstrated here, this method also allows for the observation of co-localization and
quantitative measurement of multiple staining components. Unmixing is based on the
absorbance spectra of the labels, is not affected by overall label intensity and is non107

subjective, meaning that IHC is no longer dependent on the chromogens showing a high
visual contrast with pigmentation or other chromogens.
Importantly, this method allows for elimination of inter-reader variability by using
spectral imaging to evaluate highly pigmented tissues. This finding improves the current
semi-quantitative method of IHC, and increases the utility of IHC for both researchers
and clinicians.
This study has many strengths. First, we have identified a non-subjective method to
quantify protein expression in pigmented melanoma tissues. Furthermore, it is likely that
this method would also provide a non-subjective method for quantification of protein
expression in non-pigmented tissues, along with tissues using multiple chromogens.
Additionally, we used archival tissues to validate that this technique can be applied to
stored samples. Stored samples serve as a valuable resource for biomarker validation
studies, but are often limited by the quality of the specimen and the loss of antigenicity
over time.
The discovery that one Azure reference spectrum can be used for every participant has
important implications. First, it will lessen the amount of time needed to image tissue
sections by eliminating the need to image an Azure reference for every participant. This
will also hasten the unmixing process, as each participant’s dual-stained image will be
unmixed using the same spectral library, allowing for batch unmixing. Finally, this will
reduce the number of tissue sections needed from each participant, thereby allowing
precious samples to be used for additional biomarker testing.
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In summary, to our knowledge, this is the first study to use spectral imaging to quantify
protein expression in pigmented tissue sections. This quantification method reduces the
subjectivity and hastens analysis of protein expression detected by IHC. For clinicians,
non-subjective quantification of protein expression in melanomas may impact the current
diagnosis and staging standards. For researchers, quantification of protein expression may
further inform melanoma etiology, progression and identification of therapeutic targets.
Therefore, we expect that these findings will advance the field of melanoma.
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3.8. Tables and Figures

3.8.1 Figure 1: Azure Spectra do not vary between melanoma tissue sections

GPER

Azure

Absorbance spectra of GPER (
) and Azure acquired from
3 separate melanoma tissues (
).

3.8.2 Figure 2: Component images unmixed with different spectral libraries
A:

B.

Original image A unmixed
with Spectral Library A

Original image A unmixed
with Spectral Library B

Original image A unmixed
with Spectral Library C

A: Original image: GPER-DAB and Azure in Melanoma (Participant A). This is a single image
representation of a spectral image cube (containing 16 individual images).
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B. Component images representing GPER-DAB in melanoma: Original image (Participant A)
unmixed with three spectral libraries.

3.8.3 Supplemental Figure 1: Proposed mechanism for Azure binding to
melanin
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3.9 Abstract

LC3 and Beclin 1 Expression in Melanoma Lesions: Association with UV
Exposure and Prognostic Indicators.
Background: The activation of the autophagy pathway in BRAF melanomas is one
proposed mechanism involved in progression. Autophagy, a catabolic process, has been
shown to both inhibit and promote tumorigenicity. Autophagy inhibition is under
investigation in melanoma treatment. However, the melanoma risk factor, UV exposure,
activates autophagy. Here we investigated UV exposure and autophagy by BRAF/NRAS
status to test for differential contributions to melanoma prognostic factors and survival.

Methods: Sections from n melanoma tumors and n benign nevi were analyzed for
Beclin1 and LC3 expression, using immunohistochemistry. BRAF /NRAS status was
determined by sequencing. Beclin1 and LC3 expression levels measured by IHC were
correlated with UV exposure data. The effect of NRAS and BRAF pathways on autophagy
proteins was evaluated.

Results: We found that the autophagy pathway is activated with UV exposure in
melanoma tumors compared to benign nevi. We observed critical proteins in the
autophagy pathway associated with decreased Breslow depth (Beclin1) as well as
decreased mortality (LC3).
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Conclusions: The expression of Beclin1 and LC3 was not directly linked BRAF or NRAS
mutations in melanoma; rather, autophagy was activated in response to UV exposure and
associated with prognostic indicators and survival. These findings may have implications
concerning the biology of melanoma and for ongoing autophagy inhibition clinical trials.
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3.10 Introduction:
Invasive melanoma has an increasing incidence of 6% each year but with new
clinical treatment options for advanced melanoma. The American Cancer Society
estimates that in 2015, 73,870 new melanomas will be diagnosed and 9,940 people will
die from their disease. Despite the introduction of new therapies, the 5-year survival rate
for stage IV melanoma will remain unchanged at 15% to 20%.1
Autophagy is a cellular recycling pathway involved in normal physiological
processes including nutrient and/or stress responses, antigen presentation, and aging.3–8 In
cancer, autophagy appears to be an important energy source for nutrient depleted tumors.
9–11

In melanoma, basal levels of autophagy appear to vary by tumor stage, and higher

levels of autophagic flux are associated with increased hypoxia and poor clinical
prognosis. 11–15 Mutations in BRAF and NRAS differentially regulate autophagy. 16–22 In
2010, Lazova and colleagues reported that melanoma cells contain high levels of
autophagosomes, a cellular structure associated with autophagic flux, as measured by the
proxy marker microtubule-associated protein 1 light chain 3 (LC3), an autophagy related
(ATG) protein.11 LC3 is integrated into the membrane of a critical structure in autophagy,
called the autophagosome, in order to facilitate the recycling of products targeted for
degradation. This integration creates a punctate LC3-staining pattern, which is used as a
proxy marker for the rate of autophagy. 11 The role of LC3 and another critical protein in
autophagy initiation, Beclin 1 (Becn1), may have a biphasic role in cancer. 3 LC3 levels
have been shown to be elevated in the cytoplasm of cancer cells including
gastrointestinal23 and pancreatic cancer.24 and have been reported to be associated with
stress response, metastasis and poor clinical prognosis in melanoma.15,19,25,26 Becn1 has
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been reported to be associated with increased stage27, lower relapse-free survival 28 and
decreased 5-year survival in several cancers.29 Elevated levels of LC3 and Becn1 as well
as other autophagic proteins correlated with poor prognosis or cancer progression have
prompted Phase I/II clinical trials to investigate autophagy inhibition as a co-therapy,
particularly in melanoma.30–32
Conversely, it also appears that there is an inverse relationship between expression of
autophagy markers and malignant potential, so in some cancers lower levels of autophagy
are associated with worse prognosis. This implies that defects in cellular autophagy may
contribute to the development of cancer33 and that cancer cells may have lower basal
autophagic activity. 34–37 Low levels of both Becn1 and LC3 have also both been reported
to associate with poor clinical pathological markers and decreased survival 38–40 in
melanoma, among other tumors.41,42 Becn1 in particular has been shown to exhibit antioncogenic functions, has been found to be monoallelically deleted in breast, ovarian and
prostate tumors.43–46 Finally, low levels of Becn1 have also been reported in nodular
melanomas to be associated with increased risk of early death.47

The dual role of

autophagy in the regulation and progression of melanoma require further investigation.
The role of these two autophagy proteins (LC3 and Becn1) in melanoma may, in part, be
influenced by their interaction with other factors including ultra-violet (UV) exposure.
UV’s impact on progression and survival in melanoma is also complex and unclear. 48,49
As autophagy appears to have a role in the resolution of double-stranded DNA
breaks50,51, it may be that UV induces autophagy and improves melanoma-specific
survival at the same time that it is the major risk factor for melanoma. The impact of UV
exposure on autophagic processes in skin has not been well characterized and there is a
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need for in-depth evaluation of role of autophagy in a set of well-defined melanoma
samples.52
In the current study, we seek to determine whether autophagy differentially regulates
prognostic characteristics and survival in melanoma depending on the timing of UV
exposure. We evaluated autophagy in 51 melanoma and 17 benign nevus tissue sections,
for LC3 and Becn1 protein expression, using immunohistochemistry (IHC) to determine
if autophagic flux is associated with clinical stage in melanoma. For the same samples,
using extensive questionnaire data, we evaluated the impact of estimated lifetime sun
exposure on survival and correlated these data with prognostic factors as well as available
information on autophagy levels. These results assessed whether autophagic flux is
modified by UV exposure. We hypothesized that UV exposure is associated with levels
of autophagy and autophagy markers are prognostic for clinical characteristics of
melanoma survival.
3.11 Material and Methods:
3.11.1 Patient Characteristics:
The New Mexico Tumor Registry and the University of New Mexico Cancer Center
identified study participants in which a skin biopsy was taken to rule out melanoma.
Study participants with melanoma or a benign skin biopsy (n=98) were interviewed using
a validated questionnaire for UV exposure.48,53 Institutional Review Boards of all
participating institutions approved the protocol and informed consent was obtained from
each participant. 46 melanoma and 17 patients who had a benign nevi excised, were
consented, enrolled and interviewed and selected based on availability of a tissue block
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(see patient characteristics below, Table 1-2). Survival was determined using the National
Death Index and provided by the Tumor Registry.
3.11.2 IHC Staining of LC3 and Becn1:
Formalin-fixed paraffin embedded (FFPE) control and melanoma sections were made
using archival tissue blocks from patient biopsies. Expression of LC3 and Becn1 in these
sections were measured as a proxy for levels of autophagy. Standard immunoperoxidase
techniques for immunohistochemistry using anti-LC3 and anti-beclin1 antibodies (MBL,
Woburn, MA; Cell Signaling Technology, Danvers, MA; 1:200; with citric acid/ antigen
retrieval) was used to quantify expression in melanoma cells (brown) compared to
tumor-associated melanophages (azure). Azure B stains melanin green blue and is easily
distinguished from the brown diaminobenzidine chromogen54. Original images were
obtained using a Nikon Scope from the UNM Fluorescence Microscopy Shared
Resource, equipped with a spectral imaging camera. Becn1 and LC3 staining intensity
were quantified by Spectral imaging software.55

3.11.3 BRAF, NRAS status:
Genomic DNA was isolated from FFPE tumor sections using Qiagen QIAamp DNA
FFPE kit (Qiagen, Inc., Valencia, CA). Patients’ BRAF/NRAS mutation status was
evaluated using standard PCR technique to amplify the coding region of interest. All
amplicons were directly sequenced on an ABI 3730xl DNA Analyzer (Applied
Biosystems, Foster City, CA) using BigDye Terminators (Applied Biosystems) according
to the manufacturer's specifications for sequencing. A 224 bp BRAF PCR product
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(chr7:140453033-140453256) was amplified using the primers 5′TCATAATGCTTGCTCTGATAGGA-3′ and 5′-GGCCAAAAATTTAATCAGTGGA-3′
and a 272 bp NRAS PCR product (chr1:115256298-115256569) was amplified using the
primers 5′- GGTGAAACCTGTTTGTTGGA-3′ and 5′AACCTAAAACCAACTCTTCCCA-3′ in a 50 ml reaction containing the 10 μL
(40ng/μl) DNA template, 5 μM of each primer, 2× Premix F (Epicentre, Madison,
Wisconsin) and 0.5 U of Taq polymerase in a PCR reaction as described above. DNA
template was denatured at 94°C for 4 min and cycled 26 times through steps of
denaturing at 94°C for 1 min, annealing 63-0.5c and denaturation. An additional 10
cycles of denaturing at 94°C for 1 min, annealing 50c and extension at 72°C; final DNA
extension was at 72°C for 10:00 minutes. PCR products were purified using ExoSap
(Affymetrix, Santa Clara, CA) according to manufacturer's instructions.
Sequencing chromatograms were read with the aid of FinchTV software version 1.4.0
(Geospiza, Inc., http://www.geospiza.com/Products/finchtv.shtml)
3.11.4 Clinical Stage:
Histopathology was characterized by a board-certified pathologist using Hematoxylin &
Eosin (H&E) stained slides and clinical stage was determined including Breslow
thickness, mitotic index and ulceration. Mitoses were defined as present or absent. 56 All
cases were characterized using these variables. Patient vital status was obtained through
linkage with the NM Tumor Registry, using an honest broker system with IRB approval
(HRRC 08-433).
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3.11.5 UV Exposure:
Using extensive questionnaire data, participants were retrospectively evaluated for UV
ambient exposure in the first decade of life and near the time of diagnosis. Questionnaire
data, which has been previously described,53 includes the following variables: daily sun
exposure on weekdays and weekends at each decade; sun exposure at the site of the
melanoma at each decade; and waterside recreational sun exposure at each decade.
3.11.6 Data Analysis:
Frequency tables were used to summarize the clinical distributions and UV exposures for
controls and melanoma cases (Table 1-2). Analysis of UV data with participant
characteristics was correlated with oncogene status and levels of LC3 and Becn1 protein
in melanoma tissue sections. Wilcoxon rank-sum tests and Pearson chi-squared tests were
performed for pair-wise associations. ORs and 95% CIs were calculated from nonparametric logistic regression models using data from cases and benign nevi controls to
assess the association with LC3 and Becn1 expression. The Pearson’s coefficient was
used to assess linear relationships. The relationship between categorical variables was
analyzed by Chi-square test or Fisher’s exact test. Univariate and multivariate analyses of
prognostic factors were performed by the Cox proportional hazards regression model.
ORs and 95% confidence intervals estimated from coefficients were used to summarize
the associations. For all tests, a two-sided P value <0.05 was considered statistically
significant.
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3.12 Results:
In the overall population we identified 24 BRAF T1799A (V600E) point mutations in 16
cases and 8 controls. Additionally, we found 6 cases with NRAS A182G (Q61R)
mutations. No controls had an NRAS mutation. There were 24 melanoma cases and 9
controls without a mutation in BRAF or NRAS. Protein levels were evaluated in 48
melanoma biopsies and 17 control tissues using the novel IHC quantification method we
developed and is described previously in chapter 3 (Table 2; Table 4).
After adjustments for age and sex, high Becn1 expression was associated with decreased
Breslow thickness (p=0.05), whereas high levels of LC3 were correlated with decreased
mortality among patients (p=0.02). Furthermore, females were more likely to have
tumors with high Becn1 expression (p=0.02) (Table 3). Melanoma participants who
reported ever having a blistering sunburn were more likely to have high Becn1
expression (p=0.01) (Table 4). Becn1 expression was not associated with NRAS* or
BRAF* status. Superficial spreading histology (Table 3) and report of blistering sunburns
in early life had borderline associations with high levels of Becn1 and LC3 (P = 0.09, P =
0.08, respectively) (Table 4).
High LC3 expression was also positively associated with the expression of punctate LC3
(p=0.0007) (Table 3). High cytosolic LC3 expression correlated with NRAS WT
genotype (p=0.01) when compared to NRAS mutant Table 3). A lack of painful sunburns
for two or more days (p=0.03) was associated with high LC3 expression (Table 4). High
LC3 expression had a borderline significant associations with unprotected prolonged sun
exposure (p=0.06), boating activities and any outdoor activity sun exposure (p=0.08)
(Table 4).
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3.13 Discussion:
This study was designed to assess the association of oncogene status and UV exposure
with protein levels of Becn1 and LC3 in cutaneous melanoma. UV is associated with
both autophagy activation and melanoma incidence, and as both UV and autophagy are
complex.
Previously, it has been shown that Becn1 and LC3 protein levels are altered in several
human cancer types including melanoma and our data supports the fact that protein levels
vary between melanoma and control patient samples. 57 We also found that expression of
autophagy markers varied by Clark’s level and survival status.
High levels of Becn1 and LC3 are consistently inversely associated with poor prognostic
markers and/or survival. High Becn1 expression was associated with decreased Breslow
depth (the strongest prognostic indicator for melanoma) (p=0.05) (Table 3), whereas high
levels of punctate LC3 indicating autophagosome formation, had an association with
decreased mortality among patients (p=0.04) (Table 5). Early autophagy, as represented
by Becn1, was associated with lower stage at diagnosis, while late stage autophagy, as
represented by lower punctate LC3 expression, and was associated with decreased
mortality from melanoma (Table 5). Autophagy genes have previously been implicated
both in tumor suppression and tumor development.44 Becn1 has multiple functions. In
addition to its role in autophagy initiation, it is implicated in both the differentiation and
apoptosis of cancer cells.58,59 Lower Becn1 expression has been reported in both breast
cancer,60 and melanoma42 and the loss of Becn1 has been correlated with poor prognosis
in colon61 and liver50 cancer, lymphomas62 and squamous cell carcinoma.27
Overexpression of Becn1 is also correlated with progression of gastric and colorectal
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cancer63 and with poor prognosis in endometrial cancer. 29In our study the association of
high Becn1 with decreased Breslow thickness might indicate that it is acting as a tumor
suppressor in melanoma patients.
In our study, the expression of the Becn1 protein and also of the autophagosome protein
LC3 was found to be lower in melanomas with more aggressive prognostic indicators,
similar to findings in ovarian cancer. 38The expression of Becn1 and LC3 could also be
associated with UV in melanoma as both of these proteins were associated with UV
exposure
The relationship between UV and autophagy may have important implications for data
describing the autophagy pathway in melanoma progression.17,26 While melanoma only
accounts for approximately 2.4% of all cancer related deaths, it is the one of the most
common cancers in young adults, age 25-29, particularly in young women. This is of
particular importance as the mean survival rate of patients diagnosed with metastatic
melanoma is six months, with five year survival rates of less than 5%. UV exposure
causes DNA damage and can induce the activation of autophagy.
Extensive studies of the role of UV in survival with melanoma have been based on
careful measurement of UV and melanoma risk,53 and sun exposure and survival with
melanoma.48,64 We evaluated sun exposure at three times in life: early life up to the age
of 10, in the 10 years prior to diagnosis, and averaged over the lifetime. Studies have
shown that an individual’s lifetime sun exposure is well represented by the sum of their
exposures at each decade (e.g., 10, 20) of age. 65 We also evaluated sunburns and waterrelated activities. While not significant our study identified an association between water
activities and boating activities and increased Becn1 expression (Table 3).
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Previously it has been reported that the only significant UV predictors of melanoma
survival are UVB dose up to the age of 10 and sunburns in the decade prior to diagnosis.
48

Strangely, UVB dose up to the age of 10 increased the risk of dying from melanoma,

yet any sunburns in the decade prior to diagnosis decreased the risk of dying from
melanoma, even after adjusting for clinical characteristics.

As autophagy acts as a

cytoprotective mechanism against ultraviolet (UV)-induced apoptosis, Becn1 and LC3
expression may be upregulated following DNA damage from sun exposure.66
UV-radiation is an established risk factor for melanoma and increases autophagic flux. 67
UV exposure triggers defense mechanisms, including an increase in DNA repair
capacity,49,68 and autophagy has an established role in DNA repair by removing products
of DNA damage.
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Some researchers have found evidence that high levels of sun

exposure prior to diagnosis were associated with better melanoma survival.64 However,
contradictory evidence indicates high levels of UV exposure in childhood are associated
with worse survival and that high levels of UV exposure prior to diagnosis are associated
with better overall survival but not with better melanoma-specific survival. 48 In our study
we identified that UV exposure is independently associated with levels of autophagy as
shown by the high LC3 protein expression in individuals with decreased sunburns or no
participation in water sports (Table 4).
Our study is limited by the possibility that cells use other mechanisms, including post
translational modifications, to regulate protein expression so LC3/Beclin1 may stay
consistently expressed under variable conditions. In addition, our small sample size may
not really be representative of a larger population-based sample.
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In our study, high level of Beclin 1 and LC3 expression in tumors, correlated with less
aggressive histopathological markers including Breslow thickness, as well as better
overall survival of the patients. The present data support the idea that while autophagy is
associated with melanoma tumors, low level of autophagy favors cancer progression and
that autophagy may support more indolent melanoma phenotype. Understanding the
relationships between autophagy status, UV exposure and melanoma progression will
help to elucidate the molecular mechanisms that contribute to this disease.

Conflict of interest: The authors have declared that no conflict of interest exists.

3.14 ACKNOWLEDGEMENTS:
Financial support from NIH CTSA at UNM (UL1TR000041); K05 award
(K05CA131675); R21 1R21ES018705-01A1

126

3.15 REFERENCES
1.

American Cancer Society Facts and Statistics 2015 | Research | American Cancer
Society.
http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/.
Accessed June 8, 2015.

2.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013.

3.

Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword.
Science. 2004;306(5698):990-995. doi:10.1126/science.1099993.

4.

Choi AMK, Ryter SW, Levine B. Autophagy in human health and disease. N Engl
J Med. 2013;368(7):651-662. doi:10.1056/NEJMra1205406.

5.

Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for
cancer growth. Genes Dev. 2009;23(5):537-548. doi:10.1101/gad.1756509.

6.

Yang Z, Goronzy JJ, Weyand CM. Autophagy in autoimmune disease. J Mol Med
(Berl). 2015;93(7):707-717. doi:10.1007/s00109-015-1297-8.

7.

Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer:
therapeutic implications. Mol Cancer Ther. 2011;10(9):1533-1541.
doi:10.1158/1535-7163.MCT-11-0047.

127

8.

Espert L, Beaumelle B, Vergne I. Autophagy in Mycobacterium tuberculosis and
HIV infections. Front Cell Infect Microbiol. 2015;5:49.
doi:10.3389/fcimb.2015.00049.

9.

Sato K, Tsuchihara K, Fujii S, et al. Autophagy is activated in colorectal cancer
cells and contributes to the tolerance to nutrient deprivation. Cancer Res.
2007;67(20):9677-9684. doi:10.1158/0008-5472.CAN-07-1462.

10.

Townsend KN, Hughson LRK, Schlie K, Poon VI, Westerback A, Lum JJ.
Autophagy inhibition in cancer therapy: metabolic considerations for antitumor
immunity. Immunol Rev. 2012;249(1):176-194. doi:10.1111/j.1600065X.2012.01141.x.

11.

Lazova R, Klump V, Pawelek J. Autophagy in cutaneous malignant melanoma. J
Cutan Pathol. 2010;37(2):256-268. doi:10.1111/j.1600-0560.2009.01359.x.

12.

Lazova R, Pawelek JM. Why do melanomas get so dark? Exp Dermatol.
2009;18(11):934-938. doi:10.1111/j.1600-0625.2009.00933.x.

13.

Schaaf MBE, Cojocari D, Keulers TG, et al. The autophagy associated gene,
ULK1, promotes tolerance to chronic and acute hypoxia. Radiother Oncol.
2013;108(3):529-534. doi:10.1016/j.radonc.2013.06.015.

14.

Lazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM.
Punctate LC3B expression is a common feature of solid tumors and associated

128

with proliferation, metastasis, and poor outcome. Clin Cancer Res.
2012;18(2):370-379. doi:10.1158/1078-0432.CCR-11-1282.
15.

Marino ML, Pellegrini P, Di Lernia G, et al. Autophagy is a protective mechanism
for human melanoma cells under acidic stress. J Biol Chem. 2012;287(36):3066430676. doi:10.1074/jbc.M112.339127.

16.

Xie X, Koh JY, Price S, White E, Mehnert JM. Atg7 Overcomes Senescence and
Promotes Growth of BrafV600E-Driven Melanoma. Cancer Discov.
2015;5(4):410-423. doi:10.1158/2159-8290.CD-14-1473.

17.

Strohecker AM, Guo JY, Karsli-Uzunbas G, et al. Autophagy sustains
mitochondrial glutamine metabolism and growth of BrafV600E-driven lung
tumors. Cancer Discov. 2013;3(11):1272-1285. doi:10.1158/2159-8290.CD-130397.

18.

Guo JY, Chen H-Y, Mathew R, et al. Activated Ras requires autophagy to
maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011;25(5):460470. doi:10.1101/gad.2016311.

19.

Mito- WEAS. Autophagy promotes. 2014;10(2):384-385.

20.

Armstrong JL, Corazzari M, Martin S, et al. Oncogenic B-RAF signaling in
melanoma impairs the therapeutic advantage of autophagy inhibition. Clin Cancer
Res. 2011;17(8):2216-2226. doi:10.1158/1078-0432.CCR-10-3003.

129

21.

Corazzari M, Lovat PE. Cell Biology : Research & Therapy Harnessing
Autophagy for Melanoma Benefit. 2013:2-4.

22.

Corazzari M, Fimia GM, Lovat P, Piacentini M. Why is autophagy important for
melanoma? Molecular mechanisms and therapeutic implications. Semin Cancer
Biol. 2013;23(5):337-343. doi:10.1016/j.semcancer.2013.07.001.

23.

Yoshioka A, Miyata H, Doki Y, et al. LC3, an autophagosome marker, is highly
expressed in gastrointestinal cancers. Int J Oncol. 2008;33(3):461-468.
http://www.ncbi.nlm.nih.gov/pubmed/18695874. Accessed September 1, 2015.

24.

Fujii S, Mitsunaga S, Yamazaki M, et al. Autophagy is activated in pancreatic
cancer cells and correlates with poor patient outcome. Cancer Sci.
2008;99(9):1813-1819. doi:10.1111/j.1349-7006.2008.00893.x.

25.

Han C, Sun B, Wang W, et al. Overexpression of microtubule-associated protein-1
light chain 3 is associated with melanoma metastasis and vasculogenic mimicry.
Tohoku J Exp Med. 2011;223(4):243-251.
http://www.ncbi.nlm.nih.gov/pubmed/21415575. Accessed August 26, 2015.

26.

Ma X, Piao S, Dey S, et al. Targeting ER stress – induced autophagy overcomes
BRAF inhibitor resistance in melanoma. 2014;124(3). doi:10.1172/JCI70454DS1.

27.

Wang J, Pan X-L, Ding L-J, Liu D-Y, Da-Peng Lei, Jin T. Aberrant expression of
Beclin-1 and LC3 correlates with poor prognosis of human hypopharyngeal

130

squamous cell carcinoma. PLoS One. 2013;8(7):e69038.
doi:10.1371/journal.pone.0069038.
28.

Zhao Y, Chen S, Gou W, Xiao L, Takano Y, Zheng H. Aberrant Beclin 1
expression is closely linked to carcinogenesis, differentiation, progression, and
prognosis of ovarian epithelial carcinoma. Tumour Biol. 2014;35(3):1955-1964.
doi:10.1007/s13277-013-1261-6.

29.

Giatromanolaki A, Koukourakis MI, Koutsopoulos A, Chloropoulou P, Liberis V,
Sivridis E. High Beclin 1 expression defines a poor prognosis in endometrial
adenocarcinomas. Gynecol Oncol. 2011;123(1):147-151.
doi:10.1016/j.ygyno.2011.06.023.

30.

The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic
Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine
in Patients With Advanced BRAF Mutant Melanoma - No Study Results Posted ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02257424. Accessed
August 23, 2015.

31.

Vogl DT, Stadtmauer EA, Tan K-S, et al. Combined autophagy and proteasome
inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with
relapsed/refractory myeloma. Autophagy. 2014;10(8):1380-1390.
doi:10.4161/auto.29264.

32.

Rangwala R, Chang YC, Hu J, et al. Combined MTOR and autophagy inhibition:
phase I trial of hydroxychloroquine and temsirolimus in patients with advanced
131

solid tumors and melanoma. Autophagy. 2014;10(8):1391-1402.
doi:10.4161/auto.29119.
33.

Mathew R, Karantza-wadsworth V, White E. Role of autophagy in cancer.
2007;7(december):961-967.

34.

Kopitz J, Kisen GO, Gordon PB, Bohley P, Seglen PO. Nonselective autophagy of
cytosolic enzymes by isolated rat hepatocytes. J Cell Biol. 1990;111(3):941-953.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2116292&tool=pmcen
trez&rendertype=abstract. Accessed July 20, 2015.

35.

Kisen GO, Tessitore L, Costelli P, et al. Reduced autophagic activity in primary rat
hepatocellular carcinoma and ascites hepatoma cells. Carcinogenesis.
1993;14(12):2501-2505. http://www.ncbi.nlm.nih.gov/pubmed/8269618. Accessed
August 26, 2015.

36.

Otsuka H, Moskowitz M. Differences in the rates of protein degradation in
untrasformed and transformed cell lines. Exp Cell Res. 1978;112(1):127-135.
http://www.ncbi.nlm.nih.gov/pubmed/631208. Accessed August 26, 2015.

37.

Knecht E, Hernández-Yago J, Grisolía S. Regulation of lysosomal autophagy in
transformed and non-transformed mouse fibroblasts under several growth
conditions. Exp Cell Res. 1984;154(1):224-232.
http://www.ncbi.nlm.nih.gov/pubmed/6088263. Accessed August 26, 2015.

132

38.

Valente G, Morani F, Nicotra G, et al. Expression and clinical significance of the
autophagy proteins BECLIN 1 and LC3 in ovarian cancer. Biomed Res Int.
2014;2014:462658. doi:10.1155/2014/462658.

39.

Sakurai T, Okumura H, Matsumoto M, et al. The expression of LC-3 is related to
tumor suppression through angiogenesis in esophageal cancer. Med Oncol.
2013;30(4):701. doi:10.1007/s12032-013-0701-x.

40.

Deng Q, Wang Z, Wang L, et al. Lower mRNA and protein expression levels of
LC3 and Beclin1, markers of autophagy, were correlated with progression of renal
clear cell carcinoma. Jpn J Clin Oncol. 2013;43(12):1261-1268.
doi:10.1093/jjco/hyt160.

41.

Lovat MC and PE. Harnessing Autophagy for Melanoma Benefit. Cell Biol Res
Ther. http://www.scitechnol.com/harnessing-autophagy-for-melanoma-benefitxYl7.php&&article_id=1019. Accessed August 26, 2015.

42.

Miracco C, Cevenini G, Franchi A, et al. Beclin 1 and LC3 autophagic gene
expression in cutaneous melanocytic lesions. Hum Pathol. 2010;41(4):503-512.
doi:10.1016/j.humpath.2009.09.004.

43.

Aita VM, Liang XH, Murty V V, et al. Cloning and genomic organization of
beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics.
1999;59(1):59-65. doi:10.1006/geno.1999.5851.

133

44.

Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous
disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112(12):1809-1820.
doi:10.1172/JCI20039.

45.

Russell SE, Hickey GI, Lowry WS, White P, Atkinson RJ. Allele loss from
chromosome 17 in ovarian cancer. Oncogene. 1990;5(10):1581-1583.
http://www.ncbi.nlm.nih.gov/pubmed/2250914. Accessed August 26, 2015.

46.

Eccles DM, Russell SE, Haites NE, et al. Early loss of heterozygosity on 17q in
ovarian cancer. The Abe Ovarian Cancer Genetics Group. Oncogene.
1992;7(10):2069-2072. http://www.ncbi.nlm.nih.gov/pubmed/1408149. Accessed
August 26, 2015.

47.

Sivridis E, Koukourakis MI, Mendrinos SE, et al. Beclin-1 and LC3A expression
in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1.
Melanoma Res. 2011;21(3):188-195. doi:10.1097/CMR.0b013e328346612c.

48.

Berwick M, Reiner AS, Paine S, et al. Sun exposure and melanoma survival: a
GEM study. Cancer Epidemiol Biomarkers Prev. 2014;23(10):2145-2152.
doi:10.1158/1055-9965.EPI-14-0431.

49.

Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma
induced by ultraviolet radiation. N Engl J Med. 1999;340(17):1341-1348.
doi:10.1056/NEJM199904293401707.

134

50.

Lin W, Yuan N, Wang Z, et al. Autophagy confers DNA damage repair pathways
to protect the hematopoietic system from nuclear radiation injury. Sci Rep.
2015;5:12362. doi:10.1038/srep12362.

51.

Liu EY, Xu N, O’Prey J, et al. Loss of autophagy causes a synthetic lethal
deficiency in DNA repair. Proc Natl Acad Sci U S A. 2015;112(3):773-778.
doi:10.1073/pnas.1409563112.

52.

Liu H, He Z, Simon H-U. Targeting autophagy as a potential therapeutic approach
for melanoma therapy. Semin Cancer Biol. 2013;23(5):352-360.
doi:10.1016/j.semcancer.2013.06.008.

53.

Kricker A, Armstrong BK, Goumas C, et al. Ambient UV, personal sun exposure
and risk of multiple primary melanomas. Cancer Causes Control. 2007;18(3):295304. doi:10.1007/s10552-006-0091-x.

54.

Kamino H, Tam ST. Immunoperoxidase technique modified by counterstain with
azure B as a diagnostic aid in evaluating heavily pigmented melanocytic
neoplasms. J Cutan Pathol. 1991;18(6):436-439.
http://www.ncbi.nlm.nih.gov/pubmed/1723081. Accessed May 25, 2015.

55.

White KAM, Lilyquist J, Lee RJ, Philips GK, Hughes CR TS. Quantitative
Analysis of Immunohistochemistry in Melanoma Tumors. Appl Immunohistochem.
2015;In submiss.

135

56.

Thomas NE, Kricker A, Waxweiler WT, et al. Comparison of clinicopathologic
features and survival of histopathologically amelanotic and pigmented melanomas:
a population-based study. JAMA dermatology. 2014;150(12):1306-1314.
doi:10.1001/jamadermatol.2014.1348.

57.

Eisenberg-Lerner A, Kimchi A. The paradox of autophagy and its implication in
cancer etiology and therapy. Apoptosis. 2009;14(4):376-391. doi:10.1007/s10495008-0307-5.

58.

Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy
and apoptosis. Cell Death Differ. 2011;18(4):571-580. doi:10.1038/cdd.2010.191.

59.

Wirawan E, Vande Walle L, Kersse K, et al. Caspase-mediated cleavage of Beclin1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting
the release of proapoptotic factors from mitochondria. Cell Death Dis. 2010;1:e18.
doi:10.1038/cddis.2009.16.

60.

Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of
tumorigenesis by beclin 1. Nature. 1999;402(6762):672-676. doi:10.1038/45257.

61.

Li B-X, Li C-Y, Peng R-Q, et al. The expression of beclin 1 is associated with
favorable prognosis in stage IIIB colon cancers. Autophagy. 2014;5(3):303-306.
doi:10.4161/auto.5.3.7491.

62.

Huang J-J, Li H-R, Huang Y, et al. Beclin 1 expression: a predictor of prognosis in
patients with extranodal natural killer T-cell lymphoma, nasal type. Autophagy.

136

2010;6(6):777-783. http://www.ncbi.nlm.nih.gov/pubmed/20639699. Accessed
August 30, 2015.
63.

Ahn CH, Jeong EG, Lee JW, et al. Expression of beclin-1, an autophagy-related
protein, in gastric and colorectal cancers. APMIS. 2007;115(12):1344-1349.
doi:10.1111/j.1600-0463.2007.00858.x.

64.

Berwick M, Armstrong BK, Ben-Porat L, et al. Sun exposure and mortality from
melanoma. J Natl Cancer Inst. 2005;97(3):195-199. doi:10.1093/jnci/dji019.

65.

Yu C-L, Li Y, Freedman DM, et al. Assessment of lifetime cumulative sun
exposure using a self-administered questionnaire: reliability of two approaches.
Cancer Epidemiol Biomarkers Prev. 2009;18(2):464-471. doi:10.1158/10559965.EPI-08-0894.

66.

Sui X, Chen R, Wang Z, et al. Autophagy and chemotherapy resistance: a
promising therapeutic target for cancer treatment. Cell Death Dis. 2013;4:e838.
doi:10.1038/cddis.2013.350.

67.

Zhao Y, Zhang C-F, Rossiter H, et al. Autophagy is induced by UVA and
promotes removal of oxidized phospholipids and protein aggregates in epidermal
keratinocytes. J Invest Dermatol. 2013;133(6):1629-1637.
doi:10.1038/jid.2013.26.

137

68.

Eller MS, Gilchrest BA. Tanning as part of the eukaryotic SOS response. Pigment
Cell Res. 2000;13 Suppl 8:94-97. http://www.ncbi.nlm.nih.gov/pubmed/11041364.
Accessed September 5, 2015.

138

3.16 Tables:
3.16.2 Table 1. Demographic and pathological summary of participants.
N=68
Age at diagnosis/Presentation No.
Gender
Male
Female
Oncogene Status
NRAS*
BRAF*
Wild-type
Breslow thickness (mm)
0.01-1.00
> 1.00
LC3 Punctate
Absent
Present
Anatomic site
Trunk/pelvis
Scalp/neck
Face/ears/other
Upper extremities
Lower extremities
Histological subtype
SSM
NM
LMM
Other
Mitosis
Absent
Present
Regression
Absent
Present
Ulceration
Absent
Present

Overall
59.5
No. %

Control
54.9
No. %

Case
60.7
No. %

48
44

51.1
46.8

11
6

61.1
33.3

37
38

48.7
50

7
25
45

7.4
26.6
47.9

.
1
9

.
5.6
50

7
24
36

9.2
31.6
47.4

30
32

31.9
34

.
.

.
.

30
32

39.5
42.1

30
39

31.9
41.5

6
11

33.3
61.1

24
28

31.6
36.8

15
6
13
20
17

16
6.4
13.8
21.3
18.1

.
.
.
.
.

.
.
.
.
.

15
6
13
20
17

19.7
7.9
17.1
26.3
22.4

38
19
9
2

40.4
20.2
9.6
2.1

.
.
.
.

.
.
.
.

38
19
9
2

50
25
11.8
2.6

21
29

30.8
42.7

.
.

.
.

21
29

41.2
56.9

28
26

29.8
27.7

.
.

.
.

28
26

36.8
34.2

13
44

13.8
46.8

.
.

.
.

13
44

17.1
57.9
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Clark's Level
Level 2
Level 3
Level 4
Level 5
Vital Statistics
Death from melanoma*
Alive or death from other causes

21
8
23
7

22.3
8.5
24.5
7.4

.
.
.
.

68 72.3
12 12.8

.
.
.
.
6 33.3
.
.

21
8
23
7

27.6
10.5
30.3
9.2

62 81.6
12 15.8

3.16.3 Table 2. Summary of participants UV exposure.

UV exposure
Sunlamp Use
Never
Ever
Missing
Sun exposure without any protection
Get a severe sunburn with blistering
Have a painful sunburn for a few days
with peeling
Get mildly burnt followed by some
tanning
Go brown without any sunburn
Don't Know
Missing
Repeatedly exposed to bright sunlight
Go very brown and deeply tanned
Get moderately tanned
Get mildly or occasionally tanned
Get no suntan at all or only get
freckled
Don't Know
Missing
Ever Sunburn
Never
Ever
Missing
Sunburn at age 10y
No
Yes

Overall
No. %

Control
No. %

Case
No. %

64
24
6

68.1
25.5
6.4

13
5
.

72.2
27.8
.

51
19
6

67.1
25
7.9

13

13.8

3

16.7

10

13.2

34

36.2

5

27.8

29

38.2

27

28.7

7

38.9

20

26.3

11
1
8

11.7
1.1
8.5

3
.
.

16.7
.
.

8
1
8

10.5
1.3
10.5

11
39
24

11.7
41.5
25.5

2
10
4

11.1
55.6
22.2

9
29
20

11.8
38.2
26.3

11

11.7

2

11.1

9

11.8

2
7

2.1
7.4

.
.

.
.

2
7

2.6
9.2

16
72
6

17
76.6
6.4

3
15
.

16.7
83.3
.

13
57
6

17.1
75
7.9

26
62

27.7
66

6
12

33.3
66.7

20
50

26.3
65.8
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Missing
Ever Blister
No
Yes
Missing
Blister at age 10y
No
Yes
Any occupational sun exposure
No
Yes
Occupational sun exposure
None
<P50
>=P50
Any beach or waterside activities
Never
Yes
Any outdoor poolside activities
Never
Yes
Other sunbathing
Never
Yes
Boating Activities
Never
Yes
Any Water Activity
Never
Yes
Missing

Overall
No. %
6
6.4

Control
No. %
.
.

Case
No. %
6
7.9

47
41
6

50
43.6
6.4

13
5
.

72.2
27.8
.

34
36
6

44.7
47.4
7.9

59
29

62.8
30.9

14
4

77.8
22.2

45
25

59.2
32.9

35
53

37.2
56.4

8
10

44.4
55.6

27
43

35.5
56.6

35
29
24

37.2
30.9
25.5

8
6
4

44.4
33.3
22.2

27
23
20

35.5
30.3
26.3

55
33

58.5
35.1

10
8

55.6
44.4

45
25

59.2
32.9

37
51

39.4
54.3

6
12

33.3
66.7

31
39

40.8
51.3

23
64

24.5
68.1

4
14

22.2
77.8

19
50

25
65.8

31
57

33
60.6

3
15

16.7
83.3

28
42

36.8
55.3

7
81
6

7.4
86.2
6.4

.
18
.

.
100
.

7
63
6

9.2
82.9
7.9

* Death from melanoma recorded during 2 years of follow-up.
Abbreviations: SSM, Superficial spreading melanoma; NM, Nodular
melanoma; LMM, Lentigo maligna melanoma; UV, ultraviolet radiation
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3.16.4 Table 3: Characteristics of Control and Melanoma Participants Analyzed for Demographic, Clinical Characteristics by LC3 and Beclin1
All
No.
68
All
Age at
Presentation
21
Gender
Male
23
Female
24
Clinical Characteristics:
Death from
44
Melanoma
Alive or death
10
from other causes
Breslow Thickness
<1
20
≥1
27
BRAF and NRAS
WT
43
NRAS+
6
BRAF+
24
Punctate LC3
Absent
38
Present
26

LC3 Protein Expression
Control
Case

Mean

No.

Mean

No.

Mean

1543

17

1587

51

1528

Pvalue
0.67

All

Beclin 1 Protein Expression
Control
Case

No.

Mean

No.

Mean

No.

Mean

59

2524

14

326

45

3207

0.07
1552
1580
1499

17
-

1587
-

4
23
24

1403
1580
1499

1610

5

1908

39

1572

1383

-

-

10

1383

1497
1538

17

1587

20
10

1497
1455

1567
1317
1512

9
8

1697
1465

34
6
16

1532
1317
1536

1641
1550

11
17

1763
1587

27
9

1592
1478

0.03

0.17

0.01

>0.01

Pvalue
0.02

18
18
23

930
3040
3366

14
-

326
-

4
18
23

3045
3040
3366

12

670

10

191

2

3065

37

2991

4

663

33

3273

17
23

2986
1442

14

326

17
9

2986
3179

37
6
21

2703
2868
2188

6
8

504
192

31
6
13

3128
2868
3416

34
22

2366
1374

10
14

391
326

24
8

3189
3209
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0.02

0.05

0.56

0.84

Table 4. Characteristics of Control and Melanoma Participants Analyzed for UV Exposure, LC3 and Beclin1

All
UV Exposure:

No.

Mean

Repeated Sun Exposure Without
Protection
Go Very
Brown/Deeply
28
1597
Tan
Moderately Tan
18
1539
Get Mildly Tan
6
1279
No Suntan/Only
1
1556
Freckled
Don't Know
4
1608
Missing
10
1519
Painful Sunburn (2 or
more days)
No
52
1494
Yes
4
1608
Missing
12
1734
Ever Blistering Sunburn
No
28
1464
Yes
4
1608
Any Beach/ Waterside
Activities
Never
26
1554
Ever
4
1608

LC3 Protein Expression
Control
Case
No.

Mean

No.

Mean

Pvalue

All
No.

Beclin 1 Protein Expression
Control
Case

Mean

No.

Mean

No.

Mean

0.06

Pvalue
0.46

10

1613

18

1588

24

2270

8

389

16

3210

3
2

1786
934

15
4

1489
1451

16
5

2990
1932

2
2

301
208

14
3

3374
3082

-

-

1

1556

1

3203

-

-

1

3203

2

1816

4
8

1608
1445

3
9

2831
2437

2

217

3
7

2831
3072
0.5

0.03
14
3

1518
1914

38
4
9

1485
1608
1674

4
-

1378
-

24
4

1479
1608

0.32

45
3
11

2544
2831
2354

11
3

346
253

34
3
8

3256
2831
3143

24
3

2976
2831

3
-

194
-

21
3

3374
2831

0.69
7
-

1471
-

19
4

1585
1608

0.02

0.93
23
3

2529
2831

6
-

502
-

17
3

3245
2831

Subjects consisted of 68 participants from a New Mexico tissue collection. OR values are adjusted for age as a continuous
variable. Abbreviations: CI = confidence limit; NM = nodular melanoma; HR = Hazard ratio; SSM = superficial spreading
melanoma; SD = standard deviation; Death from melanoma recorded during 2.5 years of follow-up. *Statistical significance
was set at 5%. **Unless noted otherwise odds ratios (OR) are for a one unit increase.
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3.14.6 Table 5. Univariate Logistic Regression for Melanoma Specific Mortality
Correlated with Histopathological Characteristics, UV Exposure and LC3/ Beclin 1
Expression
OR (95% CI)**
p-value*
1.00 (0.95-1.05)
0.95
Age at Diagnosis
1.00 (0.29-3434)
0.99
Sex (Female)
Clinical Characteristics:
Breslow thickness (continuous)
1.5 (1.11-2.01)
0.01
Breslow Thickness ≥ 1
5.33 (1.03-27.8)
0.05
Clark (Per Stage Increase)
1.87 (0.90-3.92)
0.1
Mitoses
1.31 (1.03-1.67)
0.03
Moles
0.94 (0.84-1.05)
0.24
Ulceration (Absent vs. Present)
13.67 (2.48-75.27)
0.003
Regression (Absent vs. Present)
0.25 (0.05-1.4)
0.12
Oncogene Status:
NRAS (heterozygous vs wt.)
BRAF (heterozygous vs wt.)

35,0 (3.21-381.59)
0.63 (0.12-3.44)

0.004
0.6

Autophagy Markers:
LC3 Expression (log-transformed)
LC3 Punctate Expression
Beclin1 Expression (log-transformed)

0.004 (0.001-0.77)
0.25 (0.06-1.08)
1.35 (0.38-4.72)

0.04
0.06
0.64

Histological Sub-type:
SSM
NM
LMM
Melanoma in situ

0.15 (0.04-0.64)
2.60 (0.69-9.8)
8.39 (1.81-38.98)
1.03 (0.23-4.61)

0.01
0.16
0.01
0.97

0.94 (0.45-1.92)

0.86

1.08 (0.68-1.73)

0.73

1.92 (0.48-7.67)
0.77 (0.14-4.17)
0.88 (0.20-3.81)
0.76 (0.39-1.48)
0.88 (0.23-3.34)
1.21 (0.31-4.76)

0.36
0.76
0.87
0.42
0.85
0.78

0.62 (0.26-1.49)

0.28

0.95 (0.24-3.71)

0.94

UV Exposure:
Weekly Sun Hours Age 10 (per 8 hour
increase)
Weekly Sun Hours at Diagnosis (per 8 hour
increase)
Sunlamp Use
Painful Sunburn (2 or more days)
Early Sunburn (by age 10)
Decades with Sunburn (per 1 decade increase)
Ever Had a Blistering Sunburn
Early Blistering Sunburn (by age 10)
Decades with Blistering Sunburn (per 1 decade
increase)
Any Occupational Exposure to Sunlight
144

Total Weekly Occupational Exposure to
Sunlight (per 1 hour increase)
Total Occupational Exposure to Sunlight
Activities:
Any Beach/Waterside Activity
Swimming Pool Activities
Sunbathing Other than Beach or Pool
Boating Activities
Any Outdoor Activity Sun Exposure
Number of Outdoor Activities (per 1 activity
increase)

1.01 (0.98-1.05)

0.47

1.22 (0.54-2.77)

0.64

2.93 (0.74-11.53)
2.05 (0.485-8.67)
0.76 (0.17-3.32)
1.57 (0.37-6.69)
0.96 (0.10-8.97)

0.12
0.33
0.72
0.54
0.97

1.42 (0.7-2.88)

0.34

Subjects consisted of 68 participants from a New Mexico tissue collection. OR values are adjusted for age
as a continuous variable. Abbreviations: CI = confidence limit; NM = nodular melanoma; OR = odds ratio;
SSM = superficial spreading melanoma; SD = standard deviation; Death from melanoma recorded during
2.5 years of follow-up. *Statistical significance was set at 5%. **Unless noted otherwise odds ratios (OR)
are for a one unit increase
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Variants in Autophagy Related Genes and Clinical Characteristics in Melanoma:

A Population-Based Study
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4.1 Abstract
Autophagy has been linked with melanoma, but polymorphisms in autophagy related
(ATG) genes have not been investigated for association with survival or histopathological
features known to be important in melanoma survival. We examined 5 ATG gene single
nucleotide polymorphisms (SNPs) in a multicenter population-based case-control study
of melanoma. DNA from 911 melanoma patients was genotyped for SNPs with suspected
impact on autophagic flux. While no association was identified with survival, several
associations with prognostic features were noted. A decreased Breslow thickness (p =
0.03) and earlier stage at diagnosis (OR 0.47, 95% CI 0.27-0.81, p = 0.02) was identified
with the minor allele for an ATG16L polymorphism (rs2241880) and the heterozygous
genotype was associated with younger diagnosis age (p = 0.02). In addition, two SNPs in
ATG5 (rs2245214 and rs510432) were associated with increased stage of melanoma (OR
1.84 95% CI 1.12-3.02, p=0.05; OR 1.47 95% CI 1.11-1.94, p=0.03). Finally, although
not significant at the global p-value, we identified an inverse association between the
minor alleles of ATG5 (rs2245214) and scalp or neck melanomas (OR 0.20, 95% CI
0.05-0.86, p= 0.03); ATG10 rs1864182 (OR 0.42, 95% CI 0.21-0.88, p= 0.02) and brisk
TILs, and non-brisk TILs and ATG5 rs510432 (OR 0.55 95% CI 0.34-0.87, p= 0.01). In
summary, our data suggest ATG SNPs might be associated with prognostic characteristics
although not with survival and that the direction of the ATG SNPs may be differential
due to low. It may be informative to evaluate these and other SNPs in the larger
population as these associations may be helpful to understand the role of autophagy in
melanoma.
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4.2 Introduction:
The American Cancer Society estimates that in 2015, 73,870 new melanomas will be
diagnosed and 9,940 people will die from their disease.1 The long term prognosis for
melanoma patients has not improved at the same rate as other cancers.2 One mechanism
of tumorigenesis that is under intensive investigation is autophagy. Autophagy is a
catabolic process that assists the removal of unnecessary or dysfunctional cellular
components, including damaged proteins and organelles through lysosomal degradation.3
Macroautophagy (hereafter referred to as autophagy) is tightly regulated and plays a role
in a wide variety of normal physiological processes including energy metabolism, stress
responses, growth regulation, and aging4,5 and can be induced in response to nutrient
deprivation.6 Accumulating evidence indicates that autophagy is involved in cancer
progression.5 In addition, the idea of melanoma addiction to autophagy7–11 has important
implications for cancer development as well as treatment options.12 There are clinical
trials ongoing at the National Institutes of Health to target inhibition of the autophagic
pathway in multiple cancer types including melanoma.13 However, the extent to which
the autophagy impacts melanoma progression and/or survival remains to be elucidated.
Single nucleotide polymorphisms (SNPs) have been implicated in the pathogenesis of
many types of cancers14 including melanoma.15–17 Relevant data from the current
literature suggests that the frequency of variants in autophagy-related (ATG) genes may
be altered in cancer patients.18 Autophagy gene variants have been associated with risk
prognosis and/or survival in autoimmune diseases, including Crohn’s disease,
tuberculosis19 and gastric, breast and thyroid cancers20–24. To our knowledge, there are no
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studies examining the relationship between ATG gene SNPs and histopathological
markers or survival in melanoma.
In this study, we analyzed germline DNA for variants (i.e. SNPs) in ATG genes from a
large population-based cohort of melanoma patients from Australia and the US. The
SNPs investigated were chosen having been identified as significantly associated with
disease outcomes and≥10% minor allele frequency in Caucasians. Our goal was to
determine whether SNPs in ATG genes were associated with factors associated with
tumor characteristics and survival in melanoma patients. We hypothesize that ATG gene
variants are associated with histopathological markers of melanoma progression.

4.3 Materials and Methods
4.3.1 Patient Characteristics:
Over four years, 3,579 individuals from 9 study sites including eight population-based
cancer registries in the United States (New Jersey, North Carolina, California), Australia
(New South Wales, Tasmania), Canada (Ontario, British Columbia), and Italy (Turin),
and one hospital center in Michigan were enrolled in the Genes, Environment and
Melanoma (GEM), a large international population-based case control study. GEM
recruitment procedures and data collection have been previously described.25 The
Institutional Review Boards of all participating institutions approved the protocol and
informed consent was obtained from each participant. GEM is a population-based
international consortium studying risk for melanoma development and progression and
survival. From this study of a population of 1,206 individuals with multiple primary
melanoma and 2,373 with single primary melanoma, 911 genomic DNA samples were
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chosen based on tumor availability (previously reported; Thomas et. al 2015)(see patient
characteristics below, Table 1)26 and genotyped to compared ATG SNP frequencies with
histopathological data.
4.3.2 Clinical Stage:
Histopathology slides were reviewed as previously described27 and clinical stage was
determined based on pathology reports and includes Breslow thickness, mitotic index and
ulceration. Mitoses were defined as present or absent. TIL grade was scored as absent,
nonbrisk, or brisk using a previously defined grading system.27 All cases were
characterized using the T classification which describes the state of the primary tumor in
the AJCC TNM (tumor, regional nodes, and distant metastasis) melanoma staging
system.
4.3.3 Selection of SNPs and Genotyping:
5 SNPs in three critical ATG genes were selected from those identified with functional
SNPs in the literature or that were associated with cancer or disease outcomes (see Figure
1). 18,19,21,28,29 Taqman Real-Time PCR Assays (ThermoFisher Scientific, Grand Island,
NY) were used to identify SNPs in ATG genes performed with a 7900HT Fast Real-Time
PCR System (ThermoFisher Scientific, Grand Island, NY) following manufacture
recommendations. DNA was isolated from buccal cells as previously described.25,30 A
Nanodrop 2000 spectrophotometer (ThermoFisher Scientific, Grand Island, NY) was
used for quantification of DNA. The ratio of fluorescence in amplification during the
logarithmic phase was quantified to identify specific alleles in genes of interest using a
commercially available Taqman primer assay on a 7900HT Applied Biosystems qPCR
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machine. Genomic DNA samples were chosen from those samples with sufficient DNA
and tumor availability to allow for somatic analysis in future studies. 26 The genotyping
call rate for the 911 chosen samples ranged from 96% to 99% and biological replicates
were generated for 10% of the samples with 100% concordance.
4.3.4 Data Analysis:
Frequency tables were used to summarize the genotype distributions for each ATG SNP.
To assess the genotyping quality, we calculated the genotype call rates and tested the
departure from Hardy Weinberg Equilibrium for each SNP in all subjects. The
association between SNPs and histopathological features were tested under the general
genotypic inheritance (co-dominant) model. No assumptions were made on the model of
inheritance, and the genotypes for each SNP were treated as a three-level nominal
variable. Using a genotypic model to simultaneously compare heterozygous genotype
versus wildtype, and homozygous minor genotype versus wildtype, we report a global p value representing the overall significance of the two comparisons for our analysis.
Linear regression analyses were performed to assess the association between ATG gene
SNPs and log transformed Breslow thickness, which was non-normally distributed. To
evaluate the association between ATG SNPs and histopathological features, we conducted
logistic regression analyses for binary outcomes (mitosis, ulceration), ordinal logistic
regression analysis for ordinal outcome (stage), and polytomous logistic regression
analyses for nominal outcomes (histology and tumor subtype). The exponentiated
regression coefficient modeled Breslow thickness representing Breslow thickness
increases per mm. ORs and 95% confidence intervals estimated from the regression
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models were used to summarize the associations. Wald tests were used to assess the
significance of the association and statistical significance was two-sided at 5%.

4.4 Results:
Five SNPs within ATG genes that have been previously reported associated with disease
outcomes were genotyped and similar allele frequencies were identified in males and
females (data not shown). GEM minor allele frequencies are presented in Table 2 and
genotypes do not deviate from Hardy Weinberg Equilibrium (HWE) (data not shown).
After adjustment for age, sex, status (single or multiple primaries) and study center, three
ATG SNPs (rs2241880, rs510432, rs2245214) were significantly associated with
melanoma prognostic indicators. An analysis of all 5 ATG gene SNPs with Breslow
thickness, the most important prognostic marker in melanoma, revealed a significant
association between the minor allele (A) of rs2241880 (ATG16L) (Table 3a) and a
decrease in Breslow thickness (p= 0.02). A significant association was also identified
between the rs2241880 (ATG16L) minor allele and an earlier stage at diagnosis (OR 0.47
95% CI 0.27-0.81, p = 0.02) when defined as a binary variable of Stage T1a/T1b/T2a
versus T2b and higher (Table 4). Finally, presence of heterozygous (AG) of rs2241880
was significantly associated with a younger age of melanoma diagnosis (p = 0.02) (Table
3b).
In addition, two ATG5 SNPs (rs2245214 and rs510432) were found significantly
associated with increased stage of melanoma (OR 1.47, 95% CI 1.11-1.94, p=0.03; OR
1.84, 95% CI 1.12-3.02, p=0.05) (Table 4). The minor allele (CC) of rs510432 had a
borderline association with increased stage. Interestingly, only the heterozygous (CG) of
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rs2245214 was associated with this increase in stage when it was defined as a continuous
variable (Supplemental Table S1), while the other two SNPs (rs2241880, rs510432) did
not retain significance in this analysis
No associations between the 5 autophagy SNPs and mitosis, ulceration, histological
subtype or melanoma specific survival (Table 5; Supplemental Table S1) were identified.
Of interest, while they were not significant at the level of the global p-value, a decrease in
OR (OR 0.42 95% CI 0.21-0.88, p=0.02) was identified between the presence of brisk
TILs and the minor allele of SNP rs1864182, and the presence of non-brisk TILs and the
minor allele of rs510432 (OR 0.55 95% CI 0.34-0.87, p=0.01). Finally, while not
significant at the global p-value, an inverse association between the minor allele of
rs2245214 and scalp/neck melanomas was also identified (OR 0.20 95% CI 0.05-0.86,
p=0.03).

4.5 Discussion:
There are clear associations between autophagy and cancer and the role of germline SNPs
in melanoma progression and survival has remained unexplored. Autophagy in cancer is
context dependent, acting as both a tumor suppressor and as a tumor promoter depending
on the stage of development of the tumor. While a recent GWAS study reported no
association between melanoma susceptibility31 and ATG gene SNPs, we know of no other
study addressing the associations between common genetic variants in ATG genes and
melanoma development and survival.
In the current study, five SNPs were selected for analysis based on their association with
other diseases. The SNPs investigated in this study are located in genes that are critical
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to the early stage of the autophagy pathway (Figure 1) and necessary for the formation of
the autophagosome.3 As shown in Figure 1 ATG10 is essential for ATG12 conjugation to
ATG5 and ultimately to ATG16L.
Previously, variants in ATG genes have been associated with risk, prognosis or survival
in cancer18,28,29 and autoimmune conditions.32–35 In the current analysis, we examined
one SNP (rs2241880) in ATG16L which increases risk and is associated with poorer
prognosis in disease and might contribute to progression in melanoma. A
nonsynonymous polymorphism in ATG16L, rs2241880 (T300A), has been extensively
studied because its variant allele has been linked with increased risk of Crohn’s disease.23
This ATG16L SNP (AA) creates a caspase 3- and caspase 7- cleavage site and reduces the
stability of the protein resulting in decreased autophagy; clinically, presence of this
variant is associated with decreased survival and increased risk for ileal Crohn’s disease
in adults. 23 While this SNP is associated with increased susceptibility, it is also
associated with childhood (early) onset of this disease.36As illustrated in Figure 1,
ATG16L is essential for the formation of the autophagosome. Through its noncovalent
interaction with ATG12–ATG5, it facilitates the conjugation of other critical ATG
proteins. Other studies have identified a genetic association for rs2241880 and another
SNP in ATG5 (rs2245214) with nearly two-fold susceptibility to non-medullary thyroid
cancers 18 as well as an increase in disease severity associated with rs2241880.28 This
SNP (rs2241880) has also been shown to be associated with almost double the risk of
developing colorectal cancer.37
ATG5 is part of an ubiquitin-like conjugation pathway which links ATG5 with ATG16L
(ATG5-ATG16L). Specifically, ATG5 membrane binding is activated through its
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conjugation with ATG16L. Membrane binding by the ATG12–ATG5-ATG16 exerts an
E3 enzyme-like function and this binding is critical for the correct formation of the
autophagosome (Figure 1). Importantly, both rs1864182 and rs1051423, located in
ATG10, have been reported associated with a decreased risk of breast cancer.29
In the current study, three SNPs were associated with melanoma prognostic indicators.
One SNP, in a critical autophagy gene (ATG16L), had multiple associations in our
analysis. A significant association was identified between the minor allele for rs2241880
and a decrease in Breslow thickness (p = 0.03) and an earlier stage at diagnosis (OR 0.47
95% CI 0.27-0.81, p = 0.02). This SNP (rs2241880) also showed an association between
the heterozygous variant and a younger age at melanoma diagnosis (p = 0.02). This SNP
is also associated in the literature with decreased autophagy and may mediate melanoma
progression through the accumulation of protein aggregates and damaged organelles in
patients.38,39There is evidence in the literature that decreased autophagy may inhibit
melanoma tumorgeneis.7,8 Further, this ATG16L SNP has been reported in the literature
to be associated with increased IL-1β production in primary cells.23 Metastatic melanoma
cells spontaneously secrete active IL-1β40 and the association between melanoma and this
ATG variant warrants further investigation.
In ATG5, we identified a positive association with increased stage between two SNPs,
rs510432 minor allele (CC) (defined as a Stage T1a/T1b/T2a vs. T2b and higher OR 1.26
95% CI 0.81-1.95, p = 0.05) and rs2245214 heterozygous genotype (CG) (defined as
categorical stage OR 1.47 95% CI 1.11-1.94 p = 0.03), and increased stage in melanoma.
SNP rs510432 had a borderline association when it was. Interestingly, rs510432 is in the
5′ untranslated region (UTR) upstream of its first exon in the promotor region. In
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addition, this SNP (rs510432) (C) has a reported positive association with asthma (p=
0.003) 21 and is reported to confer increased promoter activity of this gene. As we also
identified a positive association with increased stage and rs510432 (C) in our population,
further studies exploring the functional role of this SNP in the rate of autophagy and
melanoma progression may elucidate ATG5 promoter activity in these participants,
leading to more advanced melanoma stage.
In addition, ATG5 has functions independent of autophagy, including critical roles in
apoptosis, mitotic catastrophe and regulation of the β-Catenin signaling pathway41,42. As
ATG5 is often down-regulated in primary melanomas,43 the association of two SNPs in
this critical ATG gene with increased melanoma stage is significant as they have the
potential to become new markers of melanoma risk, progression and/or therapeutic
targets.
Our study identified no association between the 5 ATG gene SNPs and melanoma
specific survival. There were also no significant associations identified between the SNPs
and ulceration, mitosis, or histological subtype.
While they were not significant at the global p-value, a decrease in OR (0.42 95% CI
0.21-0.88, p = 0.02) was identified between the presence of brisk TILs and the minor
allele of SNP rs1864182, and non-brisk TILs and the minor allele of rs510432 (OR 0.55
95% CI 0.34-0.87 p = 0.01). The association of TILs with autophagy variants is
significant as increased number of TILs, particularly brisk TILs, in primary melanomas
are associated with improved melanoma-specific survival.44 TIL absence in melanoma is
associated with higher stage then either the presence of non-brisk or brisk TIL. The
presence of non-brisk TILs is also associated with a 30% decrease in melanoma death
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(HR 0.7; 95% CI 0.5 to 1.0) while there is a 50% decrease associated with brisk TILs
(HR 0.5 95% CI 0.3 to 0.9).44
Finally, while not significant at the global p-value, an inverse association between the
minor allele of rs2245214 and scalp/neck melanomas was also identified (OR 0.20 95%
CI 0.05-0.86 p=0.03). As it has been previously documented that individuals with
scalp/neck melanomas have poorer outcomes than patients with melanomas on other
sites, 45 this inverse relationship warrants further studies to determine if there is a
functional significance for ATG5 and this anatomic site.
Autophagy has had a role in cancer; however the relationship between genetic variants in
autophagy genes and cancer development, progression and survival remains under
explored. In the present study, we assessed the impact of variants in ATG genes necessary
for autophagic flux in relationship to melanoma prognostic indicators and survival. Drugs
targeting the autophagy pathway are being investigated as effective therapy for many
cancers including melanoma. SNPs that alter autophagic rates may affect the
effectiveness of current treatment strategies and have clinical significance.9,46–49 In silico
analysis of results from multiple studies, and/or coordination of large studies, will have to
assess the reproducibility of these ATG gene interactions in melanoma.
This study is limited by the knowledge that alteration of autophagy might not be due to
variants in ATG genes but possibly due to other signaling pathways that regulate
autophagy or post-translational modifications. In addition, there are other probably other
functional genetic variants not included in the current study, as there are approximately
38 ATG genes specifically required for autophagy in Saccharomyces cerevisiae.50 We
found no direct association between any of the 5 ATG gene SNPs and survival although
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this may be due to insufficient sample size. Enlarging the number of samples and
incorporating functional studies may help to establish if an association with survival
exists. Our analyses did not control for multiplicative significance and false discovery
rate but employed a more stringent global p-value to reduce type 1 errors. These
limitations must be addressed in future experiments by screening for SNPs in other
relevant genes potentially using alternative technologies including deep sequencing.
In conclusion, while we found no association with survival, we have identified three ATG
gene SNPs as a genetic factors affecting melanoma progression, which, in melanoma
patients, may cause changes in ATG protein levels and alter autophagy regulation,
affecting melanomagenesis. These findings emphasize the significance of the autophagy
pathway in melanoma. As the role of autophagy in melanoma is complex and context
dependent, the reported associations may provide important insight into how SNPs in
critical autophagy genes impact melanoma progression.
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4.7 Figure and Tables:
4.7.1 Figure 1: Overview of the Autophagy related (ATG) conjugation pathway
focusing on the gene variants investigated in this study, including those in the ATG5,
ATG 10 and ATG 16L genes.

* Five variants from three autophagy related genes were selected for either an association

with or functional impact on risk or progression of disease. Two SNPs were chosen from
ATG10, two from ATG5 and one from ATG16L. From our analysis a significant
association was identified between the ATG16L polymorphism (rs2241880) and a
decrease in Breslow thickness (p = 0.03), younger age (p = 0.02) and earlier stage at
diagnosis (OR 0.47, 95% CI 0.27-0.81, p = 0.02). In addition, two SNPs in ATG5
(rs2245214 and rs510432) were associated with increased stage of melanoma (OR 1.84
95% CI 1.12-3.02, p=0.05; OR 1.47 95% CI 1.11-1.94, p=0.03). We identified an
inverse association between the ATG5 SNP rs2245214 and melanomas on the scalp or
neck (OR 0.20, 95% CI 0.05-0.86, p= 0.03); rs1864182 (ATG10) (OR 0.42, 95% CI 0.210.88, p= 0.02), and with brisk TILs. Finally, we identified an association between nonbrisk TILs and the ATG5 SNP rs510432 (OR 0.55 95% CI 0.34-0.87, p= 0.01) although
not significant at the global p-value.
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4.7.2 Table 1. Clinicopathologic characteristics among 911 melanoma cases*
No.

Characteristics
Age at diagnosis
Breslow thickness, median , mm
Gender

534
377
547
212
108
44
603
308
394

59
41
60
23
12
5
66
34
43

Scalp/neck

56

6

Face/ears/other
Upper extremities
Lower extremities
SSM
NM
LMM
Other
Missing
Absent
Present
Absent
Present
T1a
T1b
T2a
T2b
T3a
T3b
T4a
T4b

116
172
173
610
92
116
93
0
794
73
454
415
397
124
183
16
73
32
21
21

13
19
19
67
10
13
10
0
92
8
52
48
46
14
21
2
8
4
2
2

T1a/T1b/T2a
T2b+
Absent
Non-Brisk
Brisk
Absent

704
163
194
563
111
255

81
19
22
65
13
29

Breslow thickness (mm)

Status
Anatomic site

Histological subtype

Ulceration
Mitosis
AJCC stage

%

60
0.8
Male
Female
0.01-1.00
1.01-2.00
2.01-4.00
> 4.00
SPM
MPM
Trunk/pelvis

AJCC stage (T1a/T1b/T2a vs. T2b+)
TIL grade

Growth phase
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Present
Death from melanoma*
Alive or death from other causes

614
76
835

71
8
92

*Subjects comprised 911 participants from the GEM study from Australia and the United States. OR
values are adjusted for age as a continuous variable. Abbreviations: AJCC= American Joint Committee on
Cancer; CI = confidence limit; Mpm= Multiple primary melanoma; NM = nodular melanoma; OR = odds
ratio; SSM = superficial spreading melanoma; SD = standard deviation; TIL= Tumor infiltrating
lymphocytes; Spm=Single primary melanoma. Death from melanoma recorded during 7.5 years of followup.

4.7.3 Table 2. Allele frequencies of ATG genes in melanoma patients
ATG5

ATG5

ATG SNP

Genotype

Number of patients (%)

rs510432

CC
CT
TT

190 (0.22)
425 (0.48)
266 (0.30)

rs2245214

CC
CG
GG

331 (0.38)
427 (0.49)
110 (0.13)

AA
AG
GG

198 (0.23)
418 (0.490
245 (0.29)

CC
CT
TT

116 (0.13)
403 (0.47)
345 (0.40)

AA
AC
CC

238 (0.28)
424 (0.49)
200 (0.23)

ATG16L
rs2241880

ATG10
rs10514231

ATG10
rs1864182
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4.7.4 Table 3. Relationship between ATG genotype, Breslow thickness and age of
diagnosis in melanoma
4.7.4a Table 3a. Relationship between ATG genotype and Breslow thickness in
melanoma
Breslow thickness (Continuous)
ATG gene SNP
rs10514231

rs1864182

rs2241880

rs22445214

rs510432

Genotype

Coeff (95% CI)

p-value*

TT

1.00

CT

1.09 (0.98-1.22)

0.09

CC

0.99 (0.84-1.16)

0.91

CC

1.00

AC

1.05 (0.92-1.19)

0.46

AA

1.05 (0.9-0.82)

0.50

GG

1.00

AG

1.04 (0.92-0.85)

0.55

AA

0.87 (0.97-0.99)

0.06

TT

1.00

CG

1.09 (0.98-1.22)

0.11

CC

1.06 (0.9-1.26)

0.49

TT

1.00

CT

1.05 (0.94-1.19)

0.37

CC

1.12 (0.97-1.3)

0.12

Global p-value*
0.18

0.72

0.03

0.28

0.30

Genotypic model adjusted for age (continuous) sex, study center and status. Abbreviations: CI,
confidence interval; Coeff, coefficient

4.7.4b Table 3b. Age at diagnosis by genotype status among melanoma cases
Age at diagnosis, y
ATG gene SNP
rs10514231

rs1864182

rs2241880

Genotype

n

Coeff (95% CI)

TT

864

1.00

p-value*

Global p-value*
0.71

CT

0.22 (-1.95-2.39)

0.84

CC

1.33 (-1.84-4.50)

0.41

CC

862

1.00

AC

0.72 (-1.67-3.11)

0.55

AA

-0.26 (-3.09-2.57)

0.86

GG

861

1.00
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0.70
0.02

AG

-3.25 (-5.60--0.91)

0.01

AA

-2.04 (-4.83-0.74)

0.15

TT

rs2245214

868

CG

-0.59 (-2.77-1.58)

0.59

CC

-1.17 (-4.43-2.09)

0.48

TT

rs510432

1.00

881

0.75

1.00

CT

0.43 (-1.86-2.73)

0.71

CC

-0.55 (-3.33-2.23)

0.70

0.75

Genotypic model adjusted for sex, study center and status.

4.7.5 Table 4. Relationship between ATG genotype and AJCC stage in melanoma
Melanoma Stage
p-value*

Global pvalue*

1.18 (0.80-1.76)

0.41

0.46

CC

0.84 (0.46-1.54)

0.57

CC

1.00

AC

1.22 (0.79-1.89)

0.38

AA

0.98 (0.57-1.66)

0.93

ATG gene SNP

Genotype

≥ Stage T2b vs. Stage T1a/T1b/T2a

rs10514231

TT

1.00

CT
rs1864182

rs2241880

rs2245214

rs510432

GG

1.00

AG

0.88 (0.59-1.33)

0.55

AA

0.47 (0.27-0.81)

0.01

TT

1.00

CG

1.46 (0.98-2.17)

0.06

CC

1.05 (0.57-1.92)

0.88

TT

1.00

CT

1.26 (0.81-1.95)

0.30

CC

1.84 (1.12-3.02)

0.02

0.52

0.02

0.14

0.05

Genotypic model adjusted for age (continuous) sex, study center and status. Abbreviations:
AJCC, American Joint Committee on Cancer

4.7.6 Table 5. Relationship between ATG Genotype and melanoma-specific survival
ATG gene SNP

Genotype

HR (95% CI)

rs10514231

TT

1 [Reference]

CT

1.24 (0.74-2.07)
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pvalue
0.42

Wald pvalue
0.72

rs1864182

rs2241880

rs22445214

rs510432

CC

1.12 (0.54-2.35)

0.76

CC

1 [Reference]

AC

1.83 (0.93-3.59)

0.08

AA

1.89 (0.90-3.98)

0.10

GG

1 [Reference]

AG

1.04 (0.60-1.80)

0.89

AA

0.86 (0.43-1.72)

0.67

TT

1 [Reference]

CG

0.86 (0.52-1.43)

0.56

CC

0.82 (0.37-1.81)

0.63

TT

1 [Reference]

CT

0.68 (0.40-1.17)

0.16

0.18

0.85

0.80

0.13

CC
1.19 (0.67-2.12)
0.55
Survival analysis adjusted for age, sex, study center, status (Spm vs. Mpm) and time dependent crossover
in a genotypic model. Abbreviations: HR, hazard ratio; CI, confidence interval
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4.7.7 Supplemental Table S1a. Clinicopathologic characteristics by genotype status among melanoma cases*

ATG gene SNP Genotype
rs10514231

rs1864182

rs2241880

rs2245214

rs510432

Scalp/neck vs.
Trunk/pelvis

p-value*

Anatomic Site
Face/ears/ other vs.
Upper extremities vs.
Lower extremities vs.
Wald
p-value*
p-value*
p-value*
Trunk/pelvis
Trunk/pelvis
Trunk/pelvis
p-value

TT

1.00

1.00

1.00

CT

0.74 (0.39-1.39)

0.34

1.06 (0.65-1.74)

0.80

0.8 (0.53-1.2)

0.28

0.97 (0.63-1.47)

0.87

CC

0.46 (0.15-1.4)

0.17

1.36 (0.71-2.62)

0.35

0.76 (0.41-1.42)

0.39

0.97 (0.52-1.82)

0.92

CC

1.00

AC

1.56 (0.77-3.14)

0.22

1 (0.58-1.71)

0.99

0.79 (0.5-1.24)

0.31

0.68 (0.25-1.81)

0.44

AA

0.83 (0.52-1.33)

0.44

1.33 (0.72-2.47)

0.37

0.94 (0.55-1.62)

0.83

1.26 (0.73-2.17)

0.41

GG

1.00

AG

1.68 (0.83-3.4)

0.15

0.9 (0.53-1.52)

0.68

0.96 (0.62-1.5)

0.87

0.99 (0.62-1.59)

0.97

AA

0.88 (0.34-2.27)

0.79

1.18 (0.65-2.16)

0.59

0.96 (0.57-1.63)

0.88

1.09 (0.63-1.89)

0.75

TT

1.00

CG

0.73 (0.4-1.33)

0.31

0.9 (0.56-1.45)

0.66

0.73 (0.49-1.1)

0.14

0.84 (0.55-1.28)

0.41

CC

0.20 (0.05-0.86)

0.03

0.88 (0.44-1.77)

0.72

0.68 (0.37-1.26)

0.22

0.72 (0.38-1.37)

0.32

TT

1.00

CT

0.65 (0.35-1.23)

0.18

0.67 (0.41-1.11)

0.12

1.27 (0.82-1.98)

0.28

1.23 (0.78-1.95)

0.38

CC

0.45 (0.19-1.07)

0.07

0.68 (0.37-1.24)

0.21

0.88 (0.51-1.52)

0.65

0.98 (0.56-1.71)

0.94

1.00

1.00

1.00

1.00

1.00

1.00

1.00

0.70

1.00

1.00
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0.22

1.00

1.00

1.00

0.73

0.51

1.00
0.20

Histological sub-type
ATG gene SNP Genotype NM vs. SSM
rs10514231

rs1864182

rs2241880

rs2245214

rs510432

p-value

LMM vs. SSM

p-value Other vs. SSM

1.00

p-value

TT

1.00

CT

1.21 (0.70-2.07)

0.50

1.08 (0.68-1.73)

0.74

0.95 (0.59-1.54)

0.83

CC

1.78 (0.90-3.52)

0.10

1.10 (0.57-2.13)

0.77

0.46 (0.19-1.14)

0.09

CC

1.00

AC

1.58 (0.85-2.94)

0.15

1.52 (0.90-2.57)

0.12

1.00 (0.59-1.71)

0.99

AA

1.63 (0.81-3.27)

0.17

1.12 (0.59-2.11)

0.73

0.80 (0.41-1.56)

0.52

GG

1.00

AG

1.63 (0.92-2.88)

0.09

1.31 (0.78-2.19)

0.30

0.89 (0.53-1.51)

0.66

AA

1.18 (0.60-2.36)

0.63

1.18 (0.65-2.15)

0.59

0.74 (0.39-1.42)

0.36

TT

1.00

CG

1.59 (0.95-2.67)

0.08

0.88 (0.56-1.39)

0.59

1.41 (0.84-2.37)

0.20

CC

0.76 (0.31-1.85)

0.54

0.80 (0.40-1.60)

0.53

1.40 (0.68-2.90)

0.36

TT

1.00

CT

1.03 (0.60-1.78)

0.91

0.88 (0.54-1.43)

0.60

0.89 (0.53-1.49)

0.65

CC

1.33 (0.71-2.49)

0.38

0.98 (0.54-1.78)

0.94

0.93 (0.49-1.76)

0.83

Wald p-value

1.00

1.00

0.36

1.00

1.00

0.46

1.00

1.00

0.54

1.00

1.00

0.26

1.00

All genotypic analyses were adjusted for age (continuous), sex, study center and status (Spm/ Mpm/ crossover)
*Bold significance set p= 0.05
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0.96

Ulceration
ATG gene SNP

Genotype

Ulceration present vs. absent

rs10514231

TT

1.00

CT

1.04 (0.60-1.81)

0.90

CC

0.80 (0.35-1.86)

0.61

CC

1.00

AC

1.23 (0.66-2.29)

0.52

AA

0.90 (0.41-1.95)

0.78

GG

1.00

AG

0.94 (0.53-1.68)

0.84

AA

0.61 (0.28-1.31)

0.20

TT

1.00

CG

1.33 (0.77-2.28)

0.31

CC

0.70 (0.27-1.78)

0.45

TT

1.00

CT

1.27 (0.68-2.37)

0.45

CC

1.68 (0.83-3.43)

0.15

rs1864182

rs2241880

rs2245214

rs510432

p-value
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Wald pvalue

0.82

0.61

0.41

0.29

0.36

Mitosis
ATG gene SNP

Genotype

Mitosis present vs. absent

rs10514231

TT

1.00

CT
rs1864182

rs2241880

rs2245214

rs510432

p-value

Wald p-value

1.09 (0.81-1.48)

0.56

0.84

CC

1.02 (0.65-1.58)

0.95

CC

1.00

AC

0.95 (0.68-1.33)

0.77

AA

1.17 (0.79-1.74)

0.43

GG

1.00

AG

1.06 (0.76-1.48)

0.73

AA

0.86 (0.58-1.27)

0.44

TT

1.00

CG

1.33 (0.98-1.79)

0.07

CC

1.30 (0.83-2.03)

0.25

TT

1.00

CT

1.18 (0.86-1.63)

0.31

CC

1.33 (0.90-1.96)

0.15

0.50

0.49

0.17

0.34

TIL Grade
p-value

Wald pvalue

0.92 (0.54-1.59)

0.78

0.88

0.80 (0.34-1.86)

0.6

ATG gene SNP

Genotype

Non Brisk vs. Absent

rs10514231

TT

1.00

CT

0.98 (0.68-1.41)

0.91

CC

1.15 (0.67-1.98)

0.62

CC

1.00

AC

1.12 (0.74-1.68)

0.60

0.87 (0.49-1.58)

0.66

AA

0.81 (0.51-1.29)

0.37

0.42 (0.21-0.88)

0.02

rs1864182

p-value

Brisk vs Absent
1.00

1.00
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0.14

rs2241880

rs2245214

rs510432

GG

1.00

1.00

AG

0.91 (0.61-1.35)

0.63

1.02 (0.55-1.90)

0.96

AA

0.89 (0.55-1.43)

0.62

1.53 (0.76-3.08)

0.23

TT

1.00

CG

0.93 (0.65-1.34)

0.70

0.86 (0.50-1.49)

0.59

CC

0.91 (0.53-1.57)

0.74

1.01 (0.46-2.22)

0.98

TT

1.00

CT

0.74 (0.49-1.11)

0.15

0.99 (0.54-1.79)

0.96

CC

0.55 (0.34-0.87)

0.01

0.72 (0.36-1.45)

0.36

1.00

rs10514231

rs1864182

rs2241880

rs2245214

rs510432

Genotype

0.97

1.00

Melanoma Stage (continuous)
ATG gene SNP

0.42

OR (95% CI)

p-value

TT

1.00

CT

1.18 (0.90-1.56)

0.23

CC

0.92 (0.61-1.38)

0.69

CC

1.00

AC

1.07 (0.79-1.46)

0.65

AA

1.06 (0.74-1.53)

0.74

GG

1.00

AG

1.01 (0.75-1.37)

0.93

AA

0.74 (0.52-1.06)

0.10

TT

1.00

CG

1.47 (1.11-1.94)

CC

1.23 (0.82-1.85)

TT

1.00

CT
CC

Wald pvalue
0.32

0.90

0.14

0.01
0.32

0.03

1.30 (0.97-1.75)

0.08

0.14

1.37 (0.96-1.95)

0.09
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4.8 Supplemental research to chapter 4 manuscript:

4.9 Introduction:
The importance of the autophagy pathway, particularly in cancer, has been previously
described in this chapter. In addition, it has been reported that knockout of autophagy
related genes results in multiple disease states including neurodegenerative disease,
autoimmunity, and cancer. Cells dependent on this catabolic pathway with decreased
autophagic capacity to recycle nutrients will undergo programmed cell death which can
result in tissue damage and inflammation. 1 Inflammation has an important and emerging
role in cancer and has particular significance for melanoma. Melanoma inflammatory
cells, including tumor-infiltrating macrophages, have prognostic implications.2 The
presence of TILs in vertical growth phase of cutaneous melanomas has been reported to
be associated with a better prognosis 3,4 Conversely, high levels of an inflammatory
marker, C-reactive protein is a poor prognostic indicator.5 Cytokines, chemical
messengers of the immune system, have a dynamic range of expression patterns in
melanoma that changes with cancer progression. A variant in one SNP previously
described in this chapter, autophagy related 16-like 1 (T300A) (Chapter 4.4), enhances
the degradation of the ATG16L protein by caspase 3.1 Under certain conditions ATG16L
is critical for negative regulation of inflammatory cytokines9 and the T300A variant
impacts IL-1β and IL-6 production. 10
Characterizing the correlation of this SNP, which can directly impact the rate of
autophagy in cells, with the two major oncogenes in melanoma BRAF and NRAS, should
allow us to elucidate the role of autophagy in these important subtypes melanoma. For
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this analysis, I used only single primary samples which had been genotyped for
BRAF/NRAS status from GEM participants. In order to determine whether SNPs in ATG
genes are associated with BRAF/NRAS mutations in melanoma patients, I used the
procedures and premises listed in the previous part of this chapter to investigate 5 SNPs
in 3 autophagy related genes in melanoma.

4.10 Materials and Methods:
4.10.1 Patient Characteristics:
From the study of a population of 2,373 participants with single primary melanomas, we
chose 602 genomic DNA samples were based on tumor availability (previously
described in 4.3.1 and previously reported) 3 and compared ATG SNP frequencies with
oncogene status.
4.10.2 Clinical Stage:
Previous described in 4.3.2 and summary characteristics were previous reported 3
4.10.3 Selection of SNPs and Genotyping:
5 SNPs in three critical ATG genes were selected from those identified with functional
SNPs in the literature or that were associated with BRAF and NRAS status as previously
described. DNA was isolated from buccal cells as previously described in 4.3.3.4,5 SNPs
in ATG genes were characterized using Taqman Real-Time PCR Assays (ThermoFisher
Scientific, Grand Island, NY) on a 7900HT Fast Real-Time PCR System (ThermoFisher
Scientific, Grand Island, NY) following manufacture recommendations as previously
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described in 4.3.3. The identification of ATG gene alleles were identified using the ratio
of amplification fluorescence during the logarithmic phase generated from a
commercially available Taqman primer assay on a 7900HT Applied Biosystems qPCR
machine as previously described 4.3.3. Genomic DNA samples were chosen from those
samples for single primary melanoma with sufficient DNA and tumor availability to
allow for somatic analysis in future studies. 3 The genotyping call rate for the 602 chosen
samples ranged was 98 to 100% and biological replicates were generated for 10% of the
samples with 100% concordance.
4.10.4 Data Analysis:
Frequency tables were used to summarize the genotype distributions for each ATG SNP
(see Table 2). The association between SNPs and oncogene status were tested under the
general genotypic inheritance (co-dominant) model allowing for simultaneous
comparison of the heterozygous genotype versus wildtype, and homozygous minor
genotype versus wildtype. No assumptions were made on the model of inheritance, and
the genotypes for each SNP were treated as a three-level nominal variable. From this
analysis we report a global p -value which represents the overall significance for our
analysis as described previously. To evaluate the association between ATG SNPs and
BRAF or NRAS status, we conducted logistic regression analyses. ORs and 95%
confidence intervals estimated from the regression models were used to summarize the
associations. Wald tests were used to assess the global significance of the association and
statistical significance was two-sided and set at 5%.
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4.11 Results:
Five SNPs within ATG genes that have been previously reported associated with disease
outcomes were genotyped and the result correlated with oncogene status. After
adjustment for age, sex and study center, none of the 5 ATG gene SNPs were
significantly associated with BRAF or NRAS status in melanoma participants. However
the "A" allele of one SNP in ATG10 (rs1864182) showed a positive correlation with
BRAF status although it did not retain significance at the global p-value (AC) (OR 1.79
95%CI 1.12-2.87, p= 0.02) (AA) (OR 1.82 95%CI 1.06-3.12, p= 0.03). This may be due
to insufficient sample size as our power calculation was originally based on 795 samples.
I was unable to obtain DNA for all 795 participants and information on BRAF NRAS
status was unavailable for some tumors, resulting in decreased sample size.

4.12 Discussion:
In this study a SNP in ATG10 (rs1864182), while not significant at the global level,
correlated with BRAF status in our melanoma participants. Of interest, the significance of
both allelic specific models, one which examines the relationship between the
heterozygous genotype versus wildtype, and homozygous minor genotype versus
wildtype were both below .05 (p=0.02; p=0.03 respectively). Elevated expression of
ATG10 in colon cancer has been shown to be associated with increased lymph node
metastasis6 and previously this SNP has showed to be associated with increased IL-8
production (p = 0.04).7
Melanoma cells express a variety of cytokines, and their level of expression changes as
melanoma progresses. 6 Early stage melanoma with lesions less than 1 mm Breslow
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thickness exhibit low levels of cytokines including IL-8. 7 More advanced stage is
associated with increased expression of pro-inflammatory cytokines IL-1α, β, IL-6, and
IL-8. 7 The expression of IL-6 in particular has been associated with melanoma
malignancy and its production has been associated with defective autophagy.8 Of
interest, this particular SNP in ATG10 (rs1864182) was also previously reported to be
associated with decreased breast cancer risk.8 Induced autophagy in breast cancer cells
has been shown to result in autophagic regulated cell death.9 The impact of this SNP in
the function of ATG10 remains to be elucidated. Analysis of the rate of autophagy
associated with this SNP would provide insights into its association both with BRAF
oncogene status as well as correlations with melanoma progression and survival.
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4.14 Tables:
4.14.1 Table 1: BRAF/ NRAS status by SNP genotype among melanoma cases*
BRAF/ NRAS
Wald
OR (95% CI)
p-value
status
p-value
wt.
1 [Reference]
rs10514231 TT
BRAF*
1.36 (0.90-2.06) 0.15
rs10514231 CT
BRAF*
1.39 (0.77-2.50) 0.26
0.36
rs10514231 CC
NRAS*
1.37 (0.79-2.37) 0.27
rs10514231 CT
NRAS*
0.81 (0.34-1.92) 0.62
rs10514231 CC
wt.
1 [Reference]
rs1864182 CC
BRAF*
1.79 (1.12-2.87) 0.02
rs1864182 AC
AA
BRAF*
1.82 (1.06-3.12) 0.03
0.09
rs1864182
NRAS*
1.09 (0.61-1.95) 0.77
rs1864182 AC
NRAS*
0.78 (0.38-1.62) 0.51
rs1864182 AA
wt.
1 [Reference]
rs2241880 GG
AG
BRAF*
0.97
(0.62-1.53)
0.90
rs2241880
BRAF*
0.90 (0.53-1.53) 0.61
0.94
rs2241880 AA
NRAS*
1.17 (0.64-2.12) 0.70
rs2241880 AG
NRAS*
0.91 (0.45-1.86) 0.80
rs2241880 AA
wt.
1 [Reference]
rs2245214 TT
BRAF*
1.12 (0.75-1.68) 0.57
rs2245214 CG
BRAF*
0.89 (0.47-1.69) 0.73
rs2245214 CC
0.57
NRAS*
0.71 (0.41-1.21) 0.20
rs2245214 CG
NRAS*
0.93 (0.43-2.02) 0.86
rs2245214 CC
TT
wt.
1 [Reference]
rs510432
CT
BRAF*
1.12 (0.72-1.73) 0.63
rs510432
CC
BRAF*
1.03 (0.59-1.78) 0.93
0.38
rs510432
CT
NRAS*
0.86 (0.47-1.55) 0.61
rs510432
CC
NRAS*
1.51 (0.78-2.93) 0.22
rs510432
Genotypic model adjusted for age (continuous) sex, and study center. *Bold significance
set p= 0.05 Abbreviations: OR, odds ratio; CI, confidence interval
ATG SNP

Genotype
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4.14.2 Table 2: Power calculation for detecting oncogene status in 795 melanoma
patients
Minimum detectable per-allele OR
SNP
rs510432
rs2241880
rs10514231
rs2245214

Minor allele
0.447
0.471
0.359
0.367

NRAS vs wt.
1.75
1.75
1.76
1.76

BRAF vs wt.
1.53
1.53
1.55
1.55

* sample size of 795 , 80% power and 5% significance level

186

CHAPTER FIVE:

187

5.1 Conclusions:
My research offers insight into the interactions between BRAF/NRAS status, autophagy
and melanoma. Despite new treatment options and therapies the long term survival rate
for melanoma is stilllow.1 A common hypothesis has been that the autophagy pathway is
upregulated early in tumorigenesis, suppressing cancer progression, but then the pathway
is subverted and in later stages promotes tumorigencity.2,3 However, I have demonstrated
at the cellular level that, particularly in late stage melanoma, oncogene status influences
autophagy regulation.
My research involves a broad approach. Starting with cell lines from metastatic
melanoma patients, moving to melanoma and benign nevus tissues of patients in a pilot
study, and finally to a larger study of melanoma patients at the population level, I have
examined the complex relationship between melanoma, autophagy and the oncogenes
that characterize a majority of melanoma tumors. Using this broad approach, I have
identified dependence in metastatic BRAF* mutant cell lines on autophagy. In addition, in
NRAS* cell lines I identified that these cells have the ability to utilize the autophagy
pathway in response to serum starvation or chemical induction but they are not
upregulating this process for survival under basal conditions. In addition, the data
supporting the concept that BRAF* melanoma cancer cells are more susceptible to
autophagic inhibition suggest that constitutively activated BRAF* selectively upregulated
autophagy. The way in which autophagy is upregulated beyond the activation of the
MAPK pathway remains to be elucidated, but this research suggests there is an important
connection between the tumorigenicity of BRAF* melanoma and autophagy. My research
also identifies the important but subtle finding that NRAS* melanoma cells appear less
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dependent autophagy for survival at later in later stage. This differential activation of the
autophagy pathway suggests that these two oncogenes, which mutually signal through the
MAPK pathway, are interacting with other proteins to regulate autophagy. This finding is
not counter intuitive as the uncoupling of mutant NRAS signaling from BRAF, and
subsequent preferential signaling through CRAF has been previously reported.4 Still the
role of autophagy in NRAS mutant melanoma etiology presents an area for additional
research.
The relationship between autophagy regulation and melanoma was also investigated in
melanoma and control tissue sections showing that high Beclin1 expression was
associated with decreased Breslow thickness potentially implying a tumor suppressive
effect. LC3 levels correlated with decreased melanoma specific mortality. Of note my
research also identified a gender specific association in the melanoma patients. Females
in our sample population were more likely to have high Beclin1 expression in their tumor
tissue sections. This is a particularly stimulating observation as female melanoma
patients exhibit longer survival over male melanoma patients with similar stage.5 If
Beclin1 is acting as a tumor suppressor in melanoma, the higher levels of this protein
may also have prognostic implications.
Further, evaluation of UV exposure in melanoma tissue sections identified that certain
outdoor activities, indicated consistent UV exposure, and were associated with
upregulated autophagy. Melanoma participants reporting blistering sunburn were more
likely to have elevated Beclin1 expression while high LC3 was associated with a lack of
blistering sunburns. At first this finding may seem counter intuitive for a potential role
for Beclin1 as a tumor suppressor. However, previous studies have shown an inverse
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correlation between sunburn and death from melanoma.6 If Beclin1 is acting to suppress
tumorigenesis following UV exposure this interaction may help to clarify the complex
between relationships between sun exposure and melanoma progression.
Interestingly, Beclin1 expression was not associated with NRAS mutant or BRAF mutant
status in our analysis. While there may be no direct relationship between Beclin1
expression and these oncogenes, another possible reason I did not identify a relationship
between Beclin1 expression and BRAF or NRAS status might be due to low statistical
power. We did see a borderline significance with the melanoma histological subtype,
superficial spreading melanoma, that is more commonly associated with BRAF mutant
melanoma but additional investigations will be necessary to clarify this relationship.
LC3 expression is generally accepted as a proxy marker for the rate of autophagy and,
interestingly, in our sample population high LC3 was correlated with decreased
melanoma specific mortality. When I examined the interactions between mortality and
LC3 compared to the interaction of mortality with either Beclin1 or Beclin1 combined
with LC3, it was clear that LC3 protein expression alone in this model is associated with
decreased mortality. As punctate LC3 in cases was significantly associated with LC3
expression in cases, this potentially indicates an increase in the number of
autophagosomes present in these patients. To add to the complexity, while BRAF and
NRAS status were not significantly associated with LC3 expression, high cytosolic LC3
expression correlated with wildtype status in our population genotype. The presence of
high levels cytosolic of expression, coupled with the lack of punctate LC in these
participants potentially indicates deacetylation of LC3, which has been reported to
increase LC3s expression in the cytoplasm.7 This would indicate that LC3 has been
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primed for autophagy induction in the tissue of our non-oncogenic samples but that
autophagosome formation may be impaired or inhibited as indicated by the absence of
punctate LC3. The reasons for this association remain unclear and require additional
investigation. In addition, while not significant, high LC3 expression was also associated
with prolonged sun exposure on unprotected skin, boating activities and any outdoor
activity sun exposure. This indicates a role for UV exposure with autophagy activation as
evidenced by the high LC3 expression. Ultimately my results indicated that autophagy
proteins vary by tumor stage and their expression is associated with UV exposure. My
research also indicate that the expression of Beclin1 and LC3 could be beneficial as
prognostic indicators and that elevated level of these two proteins may support the
maintenance of a more indolent melanoma phenotype.
In the final study of this project, I identified SNPs associated with markers of
melanoma progression. To date, there are no other studies investigating the impact of
ATG gene SNPs in melanoma progression and survival. While the association between
oncogene status and these SNPs was not significant at a global p level, the linear
correlation between BRAF status and a SNP in ATG10 was significant for the allelic
model. This analysis could benefit from additional studies using increased sample size to
ensure sufficient power in order to adequately evaluate this correlation. In addition, I
identified three ATG SNPs (rs2241880, rs510432, rs2245214) that were associated with
prognostic indictors in melanoma. The SNP in ATG16L (rs2241880) creates a cleavage
site that results in the degradation of ATG16L and an overall decrease in the rate of
autophagy. This variant was associated with better prognostic indicators including
Breslow thickness, decreased stage and a younger age of melanoma diagnosis. This may
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indicate that reduced levels of ATG16L are associated with less aggressive melanoma. In
addition, two other SNPs in another autophagy related gene ATG5 (rs2245214 and
rs510432) were associated with increased stage of melanoma. Of particular interest, the
rs510432 SNP located in the ATG5 promoter has been associated with an increased rate
of autophagy.8 This data would appear to suggest that increased levels of ATG,
potentially resulting in increased rates of autophagy, is associated with more aggressive
stage in melanoma. The apparent contrary nature of these two findings implies that,
beyond the impact of these genetic factors that could be modulating disease severity,
other factors are regulating autophagy potentially including UV exposure. Throughout
this study, several important interactions have been elucidated implicating the
interactions between oncogenes and the autophagy pathway as impacting melanoma
progression and survival. Overall, my results support the literature indicating the dual
role of autophagy, acting tumor suppressive in earlier stages and tumor promoting,
particularly in mutant BRAF melanomas as the tumor progresses. Autophagy, as
represented by the proxy marker LC3, is upregulated in mutant BRAF melanoma cells
compared to NRAS. This is also consistent with high levels of autophagy being associated
with late stage BRAF tumor cells.
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As shown at the individual level in melanoma tissue sections, and supported by the
literature, high levels of autophagy are associated with earlier prognostic indictors
suggesting that autophagy may be tumor suppressive in earlier stages of melanoma
development. This is particularly true as Beclin1, which was associated with many
positive prognostic indicators in my study, has tumor suppressive roles in many cancers.

Finally at the population level my results indicated that decreased lifelong autophagy,
resulting from the degradation of an important autophagy related protein (Atg16L), was
associated with better prognosis, while increased autophagy, resulting from upregulation
of the promoter of an important ATG gene (ATG5), was associated with increased
melanoma stage.

Overall my results indicate that dysregulation of autophagy can impact melanoma
progression.

5.2 Future studies:
My research has broad implications for melanoma and cancer research as a whole.
With a demonstrated but context specific impact of UV exposure and oncogene status on
autophagic regulation, coupled with interactions with SNP in ATG genes potentially
modifying melanoma progression and survival, this data builds knowledge applicable to
the many autophagy associated diseases. This knowledge suggests several future
directions.
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The differential activation of the autophagy pathway suggests that these two
oncogenes, BRAF and NRAS, which mutually signal through the MAPK pathway, are
interacting with other proteins to regulate autophagy. This finding is not counter intuitive
as the uncoupling of mutant NRAS signaling from BRAF, and subsequent preferential
signaling through CRAF has been previously reported.4 NRAS mutant cell lines have the
ability to use the autophagy pathway in response to nutrient deprivation but mutant NRAS
signaling of MAPK preferentially through CRAF appears to occur without the support of
the autophagy pathway at least under basal condition. The cyclic AMP pathway (cAMP),
which is inhibited in NRAS- mutant melanomas compared to BRAF oncogenic
melanomas, has been reported to have a role in autophagy.4 BRAF signaling through
cAMP has been reported to upregulate the autophagy initiating protein Beclin 1. Further
characterization of this interaction, including the impact of oncogenic BRAF on Beclin1
as well as the role of cAMP in autophagy and how these interaction impacts melanoma
progression would help to clarify the biological regulation of autophagy. As I have stated
the importance of Beclin1 warrants further investigation in melanoma. It has already been
reported that the generation of Vitamin D3, following UV exposure, enhances the
expression of Beclin-1 resulting in increased autophagy. 9 This interaction between UV
exposure and a potential tumor suppressive role for Beclin1 could be characterized using
clinical markers for sun exposure including serum Vitamin D levels and histopathological
data from patients whose BRAF NRAS status has been established.
In addition, there is data implicating high rates of autophagy as a mechanism of
acquired resistance to BRAF mutant inhibitors including vemurafenib.10 This data
supports the need for clinical studies in which autophagy inhibition is combined with
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oncogene specific therapies in order to overcome resistance. However the effect of these
combinations on different stages of melanoma is not clear. As our data have shown there
remains a complex balance between the tumor suppressive effects of autophagy,
particularly by Beclin 1, and the tumorigenic metabolic support provide by this pathway.
Functional studies are needed in order to further characterize the anticipated outcome of
these combination therapies. The use of cell lines to characterize these interactions
further would allow for some clarification of these relationships. Ultimately, the use of
animal models would be beneficial for determining how the modulations of these
proteins, as well as the impact of UV exposure, has on autophagy and melanoma
progression and would allow for refinement in our understanding of these complex
systems.
In addition, in order to further investigate the correlations we identified in this study,
autophagy SNPs should be functionally evaluated and it should be established what, if
any linkage disequilibrium is present between these and other SNPs. At the present time,
many novel and exciting therapies are in clinical trials and some, including CTLA-4 and
PD-1/PD-L1 blockade, are showing promise for durable impact on survival and
ATG16L and ATG5 have both been shown to impact cytokine production in disease.8,11–
13

It is also important to note that focused my investigation on 5 SNPs in 3 genes. There

are currently 38 ATG genes identified and the impact of variants in any of the other
critical autophagy genes has not been established for melanoma progression or survival.
Research characterizing deep sequencing and epigenetic changes including methylation
patterns, could help to characterize the impact of the SNPs identified in this research.
Finally, functional studies designed to evaluate the impact of the SNPs investigated in
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this study as a well other ATG gene SNPs on cytokines production and autophagy
regulation will provide insights into the relationship between autophagy and melanoma
progression.

5.3 Overall conclusions and perspectives:
This dissertation has presented data suggesting that the relationships between
autophagy, melanoma and oncogene status are complex and that careful examination of
these interactions will be pivotal in the successful application of autophagy inhibitors for
melanoma co-therapy. In particular, the dependence of BRAF mutant cell lines on
autophagy to suppress apoptosis as well as the relationship between SNPs and melanoma
clinical characteristics has important implications for understanding the etiology and
progression of this disease. Factors impacting the rate of autophagy including SNPs and
UV exposure interact with oncogenic differences to impact the melanoma progression
and survival.
These findings have important repercussions in beyond melanoma. First, there are
other diseases where the autophagy pathway plays a critical role including in
cardiovascular, neurodegenerative, infectious, and metabolic diseases and the data
present in this research may inform biological mechanisms in those diseases as well.
In addition, epidemiological studies can be used to identify unique interactions
between independent and complex variables, including autophagy and UV exposure, in
order to provide insights into melanoma. The use of large population studies when
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properly modelled, allows for the statistical power to examine interactions between
multiple SNPs, exposure variables and clinical characteristics.
Importantly, these results have implications for the interaction of the autophagy
pathway in disease, particularly, where oncogenes have a critical developmental role.
Overall, this data indicates that while BRAF cells may be dependent on autophagy for
survival, and that the expression of Beclin1 and LC3 may support a more indolent
melanoma phenotype. This suggests that the role of autophagy, as well as its interactions
with other mitigating factors, should be carefully considered before inhibition of
autophagy is used universally in melanoma treatment.
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